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Assessing Lung Transplantation Outcomes
Abstract
Lung transplantation is the established treatment for patients with chronic, end-stage lung diseases such
as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis
(CF). However, its utility remains limited by the chronic shortage of donor lungs, limited lung preservation
strategies and post-transplant complications leading to graft failure. Although efforts have been made to
expand the limited pool of viable donor lungs via novel preservation strategies such as ex vivo lung
perfusion (EVLP), our limited understanding of the mechanism and progression of donor lung injury
continues to inhibit our ability to fully exploit these advances to improve lung transplant outcomes.
Furthermore, the clinical standard for post-transplant assessment is limited to whole lung measurement
such as pulmonary functional tests (PFTs) and structural imaging via radiography or HRCT, both of which
lack the necessary sensitivity to detect lung rejection early. Given these limitations of currently available
pre- and post-transplant lung assessment tools, a novel metabolic biomarker may provide higher
sensitivity for determining the viability of donated lungs, as well as for assessing the onset of rejection
before permanent structural changes in the lungs become apparent. We proposed that hyperpolarized
(HP) [1-13C]pyruvate magnetic resonance imaging (MRI)—which provides real-time metabolic
assessment of tissue based on the conversion of [1-13C] pyruvate to [1-13C]lactate via glycolysis, or to
13C bicarbonate via oxidative phosphorylation—may be an effective tool for assessing the health of
donated lungs and may also serve as an early biomarker for detecting pulmonary graft dysfunction (PGD)associated inflammation or acute lung rejection. In a rat model, we demonstrated the feasibility of using
HP [1-13C]pyruvate nuclear magnetic resonance (NMR) spectroscopy to assess the viability of ex vivo
perfused lungs. We further showed that our technique can be used to measure the improved viability of
those lungs after treatment with ascorbic acid. Finally, translating our previously developed technique to
in vivo HP [1-13C]pyruvate imaging of an inflamed rat lung, we not only demonstrated its utility for
detecting lung transplantation rejection, but found that the HP lactate-to-pyruvate ratio is a better
predictor of acute lung rejection in a rat model than computed tomography.
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ABSTRACT

HYPERPOLARIZED CARBON-13 MAGNETIC RESONANCE IMAGING AS A TOOL
FOR ASSESSING LUNG TRANSPLANTATION OUTCOMES
Sarmad Siddiqui

Rahim Rizi

Lung transplantation is the established treatment for patients with chronic, end-stage lung
diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary
fibrosis (IPF) and cystic fibrosis (CF). However, its utility remains limited by the chronic
shortage of donor lungs, limited lung preservation strategies and post-transplant
complications leading to graft failure. Although efforts have been made to expand the
limited pool of viable donor lungs via novel preservation strategies such as ex vivo lung
perfusion (EVLP), our limited understanding of the mechanism and progression of donor
lung injury continues to inhibit our ability to fully exploit these advances to improve lung
transplant outcomes. Furthermore, the clinical standard for post-transplant assessment is
limited to whole lung measurement such as pulmonary functional tests (PFTs) and
structural imaging via radiography or HRCT, both of which lack the necessary sensitivity
to detect lung rejection early. Given these limitations of currently available pre- and posttransplant lung assessment tools, a novel metabolic biomarker may provide higher
sensitivity for determining the viability of donated lungs, as well as for assessing the onset
of rejection before permanent structural changes in the lungs become apparent. We
proposed that hyperpolarized (HP) [1-13C]pyruvate magnetic resonance imaging (MRI)—
which provides real-time metabolic assessment of tissue based on the conversion of [1vi

13

C] pyruvate to [1-13C]lactate via glycolysis, or to

13

C bicarbonate via oxidative

phosphorylation—may be an effective tool for assessing the health of donated lungs and
may also serve as an early biomarker for detecting pulmonary graft dysfunction (PGD)associated inflammation or acute lung rejection. In a rat model, we demonstrated the
feasibility of using HP [1-13C]pyruvate nuclear magnetic resonance (NMR) spectroscopy
to assess the viability of ex vivo perfused lungs. We further showed that our technique can
be used to measure the improved viability of those lungs after treatment with ascorbic
acid. Finally, translating our previously developed technique to in vivo HP [1-13C]pyruvate
imaging of an inflamed rat lung, we not only demonstrated its utility for detecting lung
transplantation rejection, but found that the HP lactate-to-pyruvate ratio is a better
predictor of acute lung rejection in a rat model than computed tomography.
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Chapter 1: The Current State of Lung Transplantation

Since the first successful long-term lung transplantation was carried out in 19831, it has
become the established treatment for patients with end-stage chronic lung disease.
Approximately 85% of worldwide lung transplantations are for performed for patients with
end-stage

chronic

obstructive

pulmonary

disease

(COPD),

pulmonary

arterial

hypertension (PAH), cystic fibrosis (CF) and interstitial lung diseases (ILD). Over the past
three decades, numerous improvements in both pre- and post-operative care2,3 have
dramatically increased survival rates across all diagnoses for which transplantation is a
viable option, ensuring significantly improved lung function and overall quality of life for
the majority of recipients4. This improvement is reflected by the increasing number of
transplants performed ever year: according to the most recently data published in 2016,
there has been a 40% increase in total transplants over the past ten years5.

Unfortunately, the long-term success rate of lung transplantation remains significantly
lower than that of other solid organs. For example, post-transplant survival is 80% at 1
year and 50% at 5.8 years for the lung5, compared to 97.3% and 90.4% survival rates at
1 year for kidney and liver, the two most commonly transplanted organs—both of which
have median survivals of approximately 10 years6,7.

The comparatively poor success rate of lung transplantation has two main causes. First,
the lung faces the highest oxidative stress of any organ due to the fact that it has two
separate blood supplies and is directly exposed to air8. Secondly, a majority of transplant
lungs are sourced after donor brain death (DBD), which is associated with disrupted
endocrine function as well as an increased level of pro-inflammatory factors that include
1

cytokines interleukin-8 (IL-8) and interleukin-6 (IL-6) and human leukocyte antigen-DR
(HLA-DR), all of which have been shown to be associated with the development of primary
graft dysfunction (PGD), the leading source of transplant failure in the first year postsurgery8,910. The DBD-associated inflammatory milieu has also been shown to play a role
in the development of both acute and chronic rejection11. As such, the best way to mitigate
these issues is to optimize methods of lung preservation before transplantation, and
monitor lungs for early detection of lung failure or rejection post-transplantation.

1.1. Modes of Transplant Failure
1.1.1. Primary Graft Dysfunction (PGD)
Primary graft dysfunction (PGD) is a is a syndrome characterized by hypoxemia and
diffuse radiographic opacities without any other differential diagnoses in the first 24 to 72
hours after lung transplantation9,12. The syndrome has also been characterized as early
graft dysfunction and is most likely due to ischemia-reperfusion injury8,13. PGD is
diagnosed on a severity grade from 0 to 3, based on the ratio of arterial fraction of oxygen
(PaO2)/fraction inspired oxygen (FiO2), as listed in Table 1.1.

Grade

PaO2/FiO2

Radiographic infiltrates
consistent with edema

0

> 300

Absent

1

> 300

Present

2

200-300

Present

3

< 200

Present

Table 1.1: Criteria for grading primary graft dysfunction severity.

Up to 30% of transplant recipients are diagnosed with PGD and it is the leading cause of
death within the first 30 days after transplantation9. The pathophysiology of PGD depends
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on a number of factors during the retrieval and transplantation process, the most important
of which may the conditioning and treatment of lungs acquired after DBD. As such, a
number of donor management strategies have been applied to minimize hemodynamic or
inflammatory injury to DBD lungs. For example, treatment with the a-adrenergic
antagonist phentolamine prevents DBD-induced systemic hypertension, which can cause
increased capillary permeability leading to neurogenic pulmonary edema (NPE), thereby
improving oxygenation and lowering airway pressure compared to untreated DBD lungs14.
Treatment with a vasopressor can block injuries to the donor lung resulting from
neurogenic hypotension, such as metabolic acidosis15–17. Additionally, glucocorticoids can
be used to improve oxygenation and ameliorate inflammatory response by preventing the
cortisol deficiency which often follows DBD18–20. Pre-treatment with antioxidants, such as
Vitamin C or ascorbic acid, has been shown to lower expression of pro-inflammatory
cytokines and protect against oxidative stress and microvascular dysfunction21–23. Less
interventional tactics have also proven effective: several studies suggest that delayed
organ retrieval partially reverses DBD-induced hemodynamic injury, improving lung
transplantation outcomes by allowing for a partial reversal of early hemodynamic injury
subsequent to DBD14,24,25.

Finally, ex-vivo lung perfusion (EVLP) has recently emerged as a valuable tool for both
evaluating and reconditioning lungs prior to transplant26,27. In addition to enabling the
reassessment of lungs initially deemed unsuitable, EVLP has demonstrated the potential
to improve graft viability by enabling alveolar recruitment maneuvers, helping to clear
bronchial secretions, removing both inflammatory cells and clots in pulmonary circulation,
and reducing the microbial load in donor lungs28,29. However, because EVLP itself carries
3

a number of risks—including increased vascular stress over time, metabolic alteration of
the perfused organ, and inflammatory upregulation—tailoring the combination of perfusion
time, perfusate flow, and perfusate formula to the needs of each individual organ is critical
to optimizing its successful use26,30,31. Unfortunately, non-invasive EVLP evaluation is
typically limited to measuring the PaO2/FiO2 to determine the status of the lungs32,33. An
imaging modality that can provide more direct assessment of the lung’s metabolic state
and viability would be a boon to improving these successful lung transplant outcomes.

1.1.2. Acute and Chronic Lung Rejection
Graft rejection is mediated by the adaptive immune system. Specifically, the recognition
of allogeneic major histocompatibility complex (MHC) by the host T cells activates the
adaptive immune system, stimulating cytotoxic T cells (CTL), as well as the humoral (via
stimulated B cells) and complement response34,35. The mainstay of preventing lung
rejection is the use of immunosuppressants that minimize the T-cell response posttransplantation. Immediately after transplantation, potent induction immunosuppressive
induction agents, such as basiliximab (IL-2 inhibitor) or alemtuzumab (CD52 antibody),
are administrated to deplete or inhibit T-cell activation and proliferation36–38. However, as
the use of these drugs severely depresses the immune system, their use has to be
balanced by the increased risks of infections. As the highest immune reactivity towards
the graft is within the first three to six months, after that period the immune suppression is
maintained by low doses of drugs with non-overlapping toxicities. Typically, a combination
of a glucocorticoid, calcineurin inhibitor, and a nucleotide blocking agent are prescribed
based on the recipient’s tolerance profile37,38.
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If no acute rejection occurs within the first few days to months, lungs can undergo rejection
via chronic lung allograft dysfunction (CLAD). CLAD presents as one of two phenotypes,
bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS)11. BOS is
the predominant presentation for CLAD and manifests as an obstructive lung disease with
fibrosis of the small airways. RAS, on the other hand, is characterized by restrictive
pulmonary function. Although the etiology of CLAD is not well defined, its risk factors
include PGD, acute rejection, infection and gastroesophageal reflux (GER)39. Despite the
multitude of factors that could lead to CLAD, monitoring is based pulmonary function
decline measured via pulmonary function testing (PFT) followed by chest radiography or
high resolution computed tomography (HRCT) to confirm any observed decline.

1.2. Limitations of Current Monitoring Techniques
Typically, patients are monitored post-transplantation with routine spirometry and chest
radiographs obtained at regular intervals. Postoperative lung function is considered to be
stabilized when the variation in the forced expiratory volume in one second (FEV1) and
the forced vital capacity (FVC) has a less than five percent variance between two
measurements taken at least one week apart40. A decline of greater than 10% in
spirometry values within two days can be a sign of either acute lung rejection or infection40–
42

so follow-up for serology testing, transbronchial biopsy or radiography is needed to rule

out differential diagnoses43. Furthermore, the sensitivity of spirometry is about 60 percent
in detecting lung rejection, so stable pulmonary function as measured doesn’t necessarily
exclude acute lung rejection44.

The diagnosis of chronic lung rejection is also based on PFT measurements. Early stage
BOS is defined as an FEV1 decline of more than 20% from baseline and/or forced
5

expiratory flow between 25 and 75 percent (FEF25-75) decline of more than 25% from
baseline39 in two consecutive measurements made at least three weeks apart. It is
recommended to acquire chest radiographs or high-resolution computed tomography
(HRCT) if such a decline is observed. However, chest radiographs have a low sensitivity
for detecting early stages of BOS, although hyperinflation and bronchiectasis can be
observed in more advanced disease45,46. Although there is no consensus definition of
RAS, patients with a FEV1 decline of greater than 20% and a forced vital capacity (FVC)
decline of greater than 20% or a total lung capacity (TLC) decline of greater than 10% are
given the diagnosis of the restrictive phenotype11,47,48. CT findings are recommended to
be followed by transbronchial biopsies to confirm a specific diagnosis49.

Given the limitations of the currently available tools for both pre-transplant and posttransplant lung assessment, perhaps a metabolic biomarker may provide higher sensitivity
than conventional tools for determining the viability of donated lungs, as well as assessing
the onset of rejection before permanent structural changes in the lungs become apparent.
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Chapter 2: An Introduction to Hyperpolarized Carbon-13 Magnetic Resonance
Imaging

Abstract
Until recently, molecular imaging using magnetic resonance (MR) has been limited by the
modality’s low sensitivity, especially with non-proton nuclei. The advent of hyperpolarized
(HP) MR overcomes this limitation by substantially enhancing the signal of certain
biologically important probes through a process known as external nuclear polarization,
enabling real-time assessment of tissue function and metabolism. The metabolic
information obtained by HP MR imaging holds significant promise in the clinic, where it
could play a critical role in disease diagnosis and therapeutic monitoring. This chapter will
provide a comprehensive overview of the developments made in the field of
hyperpolarized MR, including advancements in polarization techniques and delivery,
probe development, pulse sequence optimization, characterization of healthy and
diseased tissues, and the steps made towards clinical translation.

This chapter has been adapted from Siddiqui et al., ‘The use of hyperpolarized carbon-13 magnetic
resonance for molecular imaging’ published in Advanced Drug Delivery Reviews, Vol. 113:3-23.
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2.1. Introduction
Molecular imaging refers to a gamut of imaging modalities that—as succinctly defined by
the Radiological Society of North America (RSNA)—“directly or indirectly monitor or record
the spatiotemporal distribution of molecular or cellular processes for biochemical, biologic,
diagnostic, or therapeutic applications”1. Numerous modalities fit this description, most
prominently positron emission tomography (PET) and single photon emission computed
tomography (SPECT), both of which are commonly used in the clinic for diagnosing
various disorders and monitoring therapeutic response2. More recently, fluorescence and
bioluminescence optical imaging have allowed high-sensitivity molecular imaging in preclinical research, while computed tomography (CT)—traditionally considered a structural
imaging tool—is now being used as a molecular imaging modality with the advent of celland tissue-specific nanoparticles and as a combined modality with PET or SPECT3,4.

Clinical use of magnetic resonance imaging (MRI) has largely been limited to structural
assessment. However, proton (1H), sodium (23Na), phosphorus (31P), and carbon (13C)
MRI/ nuclear magnetic resonance (NMR) are extensively used as molecular imaging tools
in pre-clinical studies in animals and cells. In these studies, the modality’s foremost
limitation—its low sensitivity—can be overcome by the use of longer scan times and signal
averaging5–7. As such, molecular MRI/NMR using conventional thermally polarized nuclei
is limited to probing quasi-steady-state metabolism. The advent of hyperpolarized (HP)
MRI/NMR overcomes this limitation by substantially enhancing the signal of certain
biologically important probes through a process known as external nuclear polarization,
enabling real-time molecular imaging with unprecedented temporal resolution. The
information obtained by HP MR has significant promise in the clinic, where imaging12

derived metabolomics could play a critical role in disease diagnosis and therapeutic
monitoring.

Hyperpolarized MR is a burgeoning field in which investigators continue to make rapid
advancements in an array of areas, which include polarization techniques and delivery,
probe development, pulse sequence optimization, characterization of healthy and
diseased tissues, and clinical translation. In light of the rapidly changing and multifarious
nature of this technology, this review aims to provide a comprehensive overview of the
current state of molecular imaging using HP MR, the developments that have led to this
point, and the central challenges that hyperpolarized technology faces as it moves towards
making a clinical impact.

2.1.1. Molecular Imaging using Non-MR Modalities
Several well-established molecular imaging techniques are actively used in basic and
clinical research. This section describes applications of each technology, their advantages
and limitations, and how they differ from HP MRI/NMR.

2.1.2. PET and SPECT
Positron emission tomography (PET) and single photon emission computed tomography
(SPECT) use radioactively labeled metabolic tracers (e.g., 18F-FDG,) to probe the cellular
uptake of their analogous biologically relevant molecules (e.g., glucose). Both techniques
are widely used in clinical2,8,9 and pre-clinical10–13 scenarios for a broad range of
applications including, but not limited to, the diagnosis, staging, and monitoring of a variety
of

cancers14–18,

drug

development—e.g., probing

pharmaceuticals19— and neuroimaging20.
13

the

bio-distribution of

new

Although PET and SPECT provide high sensitivity for detection, they suffer from poor
spatial resolution4,21. As a result CT or MRI are used for accurate reconstruction and
anatomical localization of tracers22. Another major shortcoming of both modalities is that
they are limited to revealing abnormalities in the uptake or retention of the tracers; they
are unable to reveal changes in downstream metabolites that may be crucial to the
diagnosis and staging of diseases.

On the other hand, hyperpolarized MRI—which probes analogous pathways to PET—
highlights alterations in downstream metabolites using their unique 13C NMR resonance
frequencies, thus providing non-invasive interrogation of the size of metabolite pools and
the flux through their corresponding pathways23. However, unlike PET and SPECT,
absolute quantification of HP MR substrates can be challenging due to variations in
polarization level and the use of super physiological concentrations of administered
agents24. Furthermore, despite the large signal gains achieved using hyperpolarization,
the near-unity photon detection efficiency of radionuclide agents is not achievable.
Nevertheless, hyperpolarized probes can provide complementary imaging information that
address the same diagnostic imaging goals as PET and SPECT.

2.1.3. Fluorescence and Bioluminescence Tomography
Optical tomography is widely used for the preclinical study of biology and pathology. The
major optical techniques, fluorescence and bioluminescence tomography, are based on
different underlying mechanisms, but have similar applications and limitations.
Fluorescence tomography uses injected or genetically inserted dyes and proteins which
fluoresce at different wavelengths than normal tissue to tag specific cells or molecules and
14

track their distribution, while bioluminescence tomography utilizes the intrinsic light
emission of select molecules to similar effect4,25. In the latter case, light is produced when
the light emitting pigment luciferin is catalyzed by the enzyme luciferase, which is
produced by genetically modified cells that synthesize the enzyme.

Optical imaging benefits from minimal background tissue radiation and high photon
detection efficiency, and therefore generally has an excellent signal-to-noise (SNR). Both
modalities offer spatial resolution of approximately 2-3mm. However, the need for genetic
modification of the cells to allow targeted molecular imaging limits their use within human
patients; this is particularly an issue with bioluminescence imaging. Additionally, optical
techniques suffer from low tissue penetrance and the related need for a high concentration
of imaging agent to successfully perform studies of deeper tissue. There has recently been
an interest in using fluorescent probes in applications that circumvent this limitation, such
as for more accurate identification of malignancies during surgical resection26. While PET
and hyperpolarized MRI interrogate analogous pathways, those targeted by optical
imaging are typically very different, and as such the modality can provide distinct and
perhaps complementary molecular information to the former two modalities.

2.1.4. Computed Tomography
Computed tomography (CT) has not traditionally been considered as a molecular imaging
technique. However, recent developments in nanoparticle-bound contrast agents (CAs)
have allowed for selective imaging of specific cell tissues and molecules using CT.
Iodinated nanoparticles, for example, can change the biodistribution of the iodine upon
injection depending on the characteristics of the nanoparticle. This method has shown
promise both in improving upon traditional CAs in blood pool imaging and in specifically
15

labeling certain cell types in various applications including studying angiogenesis in tumor
growth and response to therapy27–31. Iodinated nanoparticles have also been labeled with
antibodies to increase their molecular specificity to probe expression of particular
proteins32. Gold nanoparticles have also become popular due to their easy synthesis and
low toxicity33. These particles have also shown promise in vascular imaging, tumor
imaging, and bone tissue damage imaging3,34–37.

Nanoparticle based CAs are an area of interest for industry due to the wide availability of
clinical CT machines, and there are currently several clinical trials examining the safety of
gold nanoparticle based contrast agents38. Although the use of iodine and gold
nanoparticles is promising in molecular imaging, their primary role seems to be to provide
better structural contrast and anatomic localization by targeting specific proteins or cell
markers, as opposed to deriving metabolic or functional information. Furthermore, ionizing
radiation remains a fundamental limitation of this technology when used for clinical
studies.

2.2. Hyperpolarized MRI
Hyperpolarization refers to a process in which certain nuclei are aligned to a degree many
orders of magnitude greater than is normally achievable under in vivo conditions. This
leads to a magnetic resonance signal that greatly exceeds that which is otherwise
available and makes qualitatively different applications possible, including imaging of
gases and low-concentration biological molecules. If the non-equilibrium hyperpolarized
state is to be useful for medical imaging, the alignment must persist long enough for the
substance to be administered, arrive at the target organ or system, and perhaps be taken
into cells and/or metabolized. Typically, the persistent state can be achieved only if several
16

conditions are met. First, the nuclei must be what is known as “spin-½”. Spin-½ nuclei
have two distinct quantum states of orientation with respect to a magnetic field; all other
classes of nuclei either have no magnetic moment (and are therefore invisible in MRI) or
are susceptible to rapid reorientation by the large electric field gradients present in
molecules and during atomic or molecular collisions. Second, the nuclei must be relatively
segregated from all other magnetic moments, including unpaired electrons or magnetic
nuclei on the same molecule. Third, any residual magnetic interactions with the nucleus
to be hyperpolarized must be limited in duration or frequently randomized in direction,
again in order to prevent loss of alignment in an extended nuclear precession around the
depolarizing field.

As a practical matter, this limits hyperpolarization with biological applications to a few
nuclear species that are found in in vivo (13C,

15

N,

some molecules that are not acutely toxic (19F,

31

P and potentially 1H), those found in

29

Si) and the two biologically inert gases

3

He and 129Xe. Of these, the gases have been used primarily for imaging of lung function,

although molecular biosensors and imaging agents based on 129Xe have been proposed.
Agents based on the other nuclei (primarily

13

C) have been studied more extensively in

molecular imaging applications.

Two straightforward methods have been developed for transferring polarization from light
to atomic nuclei, and have been used extensively for atomic gases39,40. Unfortunately,
these techniques are not applicable to molecules41. This is primarily because the strong
coupling between coherent rotational motion and nuclear spins cases rapid loss of spin
alignment, but practical issues of chemical reactivity and short-lived electronic excited
states are also difficult to overcome. There are two alternative approaches, however, that
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can lead to polarization of order unity of selected nuclei in biologically active compounds.
These methods are dynamic nuclear polarization (DNP), and parahydrogen-induced
polarization (PHIP).

2.2.1. Dynamic Nuclear Polarization (DNP)
DNP refers to a process in which the alignment of an unpaired electron is achieved at
thermal equilibrium, and this alignment is transferred to a nearby nucleus via a process
analogous to the Overhauser effect42,43. In order to prepare a sample suitable for DNP,
the molecule of interest is mixed with a small amount (1 part in 100 or less) of stable free
radical that supplies the unpaired electron spin. This mixture is then placed in conditions
of reduced temperature and elevated magnetic field sufficient to achieve near-complete
electron alignment; as a rule of thumb, the magnetic field (in Tesla) divided by the sample
temperature (in Kelvin) must be approximately 1 to achieve full alignment. As an intimate
mixture of radical and target molecule is necessary for spin order transfer, and favorable
DNP conditions generally imply a frozen sample, additional components may be required
to assure a homogeneous (glassed) mixture 44.

The transfer of polarization from electron to nucleus is accomplished by means of a
microwave driving field tuned near the resonance frequency of the free electron in the
chosen magnetic field. The mechanism of polarization transfer is complex and may differ
between samples; however, the electron-nuclear interaction is typically described as one
of three processes: the solid effect, the cross effect, and thermal mixing. The solid effect
refers to a mechanism in which two closely-spaced magnetic dipoles, one electron and
one nucleus, simultaneously invert orientations with respect to the field. Because the vast
majority of electrons are aligned, this results in the net polarization of the nuclear
18

ensemble. This process is greatly suppressed by the large energy difference between
electronic and nuclear Zeeman transitions, and is only relevant because of the very large
number of coupled electron and nuclear pairs available in the sample. The cross effect
refers to a related process in which one nucleus and two electrons, differing in frequency
by approximately the nuclear Zeeman frequency, are excited simultaneously. Because
this process is nearly energy-conserving, it is resonant over a duration consistent with
typical solid state electron-nuclear couplings and is therefore quite rapid. However, the
number of coupled three-spin systems with the appropriate resonance frequencies is
relatively small; the relative contribution of solid effect and cross effect polarization is
therefore dependent on the details of the sample’s frozen state and external conditions
such as temperature and magnetic field45,46.

Under hyperpolarization conditions useful for molecular imaging studies, the distinction
between the above two processes (and those involving more electrons) is obscured by
the strong couplings between closely-spaced radical molecules. The polarization process
is therefore best described by thermodynamic state transitions in the band-like electron
system and couplings to the nuclear system. Incorporating aspects of the other two
processes, this theory is termed thermal mixing. Although lacking an intuitive, conceptual
explanation, the theory is well-established and successful, and is described in detail in the
literature45,47,48.

2.2.2. Practical Aspects of DNP for Biomolecules
In choosing appropriate conditions for efficient DNP, it is important to consider the
magnetic properties of the molecule to be polarized. Small biological molecules typically
consist of carbon, oxygen and hydrogen, often contain nitrogen, and sometimes contain
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other elements (e.g., phosphorus or iron). As a general rule, a nucleus that is suitable for
hyperpolarization is spin-½ (to eliminate rapid loss of alignment due to electric field
gradients)49 and is distant from other magnetic nuclei. The latter consideration is
necessary to avoid loss of alignment due to strong magnetic interactions in solution, and
as it is usually impossible to eliminate all intramolecular magnetism, small molecules (in
which interactions change direction frequently due to molecular reorientation) are more
successful than large ones. Taken together, these characteristics of polarizable nuclei
have suggested use of the spin-½ isotope

13

C, as it can be incorporated into nearly all

biomolecules in the magnetically isolated carbonyl, quaternary and carboxylic acid forms.
Small carboxylic acids in particular are near-ubiquitous as TCA cycle intermediates, amino
acids and in many other biologically central functions. For this reason, nearly all of the in
vitro and in vivo work described in this review makes use of this class of molecules.

Suitability of a molecule for hyperpolarization by DNP is also determined by the physical
properties of the bulk or dissolved compound. Because the process takes place at
cryogenic temperatures, all molecules of interest are in the solid phase; however, the
intimate radical/biomolecule mixture necessary is best achieved through dissolution in the
liquid. Substances that are gases at room temperature must be cooled or pressurized
before mixture, and those that are solids must be co-dissolved with the radical in a suitable
solvent. Furthermore, the tendency of many solutions to segregate upon freezing must be
avoided, typically by transitioning past the freezing temperature very quickly, and in many
cases including a ‘glassing agent’ in solutions that would otherwise crystalize.

Many molecules of interest, particularly those with hydrophobic regions, are sufficiently
insoluble in water that the sample to be hyperpolarized must also include additional
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ingredients to facilitate increased concentration. Thus, although some general strategies
are useful in classes of similar molecules, each sample preparation is somewhat individual
and is optimized experimentally. A detailed discussion of this process is beyond the scope
of this article, but it is described in detail in an excellent review

50

. It is worth noting that

one compound, pyruvic acid, is highly favorable from all of the above points of view; it is
a small (a three-carbon chain, molecular weight 88 Da) carboxylic acid, when 13C-labeled
in the 1 position the nucleus is remarkably isolated (the nearest magnetic nucleus is three
bonds away) such that relaxation of the hyperpolarized state is slow51, the neat acid is
liquid at room temperature and glasses without additional ingredients when frozen.
Furthermore, pyruvate is metabolized rapidly by most cells, and the metabolic fate is
indicative of cellular redox state and other biologically important factors. As is apparent in
subsequent sections of this article, this fortuitous set of circumstances has led to
pyruvate’s central role in the development of hyperpolarized agents.

The final aspect of DNP hyperpolarization under the user’s control is the choice of radical
species. In the development of the technology, several types of radical were explored,
with considerable attention paid to nitroxide moieties and those derived from the
triphenylmethyl (trityl) radical. In progressing to in vivo and human applications, the latter
has become very commonly used, because it has the long electron T1 and narrow
linewidth required to facilitate high polarization under the conditions of low temperature
and moderate microwave power used in commercial instruments. A hydrophilic derivative,
termed ‘OX063’ is widely used for pyruvate and similarly hydrophilic substrates52. A slightly
modified version, known as ‘AH111501’ or simply ‘EPA’ (for Electron Paramagnetic
Agent), is used in human studies due to the ease with which it can be removed at acidic
pH by simple filtration53. Other substrate species, including those with hydrophobic
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properties, are best polarized by other trityl derivatives with less polar functional groups,
such as the acidified Finland species successfully used for DNP of frozen Xenon54.

However, a wide variety of other radicals, including those with similar electronic properties,
may be suitable as well. Radicals derived from BDPA have been shown to behave similarly
to the trityl family52,55 and may be synthesized in a more straightforward manner56.
Nitrioxide radicals (eg., TEMPO52) are well suited to higher temperature DNP and
hyperpolarization of hydrogen, including that of water57–59. A variety of biradical species
have been explored, with the hope of maximizing the cross effect60–62 with judicious
chemical shift and coupling values. In pyruvate, there has even been exploration of
metastable radical species induced in the frozen pyruvate sample itself by ultraviolet
light63. Although as yet not consistent with the high polarization required for effective in
vivo use, such a strategy is very appealing as no additional species are required for DNP.

A few other experimental details have been found to affect the signal level or utility of
DNP-derived hyperpolarized species; we mention these here and leave the details to the
referenced literature. Inclusion of small concentrations of Gd chelates in the sample has
been shown in increase polarization substantially, perhaps through its effect on radical
electron T164, although the potential for accelerated loss of polarization after dissolution
must be considered65. The dependence of polarization on magnetic field and temperature
have been explored as well, with the finding that lower temperature and higher field, while
more technically challenging, yield generally superior results but require longer
polarization times (typical small molecules can take anywhere from less than an hour to
several hours to achieve maximum polarization at 1.4K and 3.3T)66,67. This is not found to
be true in all systems, however. Finally, certain hyperpolarized nuclei, especially those
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neighboring a nitrogen atom, require transport at elevated magnetic field to avoid
substantial loss of polarization68.

2.2.3. Parahydrogen-Induced Polarization (PHIP)
Two alternate method for liquid state sample hyperpolarization exist, termed Chemically
Induced Dynamic Nuclear Polarization (CIDNP)69,70

and Parahydrogen-Induced

Polarization (PHIP)71,72. The former mechanism is based on a nuclear state dependence
of the recombination rates of optically generated radicals; although it remains an active
research area 50 years after its discovery, the level of polarization achieved and the
diversity of target compounds are not yet such that in vivo or clinical molecular imaging
applications can be considered. Compounds polarized using parahydrogen, on the other
hand, have been used successfully in cell and animal studies73–75. Although recent efforts
have been made to design an open-source PHIP polarizer76, in general the adoption of
PHIP techniques currently lags behind DNP because of the lack of commercial
instruments, difficulties polarizing small metabolic compounds because of the required
chemical reaction, and the lack of development in ensuring a pure and safe end-product.
Nonetheless, the method has fundamental advantages with respect to production rate and
cost that may justify more widespread use in the near future.

Parahydrogen is the nuclear singlet state of hydrogen gas. Although not hyperpolarized,
the gas contains a large degree of nuclear spin order and is easily produced at modestly
reduced temperature through contact with a microscopically heterogeneous magnetic
substance77,78. After undergoing a catalyst-mediated, pairwise addition to an unsaturated
substrate, this spin order often persists to a large degree. Subsequent application of a
specialized NMR pulse sequence, analogous to the commonly-used INEPT polarization
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transfer technique79, results in near-unity transfer of spin order to hyperpolarization of a
nearby 13C 80–83. Alternately, in a process called field cycling, the transfer may be effected
by reducing the magnetic field such that the chemical shift difference approximates the
internuclear scalar couplings84,85. In either case, a level of polarization approaching or
even exceeding that which is achievable using DNP86 has led to the most detailed solution
state hyperpolarized images produced to date74,84.

Use in metabolic imaging, however, has been limited by the need for an unsaturated
precursor of the agent of interest. In many cases this precursor does not exist or is not
stable. Even in cases where a suitable precursor exists (e.g., for pyruvate or acetate), care
must be taken to ensure that only the desired hydrogenation end-product is produced87–
89

. Furthermore, the couplings between the nucleus to be hyperpolarized and the para

proton pair must differ by an amount that is large compared to other couplings to the target
nucleus90. These requirements can generally be addressed by careful choice of reaction
conditions and catalyst and by replacing nearby hydrogen by deuterium (or as appropriate,
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nitrogen by the less magnetic 15N). Details of the experimental design and catalyst choice

can be found in the referenced literature, but we note that most experimenters have made
use of a homogeneous Rh-based bis-phosphene catalyst75,86,87,91, a plunging liquid jet
reactor 92 in an ambient parahydrogen atmosphere of several bar, and somewhat elevated
temperature (to speed the hydrogenation reaction)86,93,94. More recently, PHIP using a
heterogeneous phase catalyst—consisting of platinum nanoparticles capped with
glutathione ligands—was demonstrated, enabling easier removal of the toxic catalyst, a
necessity for clinical imaging95.
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Although not significantly metabolized in vivo, the first biomedical application of PHIP
agents utilized hydroxyethyl propionate as an angiography or perfusion measurement
agent74,84. Use in molecular imaging was first demonstrated using succinate or its
esters75,96,97, which are two-step hydrogenation products of acetylene dicarboxylate.
Phospholactate has also been efficiently polarized using this method87, although biological
activity has not yet been shown.

Two important modifications to this basic scheme have been introduced recently, and
each has the potential to dramatically improve the PHIP process’ flexibility and its utility in
imaging. Reineiri et al. introduced a method to overcome the lack of suitable precursors
for pyruvate and acetate88. In this scheme, an allyl or vinyl ester of the target molecule is
para-hydrogenated, and the polarization transfer sequence operates over the ester bond
to hyperpolarize the labeled carboxyl carbon. Finally, the ester is hydrolyzed, yielding a
mixture of the hyperpolarized target and ethyl or propyl alcohol. In addition to allowing
PHIP of pyruvate, this recipe may be generally applicable to carboxylic acids, greatly
increasing the biological uses of PHIP.

Another novel technique was recently introduced by Adams et al.98, in which the spin order
of parahydrogen is transferred to a target molecule during the residence time of a shortlived, catalyst-mediated complex. This method, termed ‘NMR Signal Amplification by
Reversible Exchange’, or NMR-SABRE, has two significant advantages over traditional
PHIP. First, the need for an unsaturated precursor is relaxed in that no permanent
chemical modification of the target molecule occurs. This simplifies synthetic requirements
while broadening the set of candidate compounds. Second, the same solution may be
repolarized at will, subject only to availability of parahydrogen and catalyst spoiling.
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SABRE-polarized compounds have not yet been used in vivo for metabolic imaging, and
isolation of the target compound remains a technical challenge. Nonetheless, these
advantages (in addition to the low cost and ~1s polarization time characteristic of PHIP)
suggest a variety of very useful applications in the near future.

2.3. Hyperpolarized MRI Acquisition Techniques
2.3.1. Hardware and Equipment
The most important development in the field of DNP was the development of a fast
dissolution method that rapidly melted the frozen polarized sample with minimal loss of
polarization into a liquid state that could then be quickly delivered to an animal or specimen
in the imaging magnet99,100. This is accomplished by flushing the frozen sample with the
dissolution solvent at high pressure (~10 bar) and temperature (~ 180 oC). The most
commonly used DNP polarizer that uses this dissolution method is the commercially
available Hypersense polarizer (Oxford Instruments, United Kingdom). Generally it can
polarize up to ~200 µL of sample, limiting its use to studies in small animals. More recently,
a larger commercially-available polarizer—SpinLab (General Electric)—was developed
with a much greater throughput (4 simultaneous samples of volume greater than 1mL),
enabling HP imaging in large animals and humans101,102.

The gyromagnetic ratio of

C (gC) is approximately four times smaller than that of the

13

proton. As such, the MR system must be equipped with a broadband RF amplifier to
transmit and receive the NMR signal for multinuclear spectroscopy and imaging. This
option is available for many clinical and preclinical scanners. Additionally, the MR system
needs to be equipped with transmit/receive coils tuned to the proper frequency. For
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hyperpolarized

13

C studies, surface coils103 have been commonly used for many

applications including cardiac104, brain105 and subcutaneous tumor106,107 imaging and
spectroscopy. The key advantage of surface coils is their superior sensitivity over a small
region-of-interest. However, surface coils suffer from poor B1 homogeneity and sensitivity
profiles. Alternatively, a setup consisting of a volume transmit, surface receive coil can be
used for homogenous power transmission101. Volume transmit/receive coils offer superior
field homogeneity on both transmit/receive ends and, as such, are well suited for imaging
the larger regions of interest typically used in abdominal and thoracic applications108,109.
For small animal and perfused cell applications, cryocoils have shown to improve the SNR,
although the degree of improvement is difficult to determine with certainty109,110; imaging
researchers have reported SNR increases of 4-7 at 9.4T, consistent with theoretical
considerations under low-loading conditions109. Utility of the cryocoils is limited due to high
cost and diminishing gains for larger animals and humans, in which body noise typically
dominates.

2.3.2. Pulse Sequence and Imaging Considerations
Although hyperpolarization dramatically increases the initially available signal amplitudes,
the MR data acquisition is highly affected by irreversible signal losses caused by T1
relaxation back to thermal equilibrium and RF pulse excitations. This limits signal
availability to only a brief period after introduction of the agent. Thus, the timing of the data
acquisition is of key importance in order to obtain metabolite images with maximum signalto-noise. For many hyperpolarized substrates, a 25-second delay from the start of the
injection has been found to be appropriate as it approximately corresponds to the time of
peak amplitude for the downstream metabolites (Figure 2.1)111. Accounting for signal
dynamics is also important because for the image reconstruction it is typically assumed
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that the longitudinal magnetization is in steady state for each excitation; departure from
this condition can introduce image artifacts or blurring. Variable flip-angle strategies have
been proposed to ameliorate this problem, in which the flip angle is increased with each
excitation to compensate for the reduction in available longitudinal magnetization. The
goal of this strategy is to maintain a constant transverse magnetization throughout the
image acquisition111. This approach requires accurate calibration of the coil’s RF power,
which is typically done by placing a labeled 13C phantom inside the coil next to the subject
prior to administration of the hyperpolarized agent. Ideally, the coil’s B1 map should also
be obtained and incorporated into the reconstruction to improve image fidelity108,112. This
is particularly important when single-channel receive surface coils or multichannel phasedarray receive coils are used for parallel imaging. More difficult to deal with is the potential
for severe flow artifacts due to the presence of high concentrations of the administered
hyperpolarized agent in the blood pool. Recently, a pair of symmetric flow-sensitizing
gradients have been added to imaging pulse sequences in applications such as cardiac
and abdominal imaging to suppress image artifacts caused by rapidly flowing blood and
thereby improve the accuracy of the spatial information113,114.
In order to address these challenges and limitations, many pulse sequences have been
designed and implemented over the past few years that offer significant improvements
with respect to standard gradient echo or spin echo schemes. This has been possible by
exploiting the long T2 and T2* relaxation times of

13

C species in almost all organs74,115–118

as well as the sparse nature of the NMR spectrum in which chemical shifts of the

13

C

species of interest span a wide range of the NMR spectrum (~100ppm)119. The most
desirable imaging pulse sequences achieve superior spatial coverage as well as high
temporal resolution while providing three dimensional dynamic spectroscopic data for
accurate and meaningful measurement of cellularity and metabolic pathways.
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Figure 2.1: Signal-time courses of multiple metabolites derived from dynamic HP [1-13C]pyruvate
spectroscopy in a rat. The boxed regions specify the time window for a 17-s CSI acquisition at the
following time delays: 15 s, 25 s, and 35 s. The choice of delay determines the best SNR for the
metabolites of interest. The insert shows a waterfall plot of the different metabolite peaks:
bicarbonate, pyruvate, alanine, pyruvate-hydrate, and lactate (from left to right). Each spectrum
was acquired every 3 s. Reproduced from Ref.111 (License Number #4556230568265).

2.3.3. Global and Local Spectroscopy
The most basic pulse sequence used for hyperpolarized

13

C spectroscopy is the

nonselective pulse-and-acquire sequence used to assess the time-course of the agent
and metabolites within the detection volume of the RF coil120. This pulse sequence is ideal
for applications such as the study of perfused organs and cells104,121,122 where changes in
flux and pool size of metabolites are being investigated. Spatial selectivity can be
incorporated by adding slice selection over a region of interest. This method is useful for
organ-specific applications123,124 as well as tumor xenografts106,107. Other methods with 3D
localization have been subsequently introduced including a Point RESolved Spectroscopy
(PRESS) pulse sequence with a slice-selective 90° RF excitation pulse followed by two
refocusing pulse pairs along the other axes116.

29

2.3.4. Multi-echo Approaches to Chemical Shift Imaging
Single-point chemical shift imaging (CSI) that uses one RF excitation per sampled FID
has been used most frequently for generating maps of individual metabolites120. However,
it suffers from a long acquisition time (typically on the order of 10-20 s for a single slice
with a 16x16 matrix size and 256 RF excitations). In hyperpolarized imaging, this
necessitates the use of a low flip-angle which carries a significant signal-to-noise penalty.
However, due to its simplicity and availability on most clinical and preclinical MR scanners,
single-point CSI sequence is still a popular pulse sequence102. Furthermore, its simplicity
makes CSI relatively immune to artifacts; thus, even if higher resolutions or faster
acquisitions can be achieved using other methods, single-point CSI can yield wellunderstood reference images for validation.

Alternatively, the long T2 relaxation time of 13C allows for a long readout duration, during
which multiple echoes can be generated and spatially or spectrally encoded to reduce the
acquisition time. Echo-planar Spectroscopy Imaging (EPSI) sequences125 have been
extensively used to image hyperpolarized

13

C metabolites. In these schemes, each

readout is used to spatially encode the data while the accumulated phase between
acquisitions associated with the chemical shift, which is not refocused by symmetric
gradients, is used to encode the frequency information. Spatial encoding in this manner
reduces the number of excitations significantly when compared to the single-point CSI
sequence. For instance, a 16x16 single-slice image can be acquired using only 16 RF
excitations, drastically reducing the total imaging time and permitting the application of
higher flip angles. These improvements have allowed practical use of a 3D implementation
of the sequence126. Further improvements to spectral information quality were found when
using a double spin-echo implementation of EPSI127. This modified sequence has been
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used in many studies, including the first human studies of prostate cancer101. Multi-echo
spiral readout trajectories with multiple interleaves have also been demonstrated for
dynamic two-dimensional128,129 and volumetric imaging105. When compared to the
Cartesian echo-planar spectroscopic read-out trajectories, spatial encoding can be
performed more efficiently using a spiral readout trajectory. Additionally, spiral trajectories
are less sensitive to motion artifacts, making them very robust for cardiac applications.
Recently a concentric ring readout trajectory was introduced as another alternative to the
echo-planar readout trajectory130. This scheme can be easily combined with parallel
imaging for further acceleration, while offering improved acquisition speed and robustness
to flow artifacts with respect to the echo-planar readout.

Instead of using phase evolution over multiple echoes to encode chemical shift
information, it is also possible to use a least-square algorithm to iteratively decompose
different chemical shift components of the NMR spectrum. This method, also known as
Iterative Decomposition of water and fat with echo Asymmetry and Least square
estimation (IDEAL) obtains spectral information by shifting the echo time (TE)131. The
method is used extensively for selective imaging of water and fat in proton MRI; however
it can be extended to a larger number of resonance frequencies if at least as many echoes
are acquired as there are spectral peaks132. The reconstruction requires fewer echoes
than an EPSI sequence but it demands prior knowledge of the location of the peaks in the
NMR spectrum and a B0 map to successfully separate the individual frequency
components. The method has been successfully used with Cartesian trajectory gradient
echo sequences for two-dimensional133 and three-dimensional134 single time-point
imaging, spiral135 and Echo-Planar Imaging (EPI) readout trajectories136 for 2D dynamic
imaging, and as a single-shot spin-echo sequence with multiple Cartesian readouts120 for
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high resolution two-dimensional imaging. The latter approach showed an over 30-fold
reduction in imaging time compared to a conventional single-point CSI sequence.

2.3.5. Spatial-Spectral Excitation for Chemical Shift Imaging
A completely different approach is to exploit a sufficiently large chemical shift separation
between peaks to selectively excite individual metabolites. The advantage of this
approach is that it eliminates the need to spectrally encode the NMR signal, thereby
reducing the total imaging time and potentially offering higher signal-to-noise136. It can also
facilitate efficient time-resolved imaging126 in dynamic applications and in studies requiring
triggering such as cardiac imaging112. Spatial spectral (SPSP) excitation is achieved by
using composite pulses consisting of multiple lobes of short RF excitations accompanied
by time-varying gradients (typically an echo planar gradient waveform). Spatial selectivity
is determined by the shape of each RF pulse lobe, while spectral selectivity depends on
the envelope of all the lobes. With a priori knowledge of the underlying spectrum, SPSP
RF pulses can be optimized for hyperpolarized

13

C MRI to achieve superior spectral

selectivity and minimal duration. Multiband RF pulses can also be designed to excite each
metabolite with a different flip angle. This technique increases both signal longevity and
metabolite SNR137–140. SPSP RF pulses can be accompanied by the appropriate EPI
readout strategy to support two-dimensional136,141 and three-dimensional126,142 timeresolved imaging, or by a spiral readout for multiline cardiac imaging112, three-dimensional
imaging143 and time-resolved three-dimensional imaging of tumors144. The latter sequence
generates high-resolution metabolite images with a single SPSP excitation pulse
combined with a three-dimensional partial k-space spiral readout over multiple echoes
generated via double spin-echoes, yielding a 2-second temporal resolution. The pulse
sequence diagram is shown in Figure 2.2. Such RF pulses can be used for outer volume
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suppression in in vivo organ-specific spectroscopy145 or with multi-echo approaches, such
as the EPSI sequence for dynamic imaging136,137.

Figure 2.2: A (A) single shot three-dimensional double spin echo pulse sequence and its (B) 3D
k-space trajectory. The k-space was acquired as a stack of interleaved spirals. Specific
metabolites were excited via a spectral-spatial pulse. Reproduced from Ref.146 (Re-used under
CC-BY-4.0).

2.3.6. Other Approaches to Chemical Shift Imaging
Given the large chemical shift separation between the

13

C species, the chemical shift

displacement artifact (CSDA) can be exploited to acquire images of the individual
metabolites in a single acquisition. Several studies have demonstrated this approach for
gradient echo sequences with Cartesian readout trajectories147,148 in which the chemical
shift separation between all peaks relative to the acquisition bandwidth is sufficiently large
for complete spatial separation of their corresponding images. Alternatively, the severe
smearing artifact of off-resonance peaks when using radial149 and spiral150 readout
trajectories can be exploited to reconstruct images of a single resonance. While this
approach provides images of all metabolites simultaneously, it can suffer from blurring if
the T2* is shorter than the duration of the readout gradient. Thus, the approach constitutes
a tradeoff; progressively lower bandwidth provides superior peak separation, but requires
longer gradient durations with the potential for increased blurring.
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CSDA can also be used along the slice selection orientation by using a small bandwidth
frequency selective RF pulse excitation such that the displaced excitation band of the nondesired metabolites shifts outside of the coil146. This approach has advantages over SPSP
RF pulses due its simplicity, but provides limited slice selection accuracy and the geometry
of the coil and the subject size limits the imaging parameters.

2.3.7. Perfusion Imaging
Imaging of perfusion (non-metabolized) agents is generally much less sophisticated than
chemical shift imaging because it does not require spectral encoding. As such, single-shot
Fast Spin Echo (FSE)118 or balanced Stead-State Free Precession (bSSFP) sequences
are capable of producing high-resolution multiline or three-dimensional time-resolved
images for the quantification of organ perfusion and blood flow74,115,117,147,151. Multivalent
perfusion imaging152 or simultaneous perfusion and metabolic imaging113,153 can be
performed as well, as long as some form of spectral encoding is included as discussed
above.

2.3.8. Accelerated Imaging
Parallel imaging has been shown to yield significant reductions in acquisition speed and
generally does not carry the signal-to-noise penalty that is observed in traditional 1H
MRI130,154,155. Another approach is to implement compressed sensing into the imaging
sequence to exploit the sparsity of the NMR spectrum. Compressed sensing has been
combined with single-point CSI156, three-dimensional EPI with SPSP excitation157, EPSI
and multiband SPSP excitation158. Up to a 7-fold reduction in acquisition time has been
achieved, allowing efficient time-resolved, three-dimensional imaging.
34

2.3.9. Quantification Methods
Quantification of HP data is not straightforward because, unlike with other modalities, the
signal is not directly proportional to the concentration of the imaging agent or metabolite,
and methods for absolute calibration have not been developed. Most studies to date have
evaluated the data using one of two divergent methods: through quantification of signal
ratios or by deriving fitting parameters from a kinetic model. Relative quantification
typically reports the metabolite signal (area under the curve) normalized by either the
delivered HP probe's signal, or the total carbon metabolite signal159–162. The advantage of
this method is that it is trivial to perform, but it limits a direct comparison between studies
because the normalization does not explicitly account for the delivered probe
concentration, transport mechanics, T1 or RF-induced relaxation or other sources of signal
variation.

The second approach generates kinetic parameters (enzyme kinetic rate constants) by
fitting HP data to a set of differential equations that model the HP label exchange between
the injected probe and converted metabolites. The most commonly used model is the twosite exchange model106, although there are a number of other models and analysis
techniques that vary in complexity163–165. Deriving parameters from a fitted model has the
advantage that it reflects a physical value (i.e., the rate constants) that can be compared
to other studies. However, the generalizability of the results is limited by the constraints of
the chosen model, and thus are in most cases more accurately described as apparent rate
constants. Currently, there is no consensus on the ideal model that is applicable to all HP
MRI/NMR studies, but development of such a model is necessitated by the current push
towards clinical imaging24.
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2.4. Hyperpolarized Probes Used for Metabolic Studies
A number of different probes have been successfully polarized over the years for their use
in biological studies. As described in sections 3.2 and 3.3, the ideal probes are small,
mobile molecules that have a relatively long T1 relaxation time. Furthermore, a probe that
is used for metabolic or functional imaging must also be metabolically relevant in the organ
or tissue of interest. This section highlights the HP 13C probes that have been most actively
used in metabolic studies due to their ubiquity in the metabolism of many different tissues,
or their specific applicability to assessing the tissue's state.

2.4.1. [1-13C]Pyruvate
As alluded to in the earlier sections, the most widely used hyperpolarized DNP probe is
[1-13C]pyruvate. Its physical characteristics make it an ideal probe for DNP. The labeled
carbon is a carbonyl that is three bonds away from other magnetic species, minimizing
dipolar coupling. As a small molecule, it also has low correlation times (τC), resulting in
longer T1 than larger molecules. As a carboxylate, it also has high aqueous solubility.
These favorable physical properties enable high polarization (up to 60% polarization
reported) and long T1 of 40-60s24,166. Moreover, biologically, pyruvate is an intermediate
in several key metabolic pathways. Together, these physical and biological properties
make [1-13C]pyruvate perhaps the most attractive HP imaging probe.

Pyruvate is a downstream product of glycolysis, and serves as a key intermediate in
several metabolic pathways (Figure 2.3). It rapidly and reversibly catalyzes to lactate via
the enzyme lactate dehydrogenase (LDH)167. Physiologically, conversion of pyruvate to
lactate is determined by LDH activity and the ratio of NADH to NAD+
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168

. However, this

does not imply that the HP [1-13C]lactate signal detected after HP [1-13C]pyruvate
administration represents net conversion of the substrate. In fact, the observed metabolite
signal is largely representative of label exchange between endogenous lactate and
injected HP [1-13C]pyruvate23. As such, the observed signal reflects the endogenous
lactate pool size and the redox state of the system. Many external perturbations or
pathologies change the lactate pool, thereby allowing HP pyruvate to be used as a
biomarker in many different pathologies, including acute injury, inflammation, or
cancer102,122,169,170.

Figure 2.3: (A) The fate of the 13C labeled carbon-1 (red). In most organs, the label will be detected
on the lactate, alanine, bicarbonate (via PDH). In the liver, the label can also appear on other TCA
cycle intermediates via the enzyme pyruvate carboxylase (PC). Spectra from (B) fasted and (C)
fed states of a perfused, isolated rat liver after injection of HP [1-13C]pyruvate. Figures adapted
from Ref.171 under noncommercial and education use.

Pyruvate is also reversibly catalyzed to the amino acid alanine via the enzyme alanine
transaminase (ALT). In most tissues, HP [1-13C]alanine signal is substantially less than
that of [1-13C]lactate, due to the lower activity of ALT, or the lower alanine pool size,
compared to LDH and lactate, respectively159,172,173. However, HP[1-13C]pyruvate's
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conversion to HP [1-13C]alanine is a useful biomarker for tissues that are heavily involved
in alanine metabolism, particularly the liver and skeletal muscles120,174(p13).

The third most common fate of HP [1-13C]pyruvate is its conversion to acetyl coenzyme A
(acetyl-CoA) and

13

CO2 via pyruvate dehydrogenase (PDH). The

13

CO2 is then rapidly

converted to [13C]bicarbonate via the enzyme carbonic anhydrase (CA)175. Although the
[13C]bicarbonate SNR is too low to be easily quantifiable in most healthy tissues, it is
prominent in the heart, which is much more energetically demanding than most other
organs176. Because the acetyl-CoA is not labeled, its fate—typically incorporation into the
tricarboxylic acid (TCA) cycle via the pyruvate dehydrogenase complex (PDC) or
conversion to acetylcarnitine (ALCAR)—cannot be determined. Nonetheless, the use of
HP [1-13C]pyruvate to study TCA cycle activity is possible in the liver and other tissues
expressing pyruvate carboxylase (PC). This enzyme irreversibly catalyzes pyruvate to
oxaloacetate (OAA), which can then be used as a substrate for gluconeogenesis or
converted to other TCA cycle intermediates171.

Due to the versatility of [1-13C]pyruvate, it can be used to study a wide variety of metabolic
perturbations in many tissues. The most notable difficulty is that the signal-to-noise is too
low to be useful in true tracer applications. Thus, metabolic perturbations by
superphysiological agent concentrations (mM and above) must be considered. In some
circumstances, this may limit sensitivity to disease and the relevance of quantitative
physiological measurements165,177.
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2.4.2. [2-13C]Pyruvate
HP [2-13C]pyruvate is used much less frequently than HP [1-13C]pyruvate. As the 2-carbon
is labeled, the closest magnetic interaction is two bonds away. This results in a slightly
lower T1 than that of the 1-carbon178. Nonetheless, HP [2-13C]pyruvate imaging is much
better suited for studying oxidative phosphorylation. Unlike [1-13C]pyruvate, the HP carbon
is found on acetyl-CoA after PDH catalysis, so HP [2-13C]pyruvate can be used to study
PDC flux, fatty acid oxidation (acetoacetate, acetylcarnitine), and conversion to TCA cycle
intermediates or downstream products (e.g., [1-13C]citrate and [5-13C]glutamate)179,180.
This is particularly useful for studying cancers that disrupt oxidative phosphorylation.
Nevertheless, until recently a limited number of studies have been performed using HP
[2-13C]pyruvate because of the relatively low oxidative phosphorylation activity in many
tissues.

2.4.3. [1-13C]Acetate
HP [1-13C]acetate is typically used as a probe to study TCA flux and fatty acid oxidation.
The enzyme acetyl-CoA synthase (ACS) rapidly converts free acetate into acetyl-CoA.
The acetyl-CoA can then either enter the TCA cycle and its conversion to TCA
intermediates can be followed, or it can be reversibly converted to acetylcarnitine (ALCAR)
via the enzyme carnitine acetyltransferase (CAT), depending on the energy needs of the
tissue 181. As a probe, HP [1-13C]acetate bypasses the PDH complex, so unlike pyruvate,
it provides a direct measurement of TCA flux. HP [1-13C]acetate studies are useful in
tissues that prioritize fatty-acid metabolism as opposed to glucose metabolism, and
consequently most studies have been done in the heart or skeletal muscles182,183.
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2.4.4. [1-13C]Alanine
HP [1-13C]alanine has also been used as an alternate probe for studying pyruvate
metabolism. Upon injection, HP [1-13C]alanine is converted to HP [1-13C]pyruvate via ALT,
which can then be converted to HP [1-13C]lactate. Using HP [1-13C]alanine is
advantageous as it allows relative measurements of endogenous pyruvate and lactate
pool size 184 without the analytical difficulties arising from the large extracellular pyruvate
signal. Alanine’s metabolism varies by organ, but ALT is especially active in the muscle
and liver, which play a key role in the Cahill cycle that shuttles alanine and glucose
between the two organs185. A recent study has also used a modified alanine moiety, HP
[1-13C]alanine-NH2, to specifically target aminopeptidase N, an enzyme that is upregulated
in tumor angiogenesis186.

2.4.5. [13C]Urea
[13C]urea has also been used as a HP probe. Unlike most other probes, urea is
metabolically inactive. Instead, it has been used as a contrast agent or a perfusion agent.
It is a promising alternative to traditional contrast agents (such as gadolinium) as it offers
the unique advantages of high contrast (no background signal), more straightforward
quantification, and minimal toxicity113,117,118.

2.4.6. [1-13C]Dehydroascorbic Acid
Dehydroascorbic acid (DHA) is the oxidized form of ascorbic acid (vitamin C); the relative
concentration of the two can provide information on the intracellular redox state187. DHA
uptake varies wildly by tissue, so it cannot be used as a universal probe188,189. Unlike the
other smaller metabolites, [1-13C]DHA also has a comparatively short T1 (~20s) at high
fields (9.4-11T), so imaging at those fields requires fast imaging sequences; however, the
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reported T1 at clinical MRI fields is much higher (~57s), making studies at the lower field
much more feasible190,191.

2.4.7. [1-13C]Succinate / [1-13C]Diethyl Succinate [1,4-13C2]Diethyl Succinate
Succinate, a TCA cycle intermediate, can be reversibly catalyzed to either succinyl-CoA
via the enzyme succinyl-CoA synthetase, or to fumerate via the enzyme succinate
dehydrogenase192,193. The ability to image the fate of succinate would provide insights into
many pathologies that affect oxidative phosphorylation194,195, especially in tissues where
no TCA intermediates are detected with HP [1-13C] or [2-13C]pyruvate. [1-13C] or [1,413

C2]succinate have not been successfully polarized using DNP. However, [1-

13

C]succinate has been successfully polarized with PHIP using [1-13C, 2,3-2H2] fumaric

acid and [1-13C]acetylenedicarboxylate, with reported T1 values of 27s (at 4.7T) and ~6s
(at 1.5T), respectively96,97,196. Other attempts to polarize succinate have used ethyl groups
to protect the terminal carbonyl groups. The resultant diethyl succinate has been polarized
via both PHIP and DNP, with a reported T1 of ~38s at lower field strengths (3 and
4.7T)75,197.

2.4.8. Other Hyperpolarized Metabolites
There are other less extensively studied molecules that have also been successfully
polarized. One promising probe is [1-13C]bicarbonate, which rapidly converts into HP
13

CO2 via the enzyme carbonic anhydrase148,198. The ratio of bicarbonate-to-carbon

dioxide can be used to derive tissue pH, which is a powerful biomarker for both acute and
chronic pathologies199,200. [U-13C6, U-2H7]glucose, which lies metabolically upstream of
pyruvate, has also been successfully polarized, but its in vivo use is hindered by its short
T1 (about 10-13s) and complex spectrum201,202. For an exhaustive list of the molecules that
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have been successfully polarized, please refer to the comprehensive review by Keshari
and Wilson119.

2.5. Hyperpolarized Studies by Organ System
A number of excellent reviews on the state of hyperpolarized DNP, each focusing on
different aspects of the field, have already been published. Barnes et al.46 focus on the
physics of DNP, while Karlsson et al.50, and Keshari and Wilson119 concentrate on the
chemistry of DNP probes. Reviews with a particular biological or pathological focus, e.g.,
on cancer203 or neurology97, also exist. However, none of these reviews has described
how HP studies vary according to the different tissue or organ systems they have been
used to assess. Accordingly, this section summarizes the major HP studies by organ or
tissue in order to characterize their metabolic profile for a given set of HP probes,
highlighting the unique challenges that each tissue poses for molecular imaging. For
example, probe delivery to the brain is limited by the blood brain-barrier, whereas the lung
presents the challenge of the air-tissue interface. Ex vivo, in vivo, and in vitro studies of
the heart, liver, prostate, kidney and lung are described below.

2.51. Heart
Proton MRI is often used for structural cardiac imaging. In addition to its high spatial
resolution, MRI’s sensitivity to flow and ability to freeze motion during the cardiac cycle
make it suitable for answering many clinical important questions. Other nuclei such as 31P
have been used to obtain metabolic information about the heart in both healthy and
diseased states; however, given their low gyromagnetic ratio and metabolite
concentration, in vivo application is fairly limited.
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Hyperpolarized 13C MRI provides a new opportunity for real-time metabolic imaging of the
heart. A number of isolated perfused heart studies, as well as in vivo studies in both small
and large animals, have been carried out to characterize the metabolic profile of the
healthy heart using HP agents. Unlike most other tissues for which HP lactate labeling or
HP alanine labeling is primarily observed, significant conversion of HP [1-13C]pyruvate to
HP bicarbonate has been detected in the heart112,159,176,204. In healthy hearts, the detected
HP bicarbonate reflects PDH flux, though not necessarily flux through the TCA cycle176. A
decrease in HP bicarbonate signal has also been observed in the fasted state, when the
heart switches to fatty acid oxidation as its primary energy source159,177,204. Adding butyrate
or octanoate (even-chained fatty acids) to the perfusate has produced a similar decrease
in HP bicarbonate signal while the TCA flux measured via tissue extracts was unchanged,
providing direct evidence for decreased PDH flux in the presence of fatty acids176,205.
Adding dichloroacetate (DCA), a well-known pyruvate dehydrogenase kinase (PDK)
inhibitor, promotes PDH flux and yields a stronger HP bicarbonate signal, as
expected181,204,206,207. Adding dobutamine, a selective β-agonist, increased both PDH and
TCA flux, as determined by HP [2-13C]pyruvate MR. As the studies above clearly
demonstrate, then, different HP probes can be used to be assess different types of stress
on cardiac tissue181.

Because the heart can derive the acetyl-CoA needed for the TCA cycle from either
pyruvate decarboxylation or β-oxidation, a number of studies have focused on using [113

C]acetate's conversion to downstream TCA intermediates or reversible conversion to

acetylcarnitine as another HP biomarker to characterize cardiac metabolism183,208,209.
These in vivo studies in rats and pigs characterized TCA flux using ratiometric modeling
of HP acetate, acetylcarnitine, and citrate signals in healthy animals. More recently, HP
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[1-13C]butyrate was successfully used to characterize TCA intermediates in fed and fasted
isolated perfused rat hearts, confirming previous findings that the presence of fatty acids
limits PDH flux without affecting TCA flux205.

These HP markers have also been used to characterize a number of cardiac pathologies.
HP [1-13C]pyruvate studies of ischemia-reperfusion in rats and pigs have shown a
decrease in HP bicarbonate signal and an increase in HP lactate signal immediately after
ischemia210–212. Partial recovery to baseline was observed 15 minutes post-reperfusion210,
suggesting that HP [1-13C]pyruvate could serve as a marker for ischemia-reperfusion
injury. The ratio of HP bicarbonate to HP CO2 was also used to characterize this injury,
and it was found that post-ischemia pH was about 7.12, compared to 7.20 in healthy
rats212. An HP [2-13C]pyruvate MR study yielded complementary findings, showing an
increase in HP [2-13C]lactate labeling and a decrease in [1-13C]acetylcarnitine, [113

C]citrate, and [5-13C]glutamate in isolated perfused ischemic rat hearts212.

In vivo HP [1-13C]pyruvate NMR also showed a decrease in HP bicarbonate production in
a streptozotocin-induced type 1 diabetes model in rats159, confirming the well-established
finding that type 1 diabetes onset decreases glucose oxidation and PDH flux213.

Although earlier studies were performed in perfused hearts and small animals, the
adoption of modern pulse sequences and fast sequences has enabled more in vivo
studies, as well as studies in larger animals where the signal emanating from the heart
chambers and the myocardium can be resolved. In addition to confirming the results from
previous studies, these large animal in vivo studies have shown the particular region of
the myocardium tissue from which the bicarbonate and lactate signals originate113,142.
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2.5.2. Liver
The liver is both the largest gland and the most metabolically active organ in the human
body. Unlike most organs, it is heavily involved in whole-body metabolism214.
Unsurprisingly, a diverse set of metabolic pathways and HP probes has therefore been
studied in the liver.

The liver is largely responsible for gluconeogenesis, the process by which glucose is
synthesized from lactate and alanine (as part of the Cori and Cahill cycles, respectively)
when blood glucose levels are low185,215. An HP [1-13C]pyruvate study of the liver in fed
(high blood glucose) and fasted (low blood glucose) rats demonstrated this process in vivo
by detecting the expected decrease in alanine pool size via a decrease in HP alanine
labeling in the fasted state184. The liver is also one of the few organs that expresses
pyruvate carboxylase (PC) and phosphoenolpyruvate carboxykinase (PEPCK), allowing
conversion of HP [1-13C]pyruvate to [1-13C]oxaloacetate and additional downstream
metabolites ([1-13C]malate, [4-13C]malate and [1-13C]aspartate) (Figure 2.3)171. Changes
in the PC flux and PEPCK flux after [1-13C]pyruvate injections in a type 2 diabetic mouse
model demonstrated that this pathway could be exploited for longitudinal monitoring of
diabetes development216.

Several other studies have focused on tissue non-specific metabolic pathways and how
they differ in the liver. Using HP [1-13C]acetate injections, the acetylcarnitine pool size was
shown to be lower than that in the heart217. HP [1-13C]alanine injections have also been
used to estimate the intracellular ratio of the pyruvate and lactate pools184, a technique
that is feasible in the liver due to its relatively high ALT flux compared to other organs.
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Ethanol administration resulted in increased lactate production in a rat liver, most likely
due to increased NADH availability after ethanol breakdown124.

A large number of hepatic studies have focused on tumor imaging. Hepatocellular
carcinoma (HCC) is an aggressive primary tumor with extremely high morbidity and
mortality218, in which glutamine metabolism plays an important role. The conversion of HP
[5-13C]glutamine to HP glutamate has been shown to be a potential biomarker for cell
proliferation in human hepatoma (HepG2) cells219. Other studies have shown that the
conversion rates and T2 relaxation times of alanine and lactate from HP pyruvate are
higher in HCC tumors than in normal liver, suggesting a potential set of biomarkers for
tumor characterization116,220–222. Another in vivo study found that transcatheter arterial
embolization (TAE) of HCC in rats lead to the increased conversion of HP [1,413

C2]fumarate to HP [1,4-13C2]malate after necrosis due to extracellular fumarase, as well

as a decrease in HP [13C,15N2]urea and HP [1-13C]pyruvate signal, most likely due to
decreased blood perfusion223. The conversion of HP [1-13C]a-ketoisocaproate (KIC) to HP
leucine was also shown to be associated with branched-chain aminotransferase (BCAT)
expression, an enzyme that is more strongly expressed in HCC cells compared to normal
liver tissue221.

2.5.3. Prostate
Hyperpolarized

13

C methods have been used extensively to study the prostate, in

particular prostate cancer. Conventional clinical methods rely on prostate specific antigen
(PSA) for screening and biopsies for diagnosis. In 2011, the United States Preventive
Services Task Force (USPTF) recommended against PSA screening, as the risk may
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outweigh the benefits224. Biopsies are often difficult to justify as well, largely due to their
invasiveness and the difficulty of accurate sampling in this highly heterogeneous gland.
1

H high resolution magic angle spinning (HRMAS) spectroscopy and 1H MRSI studies

have shown that changes in choline-containing compounds, polyamines and citrates can
be used to improve cancer localization in prostates, but these compounds cannot be easily
identified using HP

13

C NMR/MRI methods225. 1H HRMAS also showed elevated lactate

and alanine concentrations in biopsy samples from human prostate cancer patients226. In
vivo imaging of these metabolites using 1H MRSI is challenging, however, as their
resonances lie close to the lipid resonances surrounding the prostate tissue. In contrast,
HP 1-13C pyruvate imaging is an ideal tool for real-time measurements of lactate and
alanine as potential biomarkers for prostate cancer.

A number of HP 1-13C pyruvate studies have been conducted that demonstrate the
technique's feasibility for evaluating prostate cancer. The most widely used animal model
is the transgenic adenocarcinoma of mouse prostate (TRAMP) model227, which has shown
increased HP lactate labeling in multiple in vivo studies170,172. The lactate signal (or lactate
to pyruvate ratio) was also correlated with increasing tumor grade228. It is important to note
that, due to the small size and multi-lobar structure of a normal mouse prostate, the tumor
lactate measurements in these studies were compared to lactate measurements from
either the kidney or liver (unchanged in control and TRAMP cohorts). All of these findings
were confirmed using emerging imaging techniques (section 4) which further showed the
heterogeneity of the tumor, especially in relationship to disease progression228,229. Other
TRAMP studies have also demonstrated the use of HP [1-13C]pyruvate spectroscopy to
extract kinetic parameters for this disease, but have found the fitted rate constants to be
heavily dose-dependent in the simplistic model used163.
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Findings from the in vivo TRAMP model have been translated to ex vivo and in vivo human
studies. Ex vivo HP [1-13C]pyruvate studies using tissue slice culture (TSC) cells derived
from radical prostatectomy specimens showed different metabolic ratios compared to
patient biopsies. However, the trend in changes between benign and cancerous tissue
were similar in all the studies: i.e., increasing lactate with increasing cancer grade230. In
2013, the first in man HP [1-13C]pyruvate study was performed in 31 patients with prostate
cancer101. As a phase 1 trial, its primary goal was to study the dose dependent effects of
delivering HP [1-13C]pyruvate. The study confirmed the safety of the technique at the
highest delivered dose of 0.43 mL/kg (of 230 mM agent), paving the way for further human
studies by demonstrating increased HP lactate/pyruvate in biopsy-confirmed regions of
cancer.

Although most work in the prostate has used HP [1-13C]pyruvate, other HP agents have
also been used to study prostate cancer. For example, HP [2-13C]fructose’s conversion to
fructose-6-phosphate via hexokinase was found to increase in the tumor region231; DHA
was also used in the TRAMP model, and the ratio of DHA to DHA plus ascorbate was
found to increase in the late stage of the disease187.

2.5.4. Kidney
Over the last decade, hyperpolarized 13C NMR/MRI has been used extensively to study
changes in blood flow and metabolism in the kidneys and renal system. The kidneys
receive approximately 20% of the cardiac output, making high 13C SNR easily achievable
following intravenous administration of a hyperpolarized bolus.
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The metabolism of healthy kidneys has been characterized using hyperpolarized [113

C]pyruvate in a manner similar to other organ systems. An in vivo rat study demonstrated

significant conversion of HP pyruvate to both HP lactate and HP bicarbonate, while there
was minimal conversion to alanine232. In another study, when pigs were given an oral
sucrose load, it was found that the lactate to pyruvate ratio correlated with the blood
glucose level, while all other metabolites of pyruvate remained unchanged102.

In addition to the metabolically active pyruvate, the metabolically inert [13C]urea has also
been used to characterize blood flow and other functional parameters in the kidneys. One
in vivo rat study using [13C]urea showed a more than three-fold difference in renal blood
flow compared to hepatic blood flow233, while another demonstrated that the T2 of
[13C,15N]urea in kidneys was greater than ten seconds, as opposed to 1.3 seconds in
blood, likely due to deoxyhemoglobin-induced paramagnetic relaxation in the latter117.
Finally, a third in vivo rat study demonstrated more rapid medullary [13C]urea
enhancement in the antidiuretic state, suggesting that [13C]urea could be used as a marker
for urea transporter UT-A1 activity234.

Hyperpolarized imaging techniques have also been used to characterize disease models
in kidneys. For instance, renal cell carcinomas (RCCs) are a broad group of tumors
affecting the kidney that have been studied in some detail using hyperpolarized

13

C. In

vitro HP [1-13C]pyruvate studies of two different RCC cell lines (UOK262 and UMRC6) and
healthy proximal tubule epithelial (HK-2) cells have shown that the observed pyruvate to
lactate ratio and the ratio of HP intracellular lactate to extracellular lactate (efflux ratio) can
be used to distinguish the three different cell lines from each other235,236. Furthermore, the
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HP lactate efflux ratio strongly correlates with MCT4 mRNA expression, suggesting its
potential use as a biomarker for differential diagnosis of RCCs.

Acute tubular necrosis (ATN) is the most frequent cause of acute kidney injury, but there
is no clinically available noninvasive tool to differentially diagnose ATN from other similar
disorders such as glomerulonephritis (GN). An in vivo mouse study showed that the
conversion of hyperpolarized [1,4-13C2]fumarate to malate was significantly greater in the
ATN cohort compared to healthy or GN cohorts237, indicating that hyperpolarized [1,413

C2]fumarate could be a useful biomarker by providing differentiable diagnostic

information on the causes of acute kidney injury.

Hyperpolarized [1-13C]pyruvate has also been used to study metabolic changes in the
renal system following the onset of diabetes. One in vivo rat study using a streptozotocin
diabetes model showed a 149% increase in the lactate to pyruvate ratio of diabetic rats
compared to controls238. Another in vivo study demonstrated that reduced oxygen
availability lead to 23% and 34% increases in lactate and alanine labeling, respectively, in
diabetic rats, whereas no such difference was observed in the control cohort.239.

2.5.5. Lung
Hyperpolarized 13C metabolic imaging of the lungs is quite challenging because of their
low tissue density, high susceptibility/B0 inhomogeneity due to air-tissue interfaces,
motion, and low metabolic rate compared to solid organs240. At the same time, however,
since the lung receives the full blood supply during each circulation and plays a key role
in whole body homeostasis, HP carbon MRI can be a valuable tool for evaluating lung
metabolism and pathology.
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HP 13C MRI was first used in the porcine lung as a contrast agent to demonstrate feasibility
as an angiography tool for evaluating pulmonary perfusion and imaging the pulmonary
vasculature74. When evaluating the suitability of specific hyperpolarized agents in different
pulmonary disorders, however, metabolic imaging is most easily performed using ex vivo
perfused lungs. HP [1-13C]pyruvate spectroscopy of an ischemia-reperfusion model in
perfused rat lungs showed a significant increase in HP lactate labeling after ischemia; the
lactate labeling was restored to baseline levels approximately 30-40 minutes after
reperfusion173. As we will see in Chapter 3, HP [1-13C]pyruvate can also been used to
investigate the mechanism by which ascorbate prolongs the viability of isolated perfused
lungs162. We found that ascorbate enhanced viability via interaction with the electron
transport chain rather than its more common role as a general antioxidant. HP signal
dynamics and the response to perfusate contents in the healthy lung were addressed
using a three-compartment model to confirm the experimental finding241 that HP lactate
labeling is primarily determined by the rate at which NAD+ is reduced to NADH, and scales
with the intracellular lactate pool size165. As discussed in Chapter 4, we also demonstrated
a greater than three-fold increase in HP pyruvate-to-lactate ratio during the inflammatory
phase of a bleomycin induced lung injury model in perfused rat lungs, which was well
correlated with histological neutrophil count122.

Current research is focused on moving towards in vivo HP 13C lung imaging. The first such
in vivo study in rats demonstrated an increase in HP lactate labeling compared to controls
in a radiation-induced lung injury (RILI) model242. These results were consistent with lung
inflammation as measured from bronchioalveolar lavage. Another pair of studies
demonstrated increased HP lactate with inflammation in a two-hit model of acute lung
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injury, as well as its attenuation with protective ventilation techniques243,244. Finally,
chapter 5 will focus on studies in which we demonstrated that increased HP lactate can
be used as an early biomarker for lung transplant rejection in a rat model.

2.6. Conclusion
Over the past fifteen years, considerable advancements have been made in developing
hyperpolarized injectable agents for use in medical imaging, and tangible progress has
begun towards the dual goals of developing affordable HP MRI biomedical applications
and the robust use of this technology in human studies245,246.

The technical improvements which HP liquid MR research has achieved over this period
are clearly visible in labs around the world. Similar to hyperpolarized gas technology a
decade earlier, molecular imaging using DNP-hyperpolarized compounds has progressed
from reliance on homemade equipment to the use of commercial devices suitable for in
vitro and small animal research and, finally, to equipment capable of safely and efficiently
producing large samples appropriate for human trials. PHIP has also undergone a
technical renaissance sparked by recent demonstrations of spin-order transfer in transient
catalytic complexes and chemical modification of the hyperpolarized compound.

Just as importantly, novel imaging methods have proven capable of using the
hyperpolarized state more efficiently by improving acquisition speed, metabolite
selectivity, spatial and temporal resolution, and immunity to motion artifacts. At the same
time, vigorous effort have also been made to extract the quantitative information (e.g., rate
uptake and metabolic flux) necessary to attain a fundamental understanding of metabolic
signals by combining imaging results with kinetic modeling. Indeed, some of the most
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promising work highlighted in the organ-specific discussion above relies on these
procedural improvements in image acquisition and analysis. For example, the primary
focus of most HP MR heart studies has been quantifying PDH flux and its modification
with physiological stress or pharmaceutical intervention. Similar efforts have been pursued
in isolated, perfused organs, for which the arterial input function is known, as well as in
brain and liver, for which it is measured. In addition to detecting low-concentration
intermediates, these studies have already yielded unique quantitative metabolic flux and
exchange data and can naturally be extended to quantitative assessments of perfusion
and/or flux in any organ and in tumors.

The central challenge moving forward will be the clinical translation of sequences and
modeling techniques suitable for quantification, with the aim of better understanding the
relationship between these new measurements and human disease. Human studies have
already begun101,247–249, and will grow dramatically in the immediate future as the solutions
to technical and regulatory challenges are disseminated.
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Chapter 3: A Mechanistic Study of Lung Viability during Ex Vivo Lung Perfusion
(EVLP) Using

31

P and Hyperpolarized (HP) [1-13C] Pyruvate Nuclear Magnetic

Resonance

Abstract
Ex vivo lung perfusion (EVLP) has recently shown promise as a means of assessing and
revitalizing the health of lung grafts and improving post-transplant graft performance.
However, perfusion of ischemic lung promotes energy depletion and leads to a
progressive loss of normal mitochondrial function; it remains unclear to what extent EVLP
itself contributes to this metabolic decline. The anti-oxidant ascorbate has been shown to
mitigate the effects of ischemia–reperfusion injury, but the nature of its effects during
EVLP are also not clear. In this study we used hyperpolarized (HP) [1-13C] pyruvate NMR
in conjunction with the more established

31

P NMR to answer a series of complementary

questions on lung metabolism during EVLP and its response to the administration of
ascorbate. Our experiments demonstrated that the oxidative phosphorylation capacity and
pyruvate dehydrogenase flux of lungs decline during ex vivo perfusion. The addition of
ascorbate to the perfusate increased the hyperpolarized 13C bicarbonate signal by a factor
of 2.7 and prolonged lung viability by 80%. Furthermore, we used HP [1-13C] pyruvate
spectroscopy to show that the ascorbate effect is not due to its antioxidant properties, but
rather due to its ability to energize pulmonary mitochondrial activity through an
independent interaction with ETC complexes. This study established that HP [1-13C]
pyruvate MRS can be used to assess the response to treatment during EVLP for improving
procurement and preservation of lungs for transplantation.
This chapter has been adapted from the published article, ‘Ascorbic acid prolongs the viability and
stability of isolated perfused lungs: A mechanistic study using 31P and hyperpolarized 13C nuclear
magnetic resonance’ in Free Radical Biology and Medicine, 89:62-71(2015)
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3.1. Introduction
Lung transplantation is the established treatment for patients with chronic, end-stage lung
disease1. However, its utility is limited both by the chronic shortage of donor lungs as well
as post-transplant complications2. Although efforts have been made to expand the pool of
available organs via aggressive donor management and novel lung preservation
strategies, our incomplete understanding of the mechanism and progression of donor lung
injury continues to limit our ability to fully exploit these advances to improve lung transplant
outcomes. In recent years, ex vivo lung perfusion (EVLP) shown promise as a valuable
technique for reassessing the health of grafts initially classified as high risk3, thereby
allowing a greater percentage of lungs to be transplanted. Moreover, as compared with
cold preservation alone, the application of EVLP before transplant results in significantly
higher post-transplant oxygenation and slower edema formation4.

Despite these highly promising developments, uncertainty about the role of ex vivo
perfusion in lung graft health remains. The most common mechanism of early mortality
subsequent to lung transplantation is ischemia–reperfusion injury (IRI)5,6, which can cause
acute graft dysfunction. When hypoxic cells are reperfused with oxygenated perfusate (or
blood), reactive oxygen species (ROS) form which are generally accepted as the major
source of the cellular damage and pulmonary edema characteristic of IRI7–10. Reperfusion
of ischemic lung leads to fundamental metabolic alterations, including a decline in
oxidative phosphorylation capacity and reduced activity of the electron transport chain
(ETC) complexes11–14; in cardiac tissue, ischemia–reperfusion has also been shown to
decrease activity of the pyruvate dehydrogenase complex (PDHc)15. It is not known,
however, whether this energy decline is due solely to the reaction of ischemic lung to
reperfusion, or whether EVLP itself contributes to these changes.
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In tandem with investigating lung health during reperfusion, recent research has focused
on identifying methods that can improve graft viability. For example, antioxidant therapy
and/or preconditioning12,14,16–19 have been shown to limit the extent of IRI, an effect
conventionally attributed to antioxidants’ mitigation of ROS-induced damage20–24. Among
all antioxidants, ascorbate appears to be the most attractive option for treating and
preventing IRI in the lung and other organs25–30. Ascorbate administration has been shown
to reduce oxidative damage in endothelial cells, improve tissue perfusion, inhibit tumor
necrosis factor α (TNF α), reduce mitochondrial swelling and damage, preserve
mitochondrial respiration, reduce edema , reduce proinflammatory chemokine expression
and reduce oxidative damage31–37.

The goal of this study was to determine whether hyperpolarized (HP) [1-13C] pyruvate
NMR can be used in conjunction with the more established

31

P NMR to answer a series

of complementary questions on lung metabolism during EVLP and its response to
ascorbate. First, is the energy decline previously observed during reperfusion completely
due to reperfusion of ischemic lungs, or does EVLP itself affect the energy status of the
lungs? Second, how does the administration of ascorbate affect lung energy status during
EVLP? Third, is the effect of ascorbate on ex vivo perfused lung metabolism a result of its
antioxidant property, or is it related to other mechanisms (e.g., its ability to energize the
respiratory chain)?

To assess these questions, we used

31

P NMR (nuclear magnetic resonance) to

continuously monitor adenine nucleotides and energy status during perfusion. We also
used HP13C NMR to noninvasively and simultaneously measure the conversion of [174

13

C]pyruvate into [1-13C]lactate and [13C]bicarbonate, which serve as indicators of

glycolytic and oxidative metabolism, respectively. Persistent lactate release during
reperfusion as a result of glycolytic upregulation has previously been observed and
correlated with lung graft quality11,12. In addition, we previously demonstrated a significant
increase in hyperpolarized [1-13C]lactate signal as a result of anaerobic metabolism of [113

C]pyruvate in ischemic isolated perfused lungs38; however, this affect has yet to be

observed during EVLP itself under normoxic conditions.

3.2. Materials and Methods

3.2.1. Animals
All animal experiments were conducted in accordance with protocols approved by the
institutional animal care and use committee of the University of Pennsylvania. Male
Sprague–Dawley rats weighing 320±70 g were used for all experiments. All rats were
housed under similar environments and dietary conditions.

3.2.2. Isolated Perfused Lungs
All imaging studies were performed in ex vivo, isolated, perfused lungs. Prior to excision
of the lungs, rats were anesthetized with intraperitoneal (IP) pentobarbital, tracheostomy
was performed, and 200 U of heparin was administered via tail vein. The lungs were
prepared for NMR study according to the previously reported method of degassing39,40. In
short, the animals were ventilated with pure O2 (50 breaths/min, 11–14 cmH2O peak
inspiration pressure) for 10 min to remove all N2 from the airways. Immediately after
ventilation, the trachea was sealed (end exhalation) with a suture, allowing residual O2 to
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be absorbed by the circulating blood and perfusate. Thoracotomy was immediately
started, the heart was cut transversely, and the pulmonary artery was cannulated via the
right ventricle. After perfusion was started, the lungs were rapidly excised and placed in a
20 mm NMR tube. Lungs were perfused at 10 ml/min with 500 ml of modified Krebs–
Henseleit buffer that contained 119 mM NaCl, 25 mM NaHCO3, 1.3 mM CaCl2, 1.2 mM
MgSO4, 4.7 mM KCl, 10 mM glucose, 2 mM lactate, 0.2 mM pyruvate, and 3% (w/v) fattyacid-free bovine serum albumin (BSA, Fisher Bioreagents). The perfusate was passed
through an oxygenating column under a constant flow of 1 atm 95:5 O2 /CO2 and warmed
via passage through water-jacketed tubing. The CO2 concentration in the oxygenating
column was chosen to maintain constant perfusate pH during oxygenation, although
periodic adjustment with 1 N HCl or NaOH was needed to maintain a physiological value
of 7.4±0.05. The lung was perfused at constant flow throughout the experiment. The
temperature of the perfusate in the NMR tube was continuously monitored and maintained
at 36.5±1 °C.

3.2.3. Preparation and Administration of Hyperpolarized [1-13C]pyruvate
Some of the studies were conducted using hyperpolarized [1-13C]pyruvate. Here, 28.7 mg
[1-13C]pyruvic acid (Cambridge Isotope Laboratories) was mixed with 15 mM OX063 trityl
radical (Oxford Instruments) and 1.5 mM Dotarem Gd chelate (Guerbet). This mixture was
polarized to approximately 20% at 1.42 K and 94.062 GHz with a HyperSense DNP
system (Oxford Instruments). Then, 4 ml of Tris-buffered saline with 100 mg/L
ethylenediaminetetraacetic acid (EDTA) was heated to 190 °C at 10 bar and was used to
rapidly dissolve the frozen sample. Next, 1 ml of this sample was further diluted in 19 ml
of oxygenated Krebs–Henseleit buffer (without BSA, which was found to cause
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unacceptable signal loss during sample transport) to yield a neutral isotonic solution of 4
mM [1-13C]pyruvate. This solution was injected into the perfusate line at 10 ml/min in lieu
of the steady-state perfusion buffer. After the 120 s required to inject the hyperpolarized
solution, normal lung perfusion was restarted.

3.2.4. Magnetic Resonance Spectroscopy
All magnetic resonance spectra and images were obtained using a 9.4-T vertical bore
magnet (Varian, Palo Alto, CA, USA) equipped with a gradient insert (Resonance
Research, Billerica, MA, USA) and a 20 mm 1 H/broadband probe (Doty Scientific, Columbia, SC, USA). After inserting the probe, the sample was tuned and matched. A 1H
gradient echo image (1 slice in each axis, field of view = 30x30 mm) was acquired to
confirm the position and integrity of the organ (lack of edema). The sample was then
shimmed on proton to a linewidth of approximately 35 Hz. The above-mentioned steps
required approximately 10 to 20 min.

In each lung studied, a series of

31

P spectra was acquired to assess high-energy

phosphate status during the entire perfusion period. In some cases, one or two sets of HP
[1-13C]pyruvate spectra were also acquired, bracketed by

31

P spectra to evaluate the

stability of the lung condition and its metabolic activity as well as the reproducibility of the
measurement. HP

13

C spectrum series were separated by the 1 hour required to

hyperpolarize another pyruvate sample. The 31P spectrum was acquired with the following
parameters: repetition time (TR) = 1 s, nominal flip angle (α) = 60 °, acquisition time (AT)
= 200 ms, spectral width (SW) = 100 kHz, and averages (NT) = 512, with a total scan time
of 8:32 min. If the 31P spectroscopy was followed by HP 13C spectroscopy, the probe was
then tuned to

13

C. During

13

C acquisition, the perfusate pump was turned off as the
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hyperpolarized solution was injected via a secondary line. Low flip-angle spectra were
acquired for the several-minute duration of the hyperpolarized signal (TR = 1 s, nominal α
= 10°, AT = 800 ms, SW = 50 kHz, 300 individual spectra acquired), after which the steadystate perfusion was restored.

3.2.5. Study Protocols
The study was divided into four sections.

3.2.5.A. Study I: Control and Ascorbate Studies
In this study, the longevity of the perfused lungs was measured in the absence (control)
and presence of 2 mM ascorbate (henceforth referred to as the “ascorbate cohort”)
dissolved in the perfusate. The perfusate was otherwise the same for the two cohorts and
was as described above. The perfused rat lungs were observed longitudinally by 31P NMR
in the two cohorts: control (n = 5) and ascorbate (n = 5). Ascorbate (Sigma–Aldrich, St.
Louis, MO, USA) was dissolved into the perfusate 10 min before the lungs were perfused.
The perfusate and the particle filter were replaced by fresh oxygenated perfusate after 3
h of perfusion to replenish depleted nutrients. A phosphorus spectrum was acquired every
40 min until the endpoint of the study was reached. The study ended when the nucleoside
signal was undetectable by

31

P NMR or when perfusion stopped due to lung edema.

Edema was detected by a gradient echo image that showed a distended lung as well as
the abrupt increase in backpressure in the perfusion apparatus.
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3.2.5.B. Study II: Hyperpolarized [1-13C]pyruvate Studies of Control and Ascorbate
Cohorts
In this study, the metabolic activity of the lungs in the absence (control, n = 11) and
presence of 2 mM ascorbate (ascorbate, n = 12) in the perfusate was evaluated. An HP
13

C spectrum series, bracketed by a pre- and post- 31P spectrum, was acquired 40 min

after lung perfusion was started. In 6 of the controls, the entire series ( 31P spectrum, HP
spectrum series, 31P spectrum) was repeated after a 1 h delay to determine the metabolic
stability of the perfused lung. In 3 of these repeated controls perfusion was continued with
the control perfusate, but in the other 3 repeats 2 mM ascorbate was dissolved in the
perfusate after the first set of spectra was acquired.

3.2.5.C. Study III: Antioxidant Studies
The goal of this study was to determine whether the primary mechanism of ascorbate’s
effect on lung stability and metabolism was due to its antioxidant effect. As such, the
perfused lungs were evaluated in the presence of the following compounds:
dehydroascorbate (DHA, n = 3), glutathione (GSH, n = 3), and α -lipoic acid (ALA, n = 3).
Here, 2 mM of each compound was added to the perfusate approximately 10 min before
starting perfusion. The effect of ascorbate’s concentration on the perfused lung was also
evaluated by dissolving 0, 0.5, 1, 2, 4, 8, and 16 mM ascorbate in the perfusate (n = 3
each except for the larger 0- and 2 mM cohorts described above). Similar to study II, the
lungs were perfused and monitored by a series of NMR acquisitions (
spectrum series, 31P spectrum).
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P spectrum, HP

3.2.5.D. Study IV: Electron Transport Chain Studies
The goal of this study was to determine the effect of activating complex IV with a
cytochrome c reducing agent and/or inhibiting complex I (via rotenone) on pyruvate
metabolism. Similar to studies I to III, the lungs (n = 13) were perfused with control
perfusate and an initial

31

P spectrum was acquired. After this acquisition, the perfusion

parameters were modified as follows. The flow rate of the perfusate was decreased to 9
ml/min, and a second infusion at a flow rate of 1 ml/min was started. The two lines were
merged so that the final flow rate was still 10 ml/min. The second reservoir contained
identical perfusate except for the addition of either rotenone or TMPD (N,N,N',N'tetramethyl-p-phenylenediamine) + ascorbate, such that the combined infusion contained
20 mM rotenone or 25 mM TMPD + 250 mM ascorbate. After perfusing the lung with either
rotenone for 10 min or TMPD + ascorbate for 40 min, the second pump was stopped and
the main line’s flow rate was returned to 10 ml/min. An HP 13C spectrum series was then
acquired, followed by post-injection

31

P spectra to assess the lung’s metabolic and

energetic state after the HP [1-13C]pyruvate study. Rotenone-perfused lungs (n = 8) were
subjected to a second HP pyruvate administration. The second HP pyruvate injection was
administered after either 40 min of treatment with 25 mM TMPD + 250 mM ASA (ascorbic
acid) (n = 5) or 40 min of additional perfusion by normal perfusate (n = 3). The
concentration of rotenone was selected based on a previously reported study that
demonstrated complete blockade of complex I and depression of whole-lung oxygen
consumption with no detectable impact on complexes III and IV

41

. To determine the

effective concentration of TMPD/ASA, the effect of different concentrations of TMPD/ASA
(12.5–100 μ M TMPD/10 # ASA, n = 3) was studied on HP pyruvate metabolism.
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3.2.6. Post-processing of Spectra
Spectra (carbon and phosphorus) were downloaded for offline processing using custom
MATLAB (MathWorks, Natick, MA, USA) routines. In general, the spectra were
automatically Fourier-transformed, line-broadened, baseline-corrected, phase-corrected,
and then peak-fitted for data evaluation.

31P spectra were least-squares fit to 13 Lorentzian peaks, allowing the individual peak
heights and common peak width to vary freely. The peak frequencies were kept fixed;
peak identities (ppm chemical shifts relative to phosphocreatine [PCr]) were PME
(phosphomonoester, 6.70), Pi (inorganic phosphate, 5.08, 4.32), GPC (glycerol 3phosphorylcholine,

3.03),

GPE

(glycerol

3-phosphorylethanolamine,

2.24),

PG

(phosphoglycans, 1.80), PCr (0.00), g-ATP + b-ADP (–2.36), a-ATP + ADP + AMP (–7.52),
diphosphodiester/NAD(H) (–8.18, –9.68, –11.49, –13.30), and b-ATP (–16.13). The quality
of the fit was found to improve substantially by including three additional peaks of fixed
position (3.5, –4, and –10 ppm) and width (3, 8, and 4 ppm, respectively) to account for
contributions from unresolved

31

P species. Although consistent with previous

measurements 42,43, the number and identity of resonances are uncertain. The b-ATP peak
was the best resolved peak with a good fit quality. Because ATP content is accepted as a
valid viability marker of cells, the b-ATP peak intensity normalized by total
(summation of all

31

P peak intensities) was used to evaluate lung viability

31

P signal

44–46

. The

duration of viability and rate of β -ATP reduction for each lung were calculated by
considering time points for which the β -ATP/total 31P ratio exceeded 50% of the initial ratio
and total 31P signals exceeded 90% of the initial value (indicating no or minimal edema).
The greater than 50% β -ATP/total 31P index was chosen as a measure of viability because
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we observed an abrupt energy status deterioration and the onset of edema once that
threshold was crossed. The lung’s energy status was evaluated by the adenylate energy
charge (EC) which is calculated from the peak intensities 47,48 as

𝐸𝐶 =

1
𝐴𝑇𝑃 + 2 𝐴𝐷𝑃

𝐴𝑀𝑃 + 𝐴𝐷𝑃 + 𝐴𝑇𝑃

13

C spectra were least-squares fit to five Lorentzian peaks, allowing the individual peak

heights to vary. The peak positions and widths were set using an initial free fit (amplitude,
width, and position) to the average of all spectra with a signal-to-noise ratio greater than
30. The peaks were identified as pyruvate, alanine, pyruvate hydrate, lactate, and
bicarbonate with ppm chemical shifts relative to pyruvate of 0.00, 5.68, 8.42, 12.26, and –
9.98, respectively. Additional peaks representing natural abundance nuclei or impurities
were not included in the fit. All metabolite signals were normalized by the integrated
pyruvate signal and the lung’s weight as calculated from the body mass49. Metabolite ratios
were calculated by dividing the individual metabolite signals by the total HP 13C metabolite
signal (lactate + alanine + bicarbonate).

3.2.7. Statistical Methods
All data in the text, figures, and tables are presented as means + standard errors (SE).
Separate two-tailed Student’s t-tests with Bonferroni correction were used to evaluate
significance and calculate P-values of the control and ascorbate cohorts in studies I and
II. In studies III and IV, to determine whether the model groups were characterized by
different means when measured using

13

C or

31

P spectroscopy, analysis of variance

(ANOVA) followed by Tukey’s HSD (honestly significant difference) post hoc test was
performed. To determine the extent of a direct relationship between the viability markers
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as measured using 13C and 31P spectroscopy, simple correlations were calculated across
all measurements in which both metrics were available. All statistical analyses were
performed using the open source R statistical package (http://www.r-project.org).

3.3. Results
Figure 3.1 shows representative time series of

31

P spectra acquired during perfusion of

the isolated lungs with (panel A) and without (panel B) 2 mM ascorbate. In all lungs,
intensities of the PCr and ATP peaks decreased with time, whereas intensity of Pi
increased. Perfused lungs in the ascorbate cohort remained viable, defined as greater
than 50% of the initial β-ATP/total

31

P ratio, for a longer duration (6.1±0.3 h) than the

control lungs (3.4±0.5 h). Figure 3.1C depicts the average β-ATP peak area as a function
of perfusion time for each cohort. As seen in the figure, the rate of β-ATP decrease was
reduced approximately 2-fold in lungs treated with ascorbate. In both cohorts, the β-ATP
decrease accelerated abruptly when the ATP/total 31P ratio was less than 50% of the initial
ratio.

Figure 3.2A displays a representative series of hyperpolarized

13

C spectra from rat lungs

of the 2 mM ascorbate cohort. The observed linewidths were typically approximately 10
Hz. Peaks corresponding to [1-13C]pyruvate and [1-13C]pyruvate hydrate appear first,
followed within a few seconds by [1-13C]lactate, [1-13C]alanine, and [13-C]bicarbonate. In
control lungs, the [13C]bicarbonate peak is typically small or undetectable in a single

13

C

spectrum, perhaps due to a combination of the lung’s low tissue density and low oxidative
metabolism. However, all of the ascorbate cohort lungs exhibited both a larger and more
rapidly appearing bicarbonate signal. The Figure 3.2A inset compares representative
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averaged

13

C spectra of control and ascorbate lungs, exemplifying this several-fold

13

C

bicarbonate signal increase.

Figure 3.1: Representative series of 31P spectra during perfusion in the presence (A) and absence
(B) of 2 mM ascorbate. 31P NMR spectra assignment: 1, PMEs; 2, Pi; 3, PCr; 4, γ- ATP and β-ADP;
5, α-ATP, α-ADP, and AMP; 6, NADs (nicotinamide adenine dinucleotides); 7, β-ATP. (C)
Comparison of 31P β-ATP peak intensity during perfusion in the absence (open circles, control) and
presence (stars, ascorbate) of 2 mM ascorbate. Data are expressed as percentage changes from
baseline. Only the points greater than 50% were used to fit the trend linear lines.

Figure 3.2.B summarizes the differences in averaged lactate, alanine, and bicarbonate
signals between the control (n = 11), and ascorbate (n = 12) lungs. On average, the
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bicarbonate signal is 2.7 times larger (P < 0.005) in the ascorbate cohort. Average lactate
and alanine intensities were also larger in the lungs perfused with ascorbate, but these
increases did not individually reach the level of significance (lactate and alanine, P = 0.70).
These ascorbate-dependent metabolic changes are summarized in Table 1.

Figure 3.2: (A) Representative time series of stacked 13C spectra (bottom) and comparison of two
averaged 13C spectra (top) for lungs in the absence and presence of 2 mM ascorbate. The stacked
series was acquired in an ascorbate lung; bicarbonate signal is typically difficult to observe in
control lungs. Undefined peaks are due to agent impurities. (B) Comparison of averaged HP 13C
metabolite production in rat lungs perfused without (control, n = 11) and with (ascorbate, n = 12) 2
mM ascorbate dissolved in the perfusate. Bicarbonate production in the ascorbate cohort is
significantly higher than in the control cohort (2.7-fold, P < 0.005). The inset shows the change
between two hyperpolarized pyruvate administrations (n = 6) with and without 2 mM ascorbate
dissolved in the perfusate after the first series of HP spectra were acquired. In all cases, the addition
of ascorbate resulted in a partial reversal of the decline in bicarbonate and the increase in lactate
signals.

On average, the total metabolite signal (lactate + alanine + bicarbonate) was 24% larger
in the ascorbate cohort. To distinguish the observed bicarbonate signal increase from
overall changes in metabolism or transport, Table 3.1 also summarizes the fraction of
apparent metabolic activity accounted for by each observed process. The bicarbonate
ratio (i.e., bicarbonate / [lactate + alanine + bicarbonate]) was still 2.3 times higher (P <
0.05) in the ascorbate group than in the control group. The inset of Figure 3.2B shows the
progression of metabolite ratios between the first and second administrations of HP
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pyruvate in both cohorts. The bicarbonate ratio decreased in all three control lungs for
which two HP administrations were performed and increased in all three lungs treated with
ascorbate. The lactate ratio increased in all control lungs and decreased in all lungs
treated with ascorbate. Differences between the cohorts are significant for both lactate
and bicarbonate ratios (P < 0.05).

Figure 3.3: (A) All averaged (n = 3 except for control, n = 11) and 2 mM control (n = 12)
hyperpolarized 13C bicarbonate signals as a function of perfusate ascorbate concentration. The
data were fitted to B = B0 + Bsat [ASA] / (K + [ASA]), where Bsat is the maximum effect achieved by
the system at maximum (saturating) substrate concentrations and K is the substrate concentration
at which the effect is half of Bsat. (B) Correlation of 13C bicarbonate ratio with the ratio of postinjection to pre- injection β-ATP/total 31P (r = 0.84, P < 0.0001). The post/pre ratio of β-ATP/total
31
P for controls is significantly lower than for the ascorbate cohort (20%, P < 0.0005). The pre/post
ratio of energy charge for controls also is significantly lower than for the ascorbate cohort (11%,
figure inset, P < 0.01).

The effective concentration of ascorbate was evaluated by observing hyperpolarized [113

C]pyruvate metabolism with varying amounts (0–16 mM) ascorbic acid added to the

perfusate. The bicarbonate signal increased in a concentration-dependent manner and
showed saturation behavior. Figure 3.3A displays the averaged [13C]bicarbonate signal B
as a function of ascorbate concentration [ASA] and the curve fit to the general form of:

𝐵 = 𝐵- +

𝐵./0 [𝐴𝑆𝐴]
𝐾 + [𝐴𝑆𝐴]
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as suggested by Kepner, et al50. In this expression, Bsat is the maximum effect achieved
by the system at maximum (saturating) substrate concentrations, and K is the substrate
concentration at which the effect is half of Bsat. Best fit parameters were Bsat/B0 = 4.9 and
K = 1.21 mM. The observed HP pyruvate metabolite signals and ratios for each ascorbate
concentration studied are summarized in Table 3.1.
Cohort

n

Conc
[mM]

Lactate

%

Alanine

%

Bicarbonate

%

Control

11

-

1.45±0.15

62.7±1.6

0.79±0.10

33.7±1.7

0.08±0.01

3.6±0.5

Ascorbate

12

2

1.58±0.13

59.9±6.0

0.87±0.08

32.0±4.7

0.20±0.03

8.1±4.7

Ascorbate

3

0.25

1.59±0.11

61.7±0.7

0.84±0.04

34.0±0.5

0.09±0.01

4.2±0.3

Ascorbate

3

0.5

1.33±0.16

59.7±2.0

0.80±0.12

35.4±1.3

0.11±0.03

4.9±1.2

Ascorbate

3

1

1.37±0.23

61.9±1.5

0.71±0.11

32.0±1.2

0.15±0.01

6.7±0.7

Ascorbate

3

4

1.66±0.04

54.6±1.6

1.16±0.12

38.1±2.3

0.22±0.03

7.4±1.3

Ascorbate

3

8

1.57±0.17

57.9±3.7

0.91±0.09

34.0±8.1

0.22±0.01

8.1±0.6

Ascorbate

3

16

1.91±0.12

62.5±2.8

0.93±0.09

30.6±3.0

0.21±0.03

6.9±0.6

DHA

3

2

1.45±0.25

61.9±1.6

0.84±0.12

35.7±1.8

0.05±0.04

2.2±0.2

DHA + ASA

3

1

1.46±0.08

57.3±0.7

0.94±0.08

36.9±1.3

0.18±0.01

6.9±0.7

ALA

3

2

1.88±0.51

65.7±5.9

0.84±0.10

32.5±5.0

0.04±0.01

1.82±0.9

GSH

3

2

1.47±0.16

59.4±0.5

0.92±0.11

37.0±0.5

0.09±0.01

3.7±0.1

TMPD/ASA

5

0.025/0.25

1.61±0.06

58.9±1.9

0.93±0.00

33.5±1.9

0.21±0.01

7.5±2.8

Rotenone(F)

8

0.02

2.23±0.17

81.7±3.6

0.51±0.15

17.3±4.6

0.03±0.00

1.1±0.1

TMPD/Roten.(S)*

5

-

1.53±0.21

64.0±3.1

0.80±0.11

32.5±3.0

0.06±0.00

2.5±0.3

Rotenone(S)

3

-

1.98±0.04

82.3±3.1

0.45±0.18

16.8±4.0

0.002±0.00

0.4±0.3

Table 3.1: HP 13C metabolite signals as a fraction of [1-13C]pyruvate signal in each of the study
cohorts. The ratios are reported as % and represent the sum of all signals acquired during a series
of spectra. The ratios reported in parenthesis are the fraction of total metabolites signals accounted
for by each metabolite. Data are reported as mean ± SE. The (F) and (S) indicate first and second
HP pyruvate injections, respectively. *Perfusate contained 25 mM TMPD + 250 μM ascorbate for
40 min after 20 μM rotenone administration for 10 min.

The energy charge of the perfused lungs increased from 0.82 ± 0.05 in controls to 0.88 ±
0.03 (P < 0.05) in the ascorbate-treated lungs (pre-injection
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P NMR, after 40 min

perfusion). Analysis of the post-injection 31P NMR spectra showed a significant decrease
in the lung energy charge of the control cohort compared with the pre-injection energy
charge (11%, P < 0.05) and no significant change in the energy charge of the ascorbate
cohort. The β-ATP/total

31

P ratio was also significantly decreased after hyperpolarized
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agent injection in the control cohort (22%, P < 0.001) but was unchanged in the ascorbate
cohort.

Across all cohorts, the bicarbonate ratio was significantly correlated to the post/pre ratio
of β-ATP/total

31

P (r = 0.80, P < 0.0001) as well as to the energy charge (r = 0.47, P <

0.05) (Figure 3.3B). The inset of Figure 3.3B compares the post/pre ratio of EC and βATP/total

31

ATP/total

31

P in the control and ascorbate cohorts. Both the post/pre ratios of EC and βP for the controls are significantly lower than corresponding ratios of the

ascorbate cohort (P < 0.01).

Metabolic changes resulting from the addition of antioxidants and the oxidized form of
ascorbate (DHA) were also examined to elucidate ascorbic acid’s mechanism of action in
the isolated lung. The effect of 2 mM GSH and 2 mM ALP, two water-soluble anti-oxidants,
on HP [

13

C]bicarbonate ratio can be seen in Figure 3.4A. Measurements of bicarbonate

production in the presence of GSH were indistinguishable from the control cohort. On the
other hand, GSH significantly increased the alanine ratio (48%) and decreased the lactate
ratio by 26% (P < 0.01; data not shown). ALP (insignificantly) decreased the bicarbonate
ratio and significantly elevated the lactate ratio by 20% (P < 0.05; data not shown). No
significant effect was observed in the post/pre ratio of EC and β-ATP/total

31

P for either

GSH or ALP cohorts. Because ascorbate is oxidized to DHA in solution during the
perfusion, the effect of 2 mM DHA and 1 mM DHA + 1 mM ASA on lung pyruvate
metabolism (Figure 3.4B) were also studied. No significant effect was observed on the
bicarbonate in the presence of DHA alone. However, 1 mM DHA + 1 mM ASA increased
the bicarbonate ratio by 94%, which is comparable to the effect of 1 mM ASA alone. The
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lactate and alanine ratios did not change in the presence of either DHA or 1 mM DHA + 1
mM ASA.

Figure 3.4: Comparison of 13C bicarbonate ratio in perfused control lungs (n = 11) and lungs treated
with 2 mM GSH (n = 3) or 2 mM ALA (n = 3) (A) and lungs treated with 2 mM DHA (n = 3), 1 mM
DHA þ 2 mM ASA (n = 3), or 1 mM ASA (B). Means with different letter designations are significantly
different from one another (P < 0.05), and means with similar letter designations do not differ
significantly (P 4 0.05).

The metabolism of [1-13C]pyruvate in perfused lungs was also studied in the presence of
rotenone and TMPD, two compounds commonly used in mitochondrial respiration and
electron transport chain activity studies, to evaluate whether the observed increase in
bicarbonate production may be related to increased ETC activity arising from ascorbate’s
reduction of cytochrome c. Figs. 5A and 5B (top) compare the lactate and bicarbonate
ratios in three cohorts of isolated perfused lungs: control (n = 11), 10 min perfusion with
20 mM rotenone (n = 8), and 40 min perfusion with 25 mM TMPD + 250 mM ASA (n = 5).
As seen in the figure, rotenone depressed the bicarbonate production ratio by
approximately 68% (P < 0.005), whereas TMPD elevated the bicarbonate ratio by
approximately 120% (P < 0.001), with respect to control lungs. Rotenone increased the
lactate signal by 32% (P < 0.005), whereas TMPD did not cause any significant change in
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the lactate ratio compared with the control. Neither rotenone nor TMPD significantly
altered alanine production (data not shown). Subsequent treatment of rotenone-perfused
lungs with 25 mM TMPD + 250 mM ASA restored the bicarbonate ratio and depressed the
lactate ratio, such that both metabolites became statistically indistinguishable from those
of the control cohort.

Figure 3.5: (A,B) Hyperpolarized 13C lactate/total metabolite ratio (A, top) and 13C bicarbonate/total
metabolite ratio (B, top). (C) Top: Effect on energy charge of treatment with 20 mM rotenone for 10
min and with 25 mM TMPD þ 0.25 mM ASA for 40 min. The bottom panels show comparison of the
lactate ratio (A), the bicarbonate ratio (B), and the energy charge (C) for two hyperpolarized
pyruvate administrations in individual lungs. “First” and “Second” indicate first and second
injections, respectively, and are linked by lines. First injections were performed after 10 min of
rotenone perfusion (filled circles). Second injections representing perfusion with 25 mM TMPD þ
0.25 mM ascorbate for 40 min after rotenone administration are shown as filled triangles. Those
representing perfusion with normal perfusate after rotenone administration are shown as filled
squares. Means with different letter designations are significantly different from one another (P <
0.01), and means with similar letter designations do not differ significantly (P > 0.01).

This increase in bicarbonate ratio and decrease in lactate ratio was seen in all lungs where
rotenone treatment was followed by TMPD + ASA, whereas those not exposed to TMPD
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+ ASA continued to decline (Figs. 5A and 5B, bottom). Rotenone treatment also depressed
the 31P-derived energy charge by 18%, and TMPD enhanced it by 14% (P < 0.001). These
results appear in Figure 3.5C. Subsequent treatment of the rotenone-perfused lung with
25 mM TMPD + 250 mM ASA also significantly improved the lung’s energy charge. The
increase in energy charge was seen in all lungs where rotenone treatment was followed
by TMPD + ASA, whereas those not exposed to TMPD + ASA continued to decline (Figure
3.5C, bottom). The calculated energy charges were significantly correlated with lactate
ratios (r = –0.71, P < 0.0001) and bicarbonate ratios (r = 0.80, P < 0.0001). These
correlations are shown in Figure 3.6.

3.4. Discussion
The studies described above yielded three principal observations which are then further
explained by additional experimental work. First, the phosphorylation capacity of control
lungs, as determined by the β -ATP peak in the

31

P spectrum, decreased to 50% of its

initial value after perfusion for 204 ± 30 min. Second, the addition of ascorbate to the
perfusate improved both the lung’s viability and metabolic stability, as evidenced by the
fact that the oxidative phosphorylation capacity dropped to 50% of its initial value only
after a significantly longer perfusion period of 366 ± 18 min. Third, the addition of ascorbate
also

shifted

hyperpolarized

[1-13C]pyruvate

metabolism

toward

the

oxidative

phosphorylation pathway, as inferred from the increased bicarbonate ratio (from 3.6% in
the control cohort to 8.1% in the ascorbate cohort).

91

Figure 3.6: Correlation of calculated energy charge with (A) HP lactate ratio (r = –0.71, P < 0.001)
and (B) HP bicarbonate ratio (r = 0.80, P < 0.001).

Further complementary studies quantified the effect of varying ascorbate concentrations
and elucidated some of the mechanisms by which ascorbate increases PDHc activity.
Ultimately, we concluded that ascorbate influences pyruvate metabolism primarily by
stimulating the electron transport chain. This in turn influences mitochondrial Ca 2+
concentration, which is known to regulate PDH activity in vertebrates51,52. The following
discussion covers two main topics: (i) the possible pathways for increasing both the HP
bicarbonate signal and the β-ATP peak intensity in the presence of ascorbate, and (ii) the
possible

mechanism

through

which

ascorbate

affects

pulmonary

oxidative

phosphorylation.

3.5.1. Origin of Increased HP Bicarbonate Signal
The HP 13C NMR and

31

P NMR experiments of study II suggest that ascorbate improves

lung viability by increasing oxidative phosphorylation. The HP pyruvate 1-13C NMR studies
showed that bicarbonate production (Figure 3.2) increased 2.7-fold in ascorbate-perfused
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lungs compared with controls. Furthermore, ascorbate slowed both the decline in apparent
PDHc activity and the increase in lactate production that was seen in repeated HP

13

C

NMR measurements of control lungs (Figure 3.2, insets), suggesting an improvement in
mitochondrial metabolism12,41,53.

Although the observed increase in labeled bicarbonate signal in the ascorbate cohort
could be due to several different pathways, we believe that the increase of HP bicarbonate
production is a result of HP [1-13C]pyruvate’s conversion to

13

CO2 and acetyl-CoA

(coenzyme A) through the pyruvate dehydrogenase complex at an increased rate. One
potential alternate explanation is the direct decarboxylation of pyruvate by intracellular
reactive oxygen species. We recently measured this process in reaction with hydrogen
peroxide54 and found that an intracellular ROS concentration approximately 105 times
higher than the steady-state physiological concentration would be needed for these
results55,56. Furthermore, the ROS concentration would need to decrease during both
extended perfusion and induced mitochondrial dysfunction (study III), and would have to
show either no response or a counterintuitive response to reduction by ascorbate or
steady-state perfusion with pyruvate57. We therefore find it highly unlikely that ROSinduced decarboxylation is a significant contributor to the observed bicarbonate signal.

While intracellular HP CO2/HCO3– could also potentially be produced by the conversion of
pyruvate to phosphoenolpyruvate during gluconeogenesis, the lung is not actively
involved in gluconeogenesis and displays low phosphoenolpyruvate carboxykinase
activity58. Furthermore, we have been unable to detect 13C aspartate or 13C malate peaks
in the hyperpolarized 13C NMR spectra, which would have been present if 13C oxaloacetate
had been generated from the hyperpolarized pyruvate (these peaks are observed during
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gluconeogenesis in the gluconeogenically active liver59). Scholz and Evans previously
reported that the majority of

14

CO2 production from [1-14C]pyruvate in the lung resulted

from PDHc activity60, and we expect the same to be true in the studies reported here:
namely, that PDHc-derived

13

CO2 is quickly brought into equilibrium with H13CO3– by

carbonic anhydrase and leads to the observed HP H13CO3- signal. Moreover, ascorbate
has been shown to increase pyruvate oxidation in different cells by minimizing oxidative
stress and serving as a reducing agent in the electron transport chain. [2-14C]-pyruvate
studies indicated that the increase in released

14

CO2 originates from decarboxylase

activity in the Krebs cycle 61–63.

3.5.2. Concentration-dependent Effect of Ascorbate
Ascorbate increased the HP bicarbonate signal in a concentration-dependent manner,
with saturation occurring at higher concentrations (Figure 3.3A). Although this saturation
could in principle arise from limited uptake or intracellular concentration as the ascorbate
concentration is increased, a variety of previously published results suggest that this is not
the case. Among all cell types of the noninflammatory lung, energy metabolism and
pyruvate uptake occur primarily in type II pneumocytes and pulmonary alveolar
macrophages (PAMs) of the normal lung64,65. According to previous studies, transport of
ascorbate into type II pneumocytes and PAMs is characterized by saturation kinetics with
KM values of 2 and 5 mM, respectively66—significantly higher than the observed saturation
kinetics in these studies. However, more detailed measurements highlight the contribution
of passive diffusion to ascorbate transport in the lung67, particularly at superphysiological
concentrations. Wright and coworkers68 presented results that are consistent with unidirectional saturable transport with KM = 0.16 mM, accompanied by diffusion such that the
two processes’ contribution to ascorbate influx is equal at an extracellular concentration
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of approximately 3 mM. This allows a quantitative estimation of steady-state intracellular
ascorbate concentrations under the conditions relevant to our work:
[𝐴𝑆𝐴]56 = [𝐴𝑆𝐴]78 +

3.3𝑚𝑀
[𝐴𝑆𝐴]78 + 𝐾<

where [ASA]in and [ASA]ex refer to intracellular and extracellular ascorbate concentrations,
respectively. This expression is consistent with previous measurements showing
intracellular accumulation such that the intracellular ascorbate level of rat lungs is 16 to
22 times higher than that in plasma at typical physiological concentrations (0.1 mM)68.
Notably, although the preceding discussion refers to cytosolic ascorbate, previous
measurements have shown the activity of sodium-dependent vitamin C transporters
(SVCTs) in transporting reduced ascorbate across the mitochondrial membrane and have
demonstrated a linear relationship between the mitochondrial and cytosolic ascorbate
isolated mitochondria69,70.

In interpreting the concentration-dependent effect of ascorbate on apparent PDHc activity,
it is important to also consider the rate at which equilibrium intracellular concentrations are
reached. In a previous measurement, perfusion of rat lungs without ascorbate caused a
17% loss of ascorbate content after 50 min67, indicating a rate constant of approximately
4.5 h to reach equilibrium under conditions where passive diffusion dominates ascorbate
transport. The results of Ref.68 also support the slow approach to equilibrium under these
conditions. It is therefore reasonable to suppose that at the high extracellular ascorbate
concentrations of Figure 3.3A (e.g., 8 and 16 mM) there was insufficient time for diffusion
to the intracellular concentration to reach its equilibrium value during the perfused lung
experiment. The observed concentration dependence may thus represent saturation of
the fundamental ascorbate-dependent process (e.g., reduction of cytochrome c), the
95

transition to diffusion-dominated ascorbate transport, or a combination of the two.
Unfortunately, the data of Figure 3.3A are not sufficient to distinguish between these
possibilities.

3.5.3. Changes in Apparent PDHc Activity
The increased bicarbonate signal could potentially be caused by a change in the uptake
of pyruvate by the lung tissue. Although not significantly, the lactate and alanine signals
were also increased in the presence of ascorbate (Figure 3.2B and Table 3.1), possibly
indicating a small effect of ascorbate on monocarboxylate transporter activity71. To
eliminate the HP pyruvate uptake effect, the bicarbonate signals were normalized by the
sum of all 13C metabolite signals, which is likely to more accurately reflect pyruvate uptake.
Unlike with other metabolites, the bicarbonate ratio of the ascorbate (2 mM)-treated lungs
is significantly higher than that of controls (by a factor of 2.3; Table 3.1), suggesting that
ascorbate’s effect on apparent PDHc activity is qualitatively different from the other
metabolic processes observed and that transport alone is not responsible for this effect.
In an attempt to remove altered transporter activity from the analysis, and in light of
uncertainty regarding the contribution of extracellular pyruvate to the observed signal,
metabolite fractions (rather than metabolite / pyruvate ratios) are employed in the following
discussion.

3.5.4. Mitochondrial Function in the Lungs
Because approximately 85% of the total lung ATP is derived from mitochondrial
respiration, and because mitochondrial aerobic metabolism is required to maintain the
lung’s normal energy status, the observed decline in ATP production over time is most
likely due to declining mitochondrial function during perfusion72. Our HP pyruvate
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metabolic studies also point to this mechanism, as the bicarbonate ratio continues to
decrease while the lactate ratio increases with perfusion time (Figure 3.2B, inset) due to
a relative increase in glycolytic metabolism73–75. Recent studies with isolated perfused
heart and ex vivo perfused lung graft models have also demonstrated increasingly
deficient mitochondrial oxidative phosphorylation and significant decline in electron
transport chain enzyme activities with increasing perfusion time12,76.

The calculated energy charge (after 40 min of perfusion) showed an 8% increase in the
ascorbate cohort compared with controls. Furthermore, the post/pre ratio (Figure 3.3B,
inset) of the control lungs’ EC (0.88) is much lower than that of the ascorbate-perfused
lungs (0.99), suggesting that the oxidative phosphorylation pathway is not only more active
in the ascorbate-perfused lungs, but also remains stable at those levels for a longer
duration. This finding is consistent with previous studies77.

3.5.5. Role of Ascorbate in Maintaining Mitochondrial Function
Ascorbate plays multiple roles in cellular regulation, the most well-understood of which is
as an antioxidant and ROS scavenger. However, based on previously reported
experiments as well as studies III and IV as interpreted below, we believe that the
observed changes to lung viability and metabolism are primarily the result of ascorbate’s
effect on the ETC rather than its role as an antioxidant.

Ascorbate is known to prevent ROS-induced damage in ischemia–reperfusion injury,
aging and as a result of drug side effects6,22,78,79. It has also been shown that PDHc activity
decreases in the presence of ROS in a concentration- and time-dependent manner 80. To
evaluate whether the observed ascorbate effect is related to altered ROS concentration in
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the lung, the effects of two physiological water-soluble antioxidants, glutathione and αlipoic acid, were studied on lung’s HP [1-13C]pyruvate metabolism. Both of these
antioxidants have been reported to have a significant effect on ischemia–reperfusion injury
14,81

.

GSH is one of the most important hydrophilic antioxidants in the lungs, protecting cells
against both exogenous and endogenous toxins, including ROS

82

. What is more, given

that the deficiency of one anti-oxidant leads to a decrease of the other, the antioxidant
effect of GSH is directly correlated with ascorbate83,84. The hyperpolarized bicarbonate
signal in the presence of 2 mM GSH in the perfusate did not change significantly relative
to controls (Figure 3.4A). Although glutathione uptake by the lung remains incompletely
understood, the significant increase in alanine ratio and decrease in lactate ratio are
consistent with previous studies and suggest that GSH was taken up by the lung cells that
are actively metabolizing pyruvate 85–87. ALA is a coenzyme of the PDHc and an effective
antioxidant against ROS and associated mitochondrial dysfunction81,88. Although the
decrease in the bicarbonate ratio in the presence of 2 mM ALA was not significant (Figure
3.4A), the increase in lactate ratio in ALA-perfused lungs shows that sufficient ALA was
taken up to influence metabolism as well89. These studies suggest that the primary means
by which ascorbic acid increases PDHc activity is not related to a general ROSscavenging or antioxidant effect.

Another related mechanism by which circulating ascorbate could affect PDHc activity is
through a reaction with its oxidized form, dehydroascorbate: dihydrolipoic acid + DHA à
ascorbate + ALA. This reaction could serve to regenerate intramitochondrial ALA, which
serves as a cofactor in PDHc activity90. Furthermore, it is worth noting that, during the
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experiments described here, ascorbic acid is slowly converted to DHA by reaction with
dissolved O291. Although this oxidation reaction occurs over a relatively long time scale of
approximately 1 h91, DHA is nonetheless always present in the studies. To assess the
effect of DHA, we performed perfusion experiments in which 2 mM DHA was added to the
perfusate as well as others in which 1 mM DHA + 1 mM ASA were used. In the former, the
hyperpolarized [13C]bicarbonate signal was indistinguishable from that of the control
cohort; in the latter, this signal was indistinguishable from that of 1 mM ASA alone (Figure
3.4B). These results suggest that oxidation of dihydrolipoic acid is not the dominant
mechanism by which ascorbate affects PDHc activity. We note, however, that although
glucose transporter 1 transports DHA [97], previous studies have suggested that DHA is
not taken up efficiently by perfused lung and lung cells91; it is therefore impossible to
entirely rule out a mechanism in which ascorbate is taken up, oxidized to DHA, and
subsequently regenerates ALA by the oxidation of dihydrolipoic acid based on the studies
described here.

Nonetheless, the most likely route by which ascorbate influences lung metabolism is
through its role as a reducing agent in the electron transport chain. Previous studies of
ascorbate’s protective effects in cardiac arrest and electrical shock, ischemia–reperfusion
injury, drug side effects and aging have shown that ascorbate plays a role as an activator
of the ETC complexes6,35,62,78,92. This study and other previous works have shown a
reduction in EC and ATP production during extended perfusion, indicating a gradual
decrease in mitochondrial function and oxidative phosphorylation12,76. Accordingly, we
hypothesized that the direct reduction of cytochrome c by ascorbate is a possible
mechanism by which PDHc flux (as observed in HP bi-carbonate signal) and mitochondrial
function (as observed in energy charge) might be simultaneously protected or
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activated93,94. Study IV was designed to evaluate this hypothesis: lungs were first perfused
with TMPD + ascorbate, a combination that reduces cytochrome c at a rate 30-fold faster
than ascorbate alone [100]. Note that adding a small amount of ascorbate is necessary to
ensure that TMPD remains in the reduced form, but that, as seen in Figure 3.3A, this
amount is too small to account for the observed effects. Additional studies were performed
in which the ascorbate concentration was increased to 500 mM (data not shown).

This change did not alter either the bicarbonate ratio or EC, confirming that ascorbate is
not the primary agent reducing cytochrome c in the presence of TMPD94. In the lung
perfused with 25 mM TMPD + 250 mM ascorbate, the bicarbonate ratio increased by a
factor of 2.2—comparable to with the addition of 2 mM ascorbate. The energy charge of
the TMPD-perfused lung also increased significantly (by 13%) compared with controls
(Figure 3.5). As shown in study II, ascorbate alone also significantly increased the lung’s
energy charge (8%), confirming previously reported data in ascorbate-treated cartilage
cells77. We may therefore conclude that the reduction of cytochrome c and concomitant
activation of ETC complex IV increases apparent PDHc flux.

In a subset of study IV, lungs perfused with 20 mM rotenone showed a significant decrease
in both the bicarbonate ratio (68%) and EC (18%). Rotenone-perfused lungs that were
then perfused with TMPD + ascorbate returned to a state indistinguishable from controls
in terms of PDHc activity and energy charge, whereas those perfused without TMPD +
ascorbate continued to decline. Moreover, in agreement with a previous study41, increased
HP lactate ratio and decreased EC were observed in the rotenone-perfused lungs due to
the inhibition of mitochondrial electron transport. Both measurements returned to baseline
after perfusion with TMPD + ascorbate as a result of ETC activation. Further evidence of
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the link between the electron transport chain and PDHc activity can be seen in the strong
positive correlation between EC and HP bicarbonate ratio across all cohorts (Figure 3.6).
A complementary effect is also observed in the strong negative correlation between EC
and HP lactate ratio across all cohorts: low ETC activity leads to overreliance on glycolytic
ATP generation and an increase in cytosolic lactate 57.

We note that both correlations are observed independent of the manner in which ETC
activity is influenced, a fact which appears somewhat counterintuitive at first. Because
TMPD is known to directly reduce cytochrome c, thereby providing a source of electrons
for respiratory activity that does not require PDHc-derived NADH, it would be reasonable
to assume that PDHc activity would be suppressed. However, it is also true that an active
electron transport chain results in an increased proton concentration gradient across the
mitochondrial membrane. To maintain charge balance, this gradient is mirrored by a Ca2+
gradient; the active mitochondrion is thus characterized by an increased intramitochondrial
Ca2+ concentration, a condition which is well understood to cause PDHc activity by
activating pyruvate dehydrogenase phosphatase51,52. We therefore hypothesize that
ascorbate maintains mitochondrial function during perfusion by activating the electron
transport chain and that the intramitochondrial Ca2+ concentration of the active ETC, rather
than a direct interaction between ascorbate and PDHc or its cofactors, is responsible for
maintaining and stimulating PDHc activity. The exact mechanism by which ascorbate
activates the ETC is unknown, although many previous studies have highlighted important
interactions with complex I and complex IV—maintaining their activity after cardiac arrest,
as well as in aging fibroblasts—which in turn prevents the loss of cytochrome c and
maintains the mitochondrial membrane polarization6,35,92,95,96. Any of these effects, either
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singly or in combination, may be responsible for increased viability and the observed
stimulation of the PDHc in ascorbate-perfused lungs.

3.6. Conclusions
In this study, we demonstrated that the energy status and PDHc activity of perfused lungs
declines during EVLP, and concluded that a part of the energy depletion and loss of
viability observed in reperfused ischemic lungs12 is due to perfusion alone. We also
provided evidence that ascorbate regulates the ex vivo perfused lung’s metabolism toward
oxidative phosphorylation. Although ascorbate’s role in lessening ischemia-reperfusion
injury via its ROS scavenging function has been discussed previously21,22, our studies
suggest that ascorbate can also slow the decline in pulmonary mitochondrial activity
through an independent interaction with ETC complexes. Based on the observation that
lungs experiencing significant decline in energy status are highly prone to edema, it seems
clear that maintaining mitochondrial function during EVLP is critical to maintaining organ
viability. Finally, we also demonstrated hyperpolarized [1-13C]pyruvate’s suitability as a tool
for evaluating the lung’s mitochondrial status in ex vivo lung perfusion models due to its
ability to simultaneously probe both glycolytic and oxidative phosphorylation pathways.
The study also demonstrates that the addition of ascorbate to the perfusate during EVLP
may be beneficial in prolonging the viability of the lungs being excised, transported and
reperfused before transplant. Further studies are warranted to assess the relevance of
these findings to human lung transplant maintenance and evaluation procedures.

102

3.7. References

1.

Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary Transplantation: the role of brain death
in
donor
lung
injury.
Transplantation.
2003;75(12):1928.
doi:10.1097/01.TP.0000066351.87480.9E

2.

Punch JD, Hayes DH, LaPorte FB, McBride V, Seely MS. Organ Donation and Utilization in
the United States, 1996–2005. American Journal of Transplantation. 2007;7(s1):1327-1338.
doi:10.1111/j.1600-6143.2007.01779.x

3.

Cypel M, Yeung JC, Liu M, et al. Normothermic Ex Vivo Lung Perfusion in Clinical Lung
Transplantation. New England Journal of Medicine. 2011;364(15):1431-1440.
doi:10.1056/NEJMoa1014597

4.

Cypel M, Rubacha M, Yeung J, et al. Normothermic Ex Vivo Perfusion Prevents Lung Injury
Compared to Extended Cold Preservation for Transplantation. American Journal of
Transplantation. 2009;9(10):2262-2269. doi:10.1111/j.1600-6143.2009.02775.x

5.

den Hengst WA, Gielis JF, Lin JY, Van Schil PE, De Windt LJ, Moens AL. Lung ischemiareperfusion injury: a molecular and clinical view on a complex pathophysiological process.
American Journal of Physiology-Heart and Circulatory Physiology. 2010;299(5):H1283H1299. doi:10.1152/ajpheart.00251.2010

6.

Sharma P, Rupar CA, Rip JW. Consequences of Aging on Mitochondrial Respiratory Chain
Enzymes in Cultured Human Fibroblasts Treated with Ascorbate. GER. 1998;44(2):78-84.
doi:10.1159/000021988

7.

Weyker PD, Webb CAJ, Kiamanesh D, Flynn BC. Lung Ischemia Reperfusion Injury: A
Bench-to-Bedside Review. Semin Cardiothorac Vasc Anesth. 2013;17(1):28-43.
doi:10.1177/1089253212458329

8.

Ovechkin AV, Lominadze D, Sedoris KC, Robinson TW, Tyagi SC, Roberts AM. Lung
ischemia–reperfusion injury: implications of oxidative stress and platelet–arteriolar wall
interactions.
Archives
of
Physiology
and
Biochemistry.
2007;113(1):1-12.
doi:10.1080/13813450601118976

9.

de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia–Reperfusion–induced Lung Injury.
Am J Respir Crit Care Med. 2003;167(4):490-511. doi:10.1164/rccm.200207-670SO

10.

Kalogeris T, Bao Y, Korthuis RJ. Mitochondrial reactive oxygen species: A double edged
sword in ischemia/reperfusion vs preconditioning. Redox Biology. 2014;2:702-714.
doi:10.1016/j.redox.2014.05.006

11.

Koike T, Yeung JC, Cypel M, et al. Kinetics of lactate metabolism during acellular
normothermic ex vivo lung perfusion. The Journal of Heart and Lung Transplantation.
2011;30(12):1312-1319. doi:10.1016/j.healun.2011.07.014

12.

Noda K, Shigemura N, Tanaka Y, et al. Hydrogen Preconditioning During Ex Vivo Lung
Perfusion Improves the Quality of Lung Grafts in Rats. Transplantation. 2014;98(5):499.
doi:10.1097/TP.0000000000000254

103

13.

Sommer S-P, Sommer S, Sinha B, et al. Ischemia-reperfusion injury–induced pulmonary
mitochondrial damage. The Journal of Heart and Lung Transplantation. 2011;30(7):811-818.
doi:10.1016/j.healun.2011.02.001

14.

Sommer A, Wieser R. Die beschränkte Körperschaftsteuerbefreiung gemeinnütziger
Bauvereinigungen als im europarechtlichen Sinn staatliche Beihilfe? wobl. 2012;25(4):140144. doi:10.1007/s00719-012-0049-y

15.

Schöder H, Knight RJ, Kofoed KF, Schelbert HR, Buxton DB. Regulation of pyruvate
dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. Biochimica
et Biophysica Acta (BBA) - Molecular Basis of Disease. 1998;1406(1):62-72.
doi:10.1016/S0925-4439(97)00088-4

16.

Ferrari RS, Andrade CF. Oxidative Stress and Lung Ischemia-Reperfusion Injury. Oxidative
Medicine and Cellular Longevity. doi:10.1155/2015/590987

17.

Nagel E, Meyer A zu V, Bartels M, Pichlmayr R. Antioxidative vitamins in prevention of
ischemia/reperfusion injury. Int J Vitam Nutr Res. 1997;67(5):298-306.

18.

Okutan H, Savas C, Delibas N. The antioxidant effect of melatonin in lung injury after aortic
occlusion–reperfusion.
Interact
CardioVasc
Thorac
Surg.
2004;3(3):519-522.
doi:10.1016/j.icvts.2004.05.005

19.

Fu Z, Liu X, Geng B, Fang L, Tang C. Hydrogen sulfide protects rat lung from ischemia–
reperfusion injury. Life Sciences. 2008;82(23-24):1196-1202. doi:10.1016/j.lfs.2008.04.005

20.

Inci I, Zhai W, Arni S, Hillinger S, Vogt P, Weder W. N-Acetylcysteine Attenuates Lung
Ischemia–Reperfusion Injury After Lung Transplantation. The Annals of Thoracic Surgery.
2007;84(1):240-246. doi:10.1016/j.athoracsur.2007.03.082

21.

Demertzis S, Scherer M, Langer F, Dwenger A, Hausen B, Schäfers H-J. Ascorbic acid for
amelioration of reperfusion injury in a lung autotransplantation model in sheep. The Annals
of Thoracic Surgery. 2000;70(5):1684-1689. doi:10.1016/S0003-4975(00)01846-4

22.

Baltalarli A, Ozcan V, Ferda B, et al. Ascorbic Acid (Vitamin C) and Iloprost Attenuate the
Lung Injury Caused by Ischemia/Reperfusion of the Lower Extremities of Rats. Annals of
Vascular Surgery. 2006;20(1):49-55. doi:10.1007/s10016-005-9284-0

23.

Adluri RS, Thirunavukkarasu M, Zhan L, et al. Cardioprotective Efficacy of a Novel Antioxidant
Mix VitaePro Against Ex Vivo Myocardial Ischemia–Reperfusion Injury. Cell Biochem
Biophys. 2013;67(2):281-286. doi:10.1007/s12013-011-9300-7

24.

Guler L, Tavlasoglu M, Yucel O, et al. Taurine attenuates lung ischemia–reperfusion injury
after lung transplantation in rats. J Anesth. 2014;28(3):347-353. doi:10.1007/s00540-0131741-2

25.

Lehr Hans-Anton, Frei Balz, Olofsson A. Maria, Carew Thomas E., Arfors Karl-E. Protection
From Oxidized LDL–Induced Leukocyte Adhesion to Microvascular and Macrovascular
Endothelium In Vivo by Vitamin C but Not by Vitamin E. Circulation. 1995;91(5):1525-1532.
doi:10.1161/01.CIR.91.5.1525

104

26.

Korkmaz A, Kolankaya D. The Protective Effects of Ascorbic Acid against Renal IschemiaReperfusion
Injury
in
Male
Rats.
Renal
Failure.
2009;31(1):36-43.
doi:10.1080/08860220802546271

27.

Lee J, Son H-Y, Kim M. Attenuation of ischemia-reperfusion injury by ascorbic acid in the
canine renal transplantation. Journal of Veterinary Science. 2006;7(4):375-379.
doi:10.4142/jvs.2006.7.4.375

28.

Lee W-Y, Lee J-S, Lee S-M. Protective Effects of Combined Ischemic Preconditioning and
Ascorbic Acid on Mitochondrial Injury in Hepatic Ischemia/Reperfusion. Journal of Surgical
Research. 2007;142(1):45-52. doi:10.1016/j.jss.2006.08.043

29.

Hsu C-C, Wang J-J. L-Ascorbic Acid and Alpha-tocopherol Attenuates Liver IschemiaReperfusion Induced of Cardiac Function Impairment. Transplantation Proceedings.
2012;44(4):933-936. doi:10.1016/j.transproceed.2012.01.098

30.

Sağsöz N, Kisa Ü, Apan A. Ischaemia–reperfusion injury of rat ovary and the effects of vitamin
C,
mannitol
and
verapamil.
Hum
Reprod.
2002;17(11):2972-2976.
doi:10.1093/humrep/17.11.2972

31.

May JM. HOW DOES ASCORBIC ACID PREVENT ENDOTHELIAL DYSFUNCTION? Free
Radical Biology and Medicine. 2000;28(9):1421-1429.

32.

Biesalski H, McGregor G. Antioxidant therapy in critical care—Is the microcirculation the
primary
target?
Critical
Care
Medicine.
2007;35(9).
doi:10.1097/01.CCM.0000278598.95294.C5

33.

Basili S, Tanzilli G, Mangieri E, et al. Intravenous Ascorbic Acid Infusion Improves Myocardial
Perfusion Grade During Elective Percutaneous Coronary Intervention. JACC: Cardiovascular
Interventions. 2010;3(2):221-229. doi:10.1016/j.jcin.2009.10.025

34.

Mo S-J, Son E-W, Rhee D-K, Pyo S. Modulation of tnf-α-induced icam-1 expression, no and
h202 production by alginate, allicin and ascorbic acid in human endothelial cells. Arch Pharm
Res. 2003;26(3):244. doi:10.1007/BF02976837

35.

Tsai M-S, Huang C-H, Tsai C-Y, et al. Ascorbic acid mitigates the myocardial injury
after cardiac arrest and electrical shock. Intensive Care Med. 2011;37(12):2033-2040.
doi:10.1007/s00134-011-2362-6

36.

Fisher BJ, Seropian IM, Kraskauskas D, et al. Ascorbic acid attenuates lipopolysaccharideinduced acute lung injury*. Critical Care Medicine. 2011;39(6):1454-1460.
doi:10.1097/CCM.0b013e3182120cb8

37.

Iwata N, Okazaki M, Xuan M, Kamiuchi S, Matsuzaki H, Hibino Y. Orally Administrated
Ascorbic Acid Suppresses Neuronal Damage and Modifies Expression of SVCT2 and GLUT1
in the Brain of Diabetic Rats with Cerebral Ischemia-Reperfusion. Nutrients. 2014;6(4):15541577. doi:10.3390/nu6041554

38.

Pullinger B, Profka H, Ardenkjaer-Larsen JH, Kuzma NN, Kadlecek S, Rizi RR. Metabolism
of hyperpolarized [1-13C]pyruvate in the isolated perfused rat lung - an ischemia study:
MEASUREMENTS OF LUNG METABOLISM USING HYPERPOLARIZED 1-13C
PYRUVATE. NMR in Biomedicine. 2012;25(10):1113-1118. doi:10.1002/nbm.2777

105

39.

Hayashi Y, Inubushi T, Nioka S, Forster RE. ^ 3^ 1P-NMR spectroscopy of isolated perfused
rat lung. Journal of Applied Physiology. 1993;74:1549–1549.

40.

Pillai RP, Buescher PC, Pearse DB, Sylvester JT, Eichhorn GL. 31P NMR spectroscopy of
isolated perfused lungs. Magn Reson Med. 1986;3(3):467-472.

41.

Bongard RD, Yan K, Hoffmann RG, et al. Depleted energy charge and increased pulmonary
endothelial permeability induced by mitochondrial complex I inhibition are mitigated by
coenzyme Q1 in the isolated perfused rat lung. Free Radical Biology and Medicine.
2013;65:1455-1463. doi:10.1016/j.freeradbiomed.2013.07.040

42.

Kasimos JN, Merchant TE, Gierke LW, Glonek T. 31P Magnetic Resonance Spectroscopy of
Human Colon Cancer. :7.

43.

Pettegrew JW, Keshavan MS, Minshew NJ. 31P Nuclear Magnetic Resonance Spectroscopy:
Neurodevelopment
and
Schizophrenia.
Schizophr
Bull.
1993;19(1):35-53.
doi:10.1093/schbul/19.1.35

44.

Riss TL, Moravec RA, Niles AL, et al. Cell Viability Assays. Eli Lilly & Company and the
National
Center
for
Advancing
Translational
Sciences;
2016.
https://www.ncbi.nlm.nih.gov/books/NBK144065/. Accessed March 24, 2019.

45.

Nishiwaki M, Fujise Y, Yoshida TO, Matsuzawa E, Nishiwaki Y. Evaluation of the effects of
photodynamic therapy with phosphorus 31 magnetic resonance spectroscopy. British Journal
of Cancer. 1999;80(1-2):133-141. doi:10.1038/sj.bjc.6690332

46.

Schunk K, Pitton M, Düber C, Kersjes W, Schadmand-Fischer S, Thelen M. Dynamic
Phosphorus-31 Magnetic Resonance Spectroscopy of the Quadriceps Muscle. Investigative
Radiology. 1999;34(2):116-125.

47.

Atkinson DE. Energy charge of the adenylate pool as a regulatory parameter. Interaction with
feedback modifiers. Biochemistry. 1968;7(11):4030-4034. doi:10.1021/bi00851a033

48.

Ballard FJ. Adenine nucleotides and the adenylate kinase equilibrium in livers of foetal and
newborn rats. Biochemical Journal. 1970;117(2):231-235. doi:10.1042/bj1170231

49.

Tillery SI, Lehnert BE. Age-bodyweight relationships to lung growth in the F344 rat as indexed
by
lung
weight
measurements.
Laboratory
Animals.
1986;20(3):189-194.
doi:10.1258/002367786780865610

50.

Kepner GR. Saturation Behavior: a general relationship described by a simple second-order
differential equation. Theoretical Biology and Medical Modelling. 2010;7(1):11.
doi:10.1186/1742-4682-7-11

51.

Denton RM, Randle PJ, Martin BR. Stimulation by calcium ions of pyruvate dehydrogenase
phosphate phosphatase. Biochemical Journal. 1972;128(1):161-163. doi:10.1042/bj1280161

52.

Denton RM. Regulation of mitochondrial dehydrogenases by calcium ions. Biochimica et
Biophysica
Acta
(BBA)
Bioenergetics.
2009;1787(11):1309-1316.
doi:10.1016/j.bbabio.2009.01.005

106

53.

Sasaki M, Fujimoto S, Sato Y, et al. Reduction of Reactive Oxygen Species Ameliorates
Metabolism-Secretion Coupling in Islets of Diabetic GK Rats by Suppressing Lactate
Overproduction. Diabetes. 2013;62(6):1996-2003. doi:10.2337/db12-0903

54.

Ghosh RK, Kadlecek SJ, Pourfathi M, Rizi RR. Efficient production of hyperpolarized
bicarbonate by chemical reaction on a DNP precursor to measure pH. Magn Reson Med.
November 2014:n/a-n/a. doi:10.1002/mrm.25530

55.

Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiological
Reviews. 1979;59(3):527-605. doi:10.1152/physrev.1979.59.3.527

56.

Cadenas E, Davies KJA. MITOCHONDRIAL FREE RADICAL GENERATION, OXIDATIVE
STRESS, AND AGING. oxidative stress.:9.

57.

Kadlecek S, Shaghaghi H, Siddiqui S, Profka H, Pourfathi M, Rizi R. The effect of exogenous
substrate concentrations on true and apparent metabolism of hyperpolarized pyruvate in the
isolated perfused lung. NMR Biomed. 2014;27(12):1557-1570. doi:10.1002/nbm.3219

58.

Scholz RW. Lipid metabolism by rat lung in vitro. Utilization of citrate by normal and starved
rats. Biochemical Journal. 1972;126(5):1219-1224. doi:10.1042/bj1261219

59.

Merritt ME, Harrison C, Sherry AD, Malloy CR, Burgess SC. Flux through hepatic pyruvate
carboxylase and phosphoenolpyruvate carboxykinase detected by hyperpolarized 13C
magnetic resonance. Proceedings of the National Academy of Sciences.
2011;108(47):19084-19089. doi:10.1073/pnas.1111247108

60.

Scholz RW, Evans RM. Pyruvate metabolism by rat lung in vitro. Lipids. 1973;8(6):360–365.

61.

Piontek GE, Milner JA, Cain CA. Effects of Hyperthermia and L-Ascorbic Acid on Glucose,
Pyruvate, and Lactate Metabolism in Ehrlich Ascites Carcinoma Cells. Experimental Biology
and Medicine. 1979;161(4):597-599. doi:10.3181/00379727-161-40604

62.

Werner P, Mytilineou C, Cohen G, Yahr MD. Impaired oxidation of pyruvate in human
embryonic fibroblasts after exposure to L-dopa. European journal of pharmacology.
1994;263(1):157–162.

63.

Lane M, Maybach JM, Gardner DK. Addition of ascorbate during cryopreservation stimulates
subsequent
embryo
development.
Hum
Reprod.
2002;17(10):2686-2693.
doi:10.1093/humrep/17.10.2686

64.

Simon LM, Robin ED, Raffin T, Theodore J, Douglas WHJ. Bioenergetic pattern of isolated
type II pneumocytes in air and during hypoxia. Journal of Clinical Investigation.
1978;61(5):1232.

65.

Massaro GD, Gail DB, Massaro D. Lung oxygen consumption and mitochondria of alveolar
epithelial and endothelial cells. Journal of applied physiology. 1975;38(4):588–592.

66.

Castranova V, Wright JR, Colby HD, Miles PR. Ascorbate uptake by isolated rat alveolar
macrophages and type II cells. Journal of Applied Physiology. 1983;54(1):208–214.

67.

Arad ID, Forman HJ, Fisher AB. Ascorbate efflux from guinea pig and rat lungs: Effect of
starvation and O2 exposure. The Journal of Laboratory and Clinical Medicine.
1980;96(4):673-681. doi:10.5555/uri:pii:0022214380900712

107

68.

Wright JR, Castranova V, Colby HD, Miles PR. Ascorbate uptake by isolated rat lung cells. J
Appl Physiol. 1981;51:1477–1483.

69.

May JM. The SLC23 family of ascorbate transporters: ensuring that you get and keep your
daily dose of vitamin C. British Journal of Pharmacology. 2011;164(7):1793-1801.
doi:10.1111/j.1476-5381.2011.01350.x

70.

Azzolini C, Fiorani M, Cerioni L, Guidarelli A, Cantoni O. Sodium-dependent transport of
ascorbic acid in U937 cell mitochondria. IUBMB Life. 2013;65(2):149-153.
doi:10.1002/iub.1124

71.

Castro MA, Angulo C, Brauchi S, Nualart F, Concha II. Ascorbic acid participates in a general
mechanism for concerted glucose transport inhibition and lactate transport stimulation.
Pflügers
Archiv
European
Journal
of
Physiology.
2008;457(2):519-528.
doi:10.1007/s00424-008-0526-1

72.

Fisher A B. Intermediary metabolism of the lung. Environmental Health Perspectives.
1984;55:149-158. doi:10.1289/ehp.8455149

73.

Fisher AB, Dodia C. Lactate and regulation of lung glycolytic rate. American Journal of
Physiology-Endocrinology
and
Metabolism.
1984;246(5):E426-E429.
doi:10.1152/ajpendo.1984.246.5.E426

74.

Brooks GA. Lactate. Sports Med. 2007;37(4):341-343. doi:10.2165/00007256-20073704000017

75.

Bassett DJ, Bowen-Kelly E. Pyruvate metabolism of perfused rat lungs after exposure to
100% oxygen. J Appl Physiol. 1986;60:1605–1609.

76.

Kurian GA. ROLE OF NORMAL PERFUSION TIME ON FUNCTIONAL ENZYME
ACTIVITIES AND PHYSIOLOGY OF INTERFIBRILLAR AND SUB-SARCOLEMMAL
MITOCHONDRIA FROM ISOLATED RAT HEART. 6(11):8.

77.

Shapiro IM, Leboy PS, Tokuoka T, et al. Ascorbic acid regulates multiple metabolic activities
of cartilage cells. Am J Clin Nutr. 1991;54(6):1209S-1213S. doi:10.1093/ajcn/54.6.1209s

78.

Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T. The effects of a high dose of
ascorbate on ischemia-reperfusion-induced mitochondrial dysfunction in canine hearts. Heart
Vessels. 1992;7(1):18-23. doi:10.1007/BF01745863

79.

Kaufmann P, Török M, Hänni A, Roberts P, Gasser R, Krähenbühl S. Mechanisms of
benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41(4):925-935.
doi:10.1002/hep.20634

80.

Tabatabaie T, Potts JD, Floyd RA. Reactive oxygen species-mediated inactivation of pyruvate
dehydrogenase. Archives of biochemistry and biophysics. 1996;336(2):290–296.

81.

He L, Liu B, Dai Z, et al. Alpha lipoic acid protects heart against myocardial ischemia–
reperfusion injury through a mechanism involving aldehyde dehydrogenase 2 activation.
European Journal of Pharmacology. 2012;678(1-3):32-38. doi:10.1016/j.ejphar.2011.12.042

82.

Aquilano K, Baldelli S, Ciriolo MR. Glutathione: new roles in redox signaling for an old
antioxidant. Front Pharmacol. 2014;5. doi:10.3389/fphar.2014.00196

108

83.

Meister A. On the antioxidant effects of ascorbic acid and glutathione. Biochemical
Pharmacology. 1992;44(10):1905-1915. doi:10.1016/0006-2952(92)90091-V

84.

Jain A, Mårtensson J, Mehta T, Krauss AN, Auld PA, Meister A. Ascorbic acid prevents
oxidative stress in glutathione-deficient mice: effects on lung type 2 cell lamellar bodies, lung
surfactant,
and
skeletal
muscle.
PNAS.
1992;89(11):5093-5097.
doi:10.1073/pnas.89.11.5093

85.

M\a artensson J, Jain A, Frayer W, Meister A. Glutathione metabolism in the lung: inhibition
of its synthesis leads to lamellar body and mitochondrial defects. Proceedings of the National
Academy of Sciences. 1989;86(14):5296–5300.

86.

Wimberger P, Ebner S, Marin-Grez M. Reduced glutathione inhibits rabbit and rat skeletal
muscle lactate dehydrogenase and prevents dinitrophenol induced extracellular acidification
by an epithelial cell line. Life Sciences. 1997;61(4):403-409. doi:10.1016/S00243205(97)00397-4

87.

Bai C, Brown LAS, Jones DP. Glutathione transport by type II cells in perfused rat lung.
American Journal of Physiology-Lung Cellular and Molecular Physiology. 1994;11(4):L447.

88.

Hagen TM, Ingersoll RT, Lykkesfeldt J, et al. (R)-α-Lipoic acid-supplemented old rats have
improved mitochondrial function, decreased oxidative damage, and increased metabolic rate.
The FASEB Journal. 1999;13(2):411-418. doi:10.1096/fasebj.13.2.411

89.

Vigil M, Berkson BM, Garcia AP. Adverse Effects of High doses of Intravenous Alpha Lipoic
Acid on Liver Mitochondria. Global Advances in Health and Medicine. 2014;3(1):25-27.
doi:10.7453/gahmj.2013.011

90.

Xu DP, Wells WW. α-Lipoic acid dependent regeneration of ascorbic acid from
dehydroascorbic acid in rat liver mitochondria. J Bioenerg Biomembr. 1996;28(1):77-85.
doi:10.1007/BF02150681

91.

Willis RJ, Kratzing CC. Transport of ascorbic acid in perfused rat lung. Pflügers Archiv.
1975;356(1):93–98.

92.

Ghneim HK, Al-Sheikh YA. The effect of aging and increasing ascorbate concentrations on
respiratory chain activity in cultured human fibroblasts. Cell Biochemistry and Function.
2010;28(4):283-292. doi:10.1002/cbf.1653

93.

Slater EC. The measurement of the cytochrome oxidase activity of enzyme preparations.
Biochemical Journal. 1949;44(3):305-318. doi:10.1042/bj0440305

94.

Kimelberg H, Nicholls P. Kinetic studies on the interaction of TMPD with cytochrome c and
cytochrome c oxidase. Archives of Biochemistry and Biophysics. 1969;133(2):327-335.
doi:10.1016/0003-9861(69)90461-5

95.

Gruss-Fischer T, Fabian I. Protection by ascorbic acid from denaturation and release of
cytochrome c, alteration of mitochondrial membrane potential and activation of multiple
caspases induced by H2O2, in human leukemia cells. Biochemical Pharmacology.
2002;63(7):1325-1335. doi:10.1016/S0006-2952(02)00863-8

109

96.

Hattori T, Watanabe K, Uechi Y, Yoshioka H, Ohta Y. Repetitive Transient Depolarizations of
the Inner Mitochondrial Membrane Induced by Proton Pumping. Biophysical Journal.
2005;88(3):2340-2349. doi:10.1529/biophysj.104.041483

110

Chapter 4: Translating from Ex Vivo Metabolic Spectroscopy to In Vivo Metabolic
Imaging of HP [1-13C] Pyruvate Using an Acute Inflammation Model

Abstract
In this study, we investigated the feasibility of hyperpolarized [1-13C]pyruvate as a potential
marker for inflammation in lung tissue. In the first part of the study, we report ex vivo
metabolic measurements in the isolated, perfused rat lung of healthy controls and in lungs
undergoing acute inflammation using hyperpolarized [1-13]C-labeled pyruvate. The overall
apparent lactate labelling was shown to increase significantly (on average by a factor of
3.3) at the 7-day acute stage and then revert substantially to baseline at 21 days, while
other markers indicating monocarboxylate uptake and transamination rate were
unchanged. In the second part of the study, we successfully translated our hyperpolarized
imaging technique for in vivo imaging. The overall lactate-to-pyruvate ratio showed a
similar trend as the ex vivo study; it was found to be significantly increased on day 7 (by
a factor of 1.6) and then reverted to baseline by day 21. Elevated lung lactate signal levels
correlated well with phosphodiester levels as determined with 31P spectroscopy and to the
presence of neutrophils as determined by histology, consistent with a relationship between
intracellular lactate pool labeling and the density and type of inflammatory cells present.

This ex vivo spectroscopy findings from this chapter have been published as ‘Metabolic
spectroscopy of inflammation in a bleomycin-induced lung injury model using hyperpolarized 1-13C
pyruvate’ by Shaghaghi et al, in NMR in Biomedicine, 27(8):939-947 (2014). Some of the in vivo
findings have been presented at the International Society for Magnetic Resonance in Imaging
(ISMRM) Conference in Paris, France as, ‘A Multimodal Imaging Approach to Characterize the
Onset of Pulmonary Fibrosis’ by Siddiqui et al. (2018).
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4.1. Introduction
The adaptive immune system’s response is essential to the process of lung rejection: the
mismatch between host and donor MHC molecules stimulates cytotoxic T cells (CTLs),
which then target the graft tissue for rejection. Directly visualizing the progression of lung
inflammation would therefore be very useful for detecting lung rejection earlier.
Unfortunately, conventional techniques for measuring inflammatory cell activity—biopsies
and lavage—are not very effective in sampling regional differences, while radiological
methods’ dependence on edema, fibrosis, emphysema, and other alterations to tissue
density than on the weak direct x-ray absorption of the inflammatory cells make them
unsuitable as well. However, it has been amply demonstrated that the metabolic state of
inflammatory cells, and particularly their glycolytic activity, is much greater than that of
normal lung tissue1. In this study, we therefore investigated the uptake of hyperpolarized
[1-13C]pyruvate as a potential marker for inflammation in lung tissue.

As described in Chapter 2, although HP MRI uses external nuclear polarization to
overcome its low sensitivity, several challenges not present in other organs have thus far
limited HP studies in lungs. These include low tissue density, high susceptibility/B0
inhomogeneity caused by air- tissue interfaces, cardiac and respiratory motion, and the
low metabolic rate of the lungs compared to solid organs. In order to minimize many of
the difficulties mentioned above, we first demonstrated that HP 13C MR spectroscopy can
be used to differentiate inflamed tissue from healthy tissue in ex vivo isolated, perfused
lungs before translating this technique to in vivo HP 13C MR imaging.

Although our ultimate goal is to develop a translatable method for imaging lung rejection,
we used a bleomycin-induced lung injury (BILI) model of inflammation for this study. The
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etiology of the BILI model is substantially different from that of lung rejection—most
significantly in that, unlike tissue rejection, it is an innate immune response primarily driven
by the infiltration of neutrophils into the tissue. Like T cells, however, neutrophils depend
on glycolysis for their energy1–3, so the successful development of HP [1-13C] pyruvate
imaging is nevertheless applicable to imaging post-transplantation outcomes. There are,
moreover, a number of advantages to using a BILI rather than a transplant model for
developing this technique. For example, the BILI model is a well-developed animal model
with a large number of studies4 characterizing its inflammatory and eventual fibrotic
response after bleomycin induction. The model induction itself is rapid, and inflammation
can be observed within three to seven days. Finally, the imaging technique can be
developed using half the number of animals that would be needed with a lung
transplantation model, which requires donor animals as well.

4.2. Materials and Methods
All animal experiments were conducted in accordance with protocols approved by the
Institutional Animal Care and Use Committee of the University of Pennsylvania. Eightweek-old male Sprague Dawley rats weighing 320 ± 20 g were used for all experiments.
All rats were carefully age matched and maintained under very similar environments and
dietary conditions. The cohort sizes for both ex and in vivo studies are listed in Table 4.1
Ex Vivo Isolated
Perfused Lung
Spectroscopy

In Vivo Lung
Imaging

Control

7

3

Day 7

10

3

Day 14

-

3

Day 21

3

2

Table 4.1: Cohort sizes for the ex vivo and in vivo studies.
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4.2.1 Bleomycin Model Induction
Bleomycin rats were anesthetized using inhaled 2.5% isoflurane, placed supine, and
intubated with a 2-inch long, 14-gauge angiocatheter. A 2.5 U/kg concentration of
bleomycin (Bedford Laboratories, Bedford, OH) was then instilled through the catheter,
followed by a 3 mL injection of air to clear the catheter. Animals were then rocked from
side to side to distribute the bleomycin throughout the lungs as evenly as possible. The
animals were subsequently recovered from anesthesia and briefly ventilated with a rodent
ventilator (CWE, Ardmore, PA); supplemental oxygen was given if they failed to recover
from anesthesia in a timely manner.

4.2.2. Preparation of Hyperpolarized [1-13C]Pyruvate
The solid-state pyruvic acid mixture was prepared similarly to the method described in the
previous chapter; however, the liquid-state concentrations and duration of the HP
injections were different for these studies. 28.5 mg [1-13C]pyruvic acid (Cambridge Isotope
Laboratories, Andover, MA, USA) mixed with 15 mM OX063 trityl radical (Oxford
Instruments, Tubney Woods, Abingdon, Oxfordshire, OX13 5QX, UK) and 1.5 mM
Dotarem Gd chelate (Guerbet, Roissy, France) was polarized to ~30% at 1.42 K and 94
GHz with a HyperSense dynamic nuclear polarization system (Oxford Instruments). 4 mL
of buffer, containing 50 mM Tris, 80 mM NaOH, and 100 mg/L EDTA, was heated to 190
°C at 10 bar and used to rapidly dissolve the frozen sample.
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4.2.3 Ex Vivo Isolated Perfused Lung Studies
4.2.3.A. Isolating Perfused Lungs
The procedure for excising and perfusing the lungs is similar to that described in the
previous chapter. In brief, animals were anesthetized with intraperitoneal (IP)
pentobarbital, tracheostomy was performed, and 200 U heparin was administered via the
tail vein. The lungs were degassed5,6 by ventilating with pure O2 for 10 minutes to remove
any residual N2. The trachea was then sealed, and a thoracotomy was performed to
access the heart. The pulmonary artery was cannulated via the right ventricle for
perfusion. Once sealed, the lungs were rapidly excised and placed in a 20 mm NMR tube.
Lungs were then perfused at 10 mL/min with a modified Krebs–Henseleit buffer: 119 mM
NaCl, 25 mM NaHCO3, 1.3 mM CaCl2, 1.2 mM MgSO4, 4.7 mM KCl, 10 mM glucose, 2
mM lactate, 0.2 mM pyruvate, and 3% (w/v) fatty-acid-free bovine serum albumin (BSA,
Fisher Bioreagents). The perfusate was passed through an oxygenating column under a
constant flow of 1 atm 95:5 O2 /CO2 and warmed via passage through water-jacketed
tubing. The CO2 concentration in the oxygenating column was chosen to maintain constant
perfusate pH during oxygenation, although periodic adjustment with 1 N HCl or NaOH was
needed to maintain a physiological value of 7.4±0.05. The lung was perfused at constant
flow throughout the experiment. The temperature of the perfusate in the NMR tube was
continuously monitored and maintained at 36.5±1 °C.

4.2.3.B. Administration of HP [1-13C]Pyruvate for Ex Vivo Spectroscopy
This 4.0mL sample from the polarizer was further diluted in 6.0 mL oxygenated Krebs–
Henseleit buffer (without BSA) to yield a neutral, isotonic solution of 32 mM [1-13C]
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pyruvate (in the studies described in the previous chapter, a much lower final
concentration of [1-13C] pyruvate was used). This solution was injected into the perfusate
line at 10 mL/min in lieu of the steady-state perfusion buffer. After the 60 s required to
inject the HP solution, lung perfusion was restored.

4.2.3.C. Ex Vivo NMR Spectroscopy for Isolated Perfused Lungs
All MR spectra and images were obtained using a 9.4 T vertical bore magnet (Varian, Palo
Alto, CA) equipped with a gradient insert (Resonance Research, Billerica, MA) and a 20
mm 1 H/broadband probe (Doty Scientific, Columbia, SC). After insertion into the bore of
the magnet, the sample was tuned, matched and shimmed to a linewidth of about 40 Hz.
This process required approximately 20 min. Immediately following, the lung was 1H
imaged (10 axial 2 mm slices, field of view = 30 × 30 mm) for positioning and to ensure
the integrity of the organ and the absence of edema. Next, a whole-lung, averaged

31

P

spectrum was acquired to assess energy status (repetition time T R = 1 s, nominal flipangle α = 60°, acquisition time AT = 200 ms, spectral width SW = 100 kHz, 512 averages).
The probe was then tuned to

13

C and the perfusate was temporarily replaced by the HP

solution. Low flip-angle spectra were acquired for the several-minute duration of the HP
signal (T R = 1 s, nominal α = 10°, AT = 800 ms, SW = 20 kHz, 300 individual spectra
acquired). Following the

13

C spectroscopy, another averaged 31P spectrum was acquired

in order to evaluate changes in ATP status due to the HP compound injection. In six
instances, the entire series was then repeated (31P spectrum, HP spectrum series,

31

P

spectrum) after a 1 h delay required to hyperpolarize another pyruvate sample. This
repetition was performed to evaluate the stability and reproducibility of the lung and its
metabolic activity.
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4.2.3.D. Quantification of NMR Spectra from Ex Vivo Perfused Lung Studies
31

P spectra were least-squares fit to 13 Lorentzian peaks, allowing the individual peak

heights and common peak width to vary freely. The peak frequencies were kept fixed;
peak identities (ppm chemical shifts relative to PCr; see figure 4.4 caption for acronyms)
were PME (6.70), Pi (5.08, 4.32), GPC (3.03), GPE (2.24), PG (1.80), PCr (0.00), γ-NTP
( 2.36), α-NTP ( 7.52), diphosphodiester/NAD(H) ( 8.18, 9.68, 11.49, 13.30), and β-NTP (
16.13). Fit quality was found to improve substantially when including three additional
peaks of fixed position (3.5, 4, and 10 ppm) and width (3, 8, and 4 ppm, respectively) to
account for contributions from unresolved 31P species. We note that the region containing
GPC, GPE, and PG is poorly resolved and likely contains other phosphodiesters as well.
Although consistent with previous measurements7,8 the number and identity of resonances
is uncertain.

13

C spectra were least-squares fit to five Lorentzian peaks, allowing the individual peak

heights to vary. The peak positions and widths were set using an initial free fit (amplitude,
width, and position) to the average of all spectra with signal-to-noise ratio > 30. The peaks
were identified as pyruvate, alanine, pyruvate hydrate, lactate and bicarbonate, with ppm
chemical shifts relative to pyruvate of 0.00, 5.68, 8.42, 12.26 and 9.98, respectively.
Additional peaks representing natural abundance nuclei or impurities were not included in
the fit. All peak fitting was done using custom software written in MATLAB (Natick, MA).

4.2.3.E. Histological Evaluation (Ex Vivo Study)
Immediately after the final MRS acquisition, nine of the lungs (three each of control, day
7, and day 21 inflammation) were prepared for histological evaluation. The steady-state
perfusion buffer was replaced by a 10% formalin solution and perfusion was continued for
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1 min, after which the lungs were submerged in 10% formalin for 5–7 days and
subsequently embedded in paraffin. Due to the uncertainty of their response to re-inflation,
the lungs were not inflated prior to fixation. Although inflating the lungs would have made
the gross structure easier to visualize, we do not expect that it would have affected our
ability to count the cells of interest. 25 transverse 5 μm sections were cut from each lung
(five groups of five contiguous sections spaced by 2 mm). Previous studies have indicated
that neutrophils and macrophages represent the bulk of the inflammatory response to
bleomycin-induced injury in rats (18,19). Sections from each group were therefore stained
with hematoxylin and eosin (H&E), and with anti-neutrophil elastase antibody (ab21595,
abcam, Cambridge, MA) or CD68 antibody (SPM130, Santa Cruz Biotechnology, Dallas,
TX), which have previously shown reactivity to rat neutrophils and macrophages,
respectively. Because of significant non-specific binding, only the H&E sections were used
to evaluate the extent of neutrophil and macrophage infiltration.

An experienced lung pathologist blindly examined the five whole lung sections from each
sample and assigned a grade from 0 to 4 with respect to neutrophils, macrophages,
lymphocytes and organizing pneumonia (OP) foci, based on the number of cells or sites
present. No distinction was made among lymphocyte types. For each cell type, lungs with
minimal cell density were assigned a grade of 0, whereas lungs with severe and widely
distributed inflammatory cells were assigned a grade of 4. The grading scale was relative
for each type of cell. For example, a section that scored a grade of 4 for both neutrophils
and macrophages had a much greater number of neutrophils than macrophages. Each
lung was then assigned a score for each cell type equal to the average rating among the
sections.
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4.2.4 In Vivo MR Imaging Studies
4.2.4.A. Administration of HP [1-13C]Pyruvate for In Vivo Imaging
4 mL/kg (~1.3mL) of the HP solution was then transferred into a syringe and injected into
the animal via a tail vein catheter within 10 s of dissolution. The injection lasted 6 s and
was followed by a 250μL saline flush. The scan started 18 s after beginning injection.

4.2.4.B. In Vivo Magnetic Resonance Imaging
Animals were anesthetized with isoflurane (2%) on 100% O2 (1.5mL/min) and a tail vein
catheter was placed before starting the imaging session. MRI imaging was performed on
a 4.7T horizontal bore magnet (Inova 200, Varian Inc, Palo Alto, CA) using a 72mm dual
tuned 1H/13C quadrature transmit/receive birdcage coil (Polarean Imaging Plc., Cleveland,
OH). A T1-weighted coronal 1H GRE of the lungs was acquired for positioning the sliceselective CSI with HP [1-13C] pyruvate. The acquisition parameters were: TR/TE = 80/1.55
ms, FOV = 60x60x2 mm3, matrix = 128x128, slices = 16, averages = 16, flip-angle = 20o,
scan time = 2:03 min. The lungs were manually shimmed using the proton channel to a
proton linewidth of about 130Hz using a 15mm slice-selective pulse acquire sequence.
HP [1-13C] pyruvate chemical shift imaging (CSI) was performed immediately after
shimming.

HP 13C CSI was performed using a spiral 2D slice-selective phase-encoded free-induction
decay chemical shift imaging (FID-CSI) sequence (Figure 4.1A). The k-space center
(kx,y = 0) was re-acquired at every 11th acquisition to de-blur the point spread function
(PSF) of the spectra (Figure 4.1B). The 15mm slice was positioned on the lungs superior
to the dome of the diaphragm. The scan was started 16 s after the start of the HP injection
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(see above). The acquisition parameters were: TR/TE =35/0.5 ms, FOV = 45x45x15 mm3,
matrix size = 16x16, spectral width = 4 kHz, spectral points = 128, flip-angle = 9o, scan
time = 9s. The matrix size and flip angle were optimized based on the available
hyperpolarization, such that enough residual signal was left after each excitation (256 for
our selected parameters).

Figure 4.1: (A) Pulse sequence diagram for the FID-CSI sequence for in vivo rat imaging. The kspace was traversed using a spiral trajectory, so Gx and Gy are not the traditional frequency and
phase encoding directions. (B) The k-space was traversed from the lower k-space to the higher kspace (‘spiral out’). Unlike a conventional trajectory, the kx,y=0 was re-acquired every 11th
acquisition and then the outward trajectory continued (shown as breaks with red arrows). The
repeated kx,y=0 acquisitions were used to deblur the reconstructed image.

4.2.4.C. MRSI Data Processing
All data were processed offline using custom routines in MATLAB 2017b (MathWorks,
Natick, MA, USA). The free-induction decays (FID) were line-broadened by 30 Hz and
then Fourier transformed to obtain the spatially resolved spectra. The periodic acquisition
of the k-space center (kx,y = 0) was used to de-blur the spectra via amplitude
normalization, thereby providing improved localization. The resultant spectra were then
baseline-corrected (fourth-order polynomial), local zero-order and global first-order phasecorrected; the lactate and pyruvate peaks were then fit to Lorentzian functions. The
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processed carbon-13 spectra were overlaid on the corresponding proton images of the
thorax and voxels were manually selected from the native lung, transplanted lung and
heart for regional quantification. Voxels overlying large vessels in the lung parenchyma
were excluded from selection. As the number of selected voxels from each region varied,
the average pyruvate, lactate and lactate-to-pyruvate was calculated by summing the
respective spectra and dividing by the number of voxels. The fitted pyruvate and lactate
spectra were also used to generate corresponding metabolic maps, which were linearly
interpolated to match the voxel size of the underlying proton images for clearer
visualization.

4.2.5. Statistical Methods
Statistical significance was tested using analysis-of-variance (ANOVA), followed by
Tukey’s HSD post-hoc test across the different cohorts. In order to determine whether
there was any evidence that the two measurements made in the same lung were
systematically different, repeated measures ANOVA was performed in the subset of six
lungs for which 13C spectroscopy was repeated as well as the 18 lungs in which repeated
31

P spectroscopy was performed. In order to determine the extent of direct relationships

between inflammation as measured using

13

C and 31P spectroscopy, as well as between

13

C spectroscopy and inflammatory cell counts, simple correlations were calculated across

all measurements in which both metrics were available. All statistical analyses were
performed using the R software. R is an open-source project that is distributed under the
GNU General Public License (copyright 2007 Free Software Foundation)
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4.3. RESULTS
4.3.1. Ex Vivo 13C Spectroscopy
Figure 4.2 displays a representative series of individual spectra from an inflamed lung.

Figure 4.2: A time-series of stacked C spectra (bottom) shows the appearance of pyruvate and
pyruvate hydrate signals, followed by lactate and alanine. The unidentified peaks are impurities
from the HP pyruvate sample and not indicative of biological activity. Signal level evolution over
time is very similar between control and inflammatory groups, with the exception of the lactate
signal, which is significantly increased in the diseased cohort. This can be seen in the three overlaid
spectra, which are averages of the ten spectra between 20 and 30 s after the end of the HP injection
(top). The day 7 inflammatory model spectrum (red) is visually indistinguishable from the day 21
(blue) and control (green) spectra, except at the position of the lactate peak.

As with all such series, peaks corresponding to [1-13C]pyruvate and [1-13C]pyruvate
hydrate appeared first, followed within a few seconds by [1-13C]lactate and [1-13C]alanine
peaks. All peaks were clearly distinguishable and quantifiable for a period of approximately
2 min after the first appearance of HP signal. Additional peaks corresponding to natural
abundance

13

C, impurities and

13

C-bicarbonate, though smaller, were also reliably
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quantifiable. In the Figure 4.2 inset, we overlaid spectra acquired 20–30 s after the end of
the HP injection in control, day 7 and day 21 inflammatory model animals. As expected,
pyruvate, pyruvate hydrate and alanine signal levels were very similar, but the integrated
lactate signal of the inflammatory model exceeded that of the control animal by a factor of
approximately three.

Figure 4.3: The full time-series of fit peak areas, in which the day 7 inflammatory group lactate
peaks exceed those of the control group at all times and by an average factor of 3.3. Note that the
signal amplitudes are scaled such that the sum of pyruvate areas Σp(t) = 1, and times are shifted
such that each injection is centered around t = 50. The inset bar graph shows the mean and average
integrated lactate signal in the control (green), day 7 (red), and day 21 (blue) groups. In both plots,
solid circles represent data acquired on the first HP 13C injection and open circles represent data
acquired on the second HP 13C injection. When only first injections are considered, the day 7 group
is statistically distinguishable from the other two groups (p = 0.0003). Although only six studies
were repeated, no systematic change is evident (visually or by repeated measures ANOVA)
between the groups due to the time delay between the two HP agent injections.

Figure 4.3 displays the result of fits to each spectrum of the timeseries in each subject.
Although the observed lactate signal is more variable among the inflammatory model
cohort, each of the day 7 inflammatory model lungs exhibited a greater observed lactate
signal at all times than any of the control lungs; integrated lactate signals in the day 7
inflammatory group exceeded those of the control group by a factor of 3.1 on average (if
repeated measurements in the same lung are excluded from the analysis, the day 7
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group’s signals are higher by an average factor of 3.3). Lactate signal levels in the day 21
cohort were midway between the control and day 7 groups, exceeding the control group
by a factor of 1.8 on average. Means and standard deviations of all three groups are
summarized in the Figure 4.3 inset.

4.3.2. Ex Vivo 31P Spectroscopy
Figure 4.4 shows two averaged

31

P spectra representing normal (green) and day 7

inflammatory (red) lung cohorts. Eight distinct

31

P-containing species can be discerned7–

10

, of which only phosphoglycans and phosphodiesters (primarily GPC and GPE) differ

significantly between the normal and inflamed lung; on average, these are elevated by a
factor of 2.5 in inflammation. Some inconsistency in the fit values arises from limited
signal-to-noise ratio in the

31

P spectra. Some inconsistency in the position and width of

the Pi peak is seen as well, which may indicate variability in tissue pH despite the narrow
range of perfusate pH.

Figure 4.4. Sample P spectra from control (black with green fit) and day 7 (black with red fit)
inflammatory model lungs show very similar patterns of high energy phosphates (NTP), inorganic
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phosphate (Pi), phosphomonoesters (PME) and phosphocreatine (PCr), but differ in a set of three
peaks consistent with the known chemical shifts of the phosphodiesters glycerophosphocholine
and glycerophosphoethanolamine (GPC/E) and, slightly upfield, phosphoglycans (PG). The figure
inset shows a comparison of the three cohorts’ summed GPC/E + GP fit peak areas. Cohort means
and standard deviations are summarized by the corresponding black bars, and individual GPC/E +
GP peak areas appear as filled/open black circles for first/second injections. Note that the individual
peak areas are offset randomly in the horizontal direction for better visibility. Only the GPC/E/PG
peaks differ between the groups; this difference is highly significant when comparing control and
day 7 bleomycin groups (p < 0.01 whether all points or only first injections are compared). The day
21 group was not significantly different from either of the other groups. All amplitudes are scaled to
the corresponding Pi peak area.

4.3.3. Histology
Representative H&E sections from the control, day 7 and day 21 inflammatory cohorts
appear in Figure 4.5. These sections were chosen to highlight the visually apparent trend
of dramatically elevated neutrophils at day 7, which were partially resolved by day 21, and
of progressively increasing macrophage count from day 7 to day 21. This trend can be
seen more clearly in the inflammatory cell scores from each lung (Table 4.2).

Neutrophil

Macrophage

Lymphocyte

Control
0.6
0.4
0.8
0.4
0.4
0.6
0.4
0.0
0.0

Day 7
2.7
2.8
1.4
1.4
1.8
2.2
0.6
0.6
1.0

Day 21
1.0
0.8
2.8
3.2
2.8
3.2
1.2
0.4
0.4

Table 4.2: Average neutrophil, macrophage and lymphocyte score for each of the nine animals
examined histologically.

On average, the neutrophil scores at 7 and 21 days exceeded the control scores by factors
of 3.8 and 2.6, respectively; the inflammatory macrophage scores exceeded the control
scores by respective factors of 3.9 and 6.6. There are some transient OP foci present in
day 7 sections, but most of these foci are resolved by day 21. The day 21 sections have
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minimal OP foci but are characterized by protein deposits (Figure 4.5) that can signify
fibrotic remodeling, and which were only minimally apparent at day 7.

Figure 4.5: Representative histological sections from control lung (a), day 7 post-bleomycin lung
(b) and day 21 post-bleomycin lung (c). The sections were chosen to highlight the common
characteristics of each group – in particular, the elevated neutrophils at 7 days and elevated
macrophages at 21 days. A more objective evaluation of inflammatory cell density can be seen in
Table 1. Note that the alveolar structure is somewhat distorted in all of the sections because the
lungs were collapsed during the NMR studies and were not reinflated for histology.

Notably, the day 21 cohort contained one subject that was visually similar to the day 7
cohort with respect to both active neutrophilic inflammation and relative lack of fibrosis.
This subject also exhibited

13

C and

31

P spectroscopy results that were elevated with

respect to both control and the other day 21 lungs, but that were consistent with the day
7 cohort (Figures 4.2 and 4.3).

Figure 4.6: Among all lungs, the increase in lactate produced by inflamed lungs is significant
(approximately a factor of 3.3 at day 7 and a factor of 1.8 at day 21) and correlates moderately well
to the GPC/E peak increase observed using time-averaged 31P spectroscopy. In the figure, the
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cohorts are distinguished as control (green), day 7 (red) and day 21 (blue). First and second
injections in the same lung are distinguished as closed and open circles, respectively.

Applying ANOVA to the 16 first

13

C measurements revealed that the three experimental

groups are characterized by significantly different means (F(2,13) = 15.9, p = 0.0004).
Further analysis using the Tukey HSD test was performed to determine whether
significance exists between the cohorts. The mean lactate labeling was significantly higher
for the day 7 bleomycin group than for both control ( p < 0.001) and day 21 (p = 0.03)
groups; on the other hand, we could not show a significant difference between the day 21
bleomycin and the control group (p = 0.33). Although with less significance, the

31

P

spectroscopy data yielded identical results in post-hoc analysis. Applying repeated
measures ANOVA to the six repeated 13C spectroscopy measurements in the two groups
(two controls, four day 7 bleomycin) showed that there was a significant difference
between the means of the two groups (F(1,4) = 193.4, p = 0.0002), and the hypothesis
that the repeated

13

C measurements are characterized by the same mean within

experimental repeats was not rejected (p = 0.88). Similarly, applying repeated measures
ANOVA among the 18 repeated

31

P spectroscopy tests in three groups (six control, ten

bleomycin day 7, two bleomycin day 21) shows that there is a significant difference among
the means of the three groups (F(1,4) = 4.27, p = 0.036). Similar to the

13

C data, there

was no difference in the repeated experimental measurements within groups (p = 0.26).
There is no statistical evidence for any interaction between the experimental group and
measurement number (p = 0.84 and 0.16 for 13C and 31P spectra, respectively). Figure 4.6
summarizes the relationship between elevated GPC/E levels and elevated lactate
production within and between study groups.
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Figure 4.7: Among all lungs for which histology was performed, the integrated lactate signal
(normalized to integrated pyruvate signal) correlates well with the average neutrophil score as
graded by a pulmonary pathologist. The correlation to the average macrophage score was not
statistically significant. Scores were assigned from 0 (normal cell count) to 4 (severe and widely
distributed inflammatory cells) based on a blinded, qualitative assessment of five H&E sections
distributed throughout the lung.

Across all study animals, a significant correlation was found (r = 0.69/0.74 if all/first
injections are analyzed; p < 0.001 in both cases). Figure 4.7 shows the correlation
between the measured lactate signal and the histologically determined neutrophil and
macrophage scores for the eight subjects for which both measures were available. The
correlation coefficient is statistically significant (r = 0.89, p < 0.005) when lactate signal
and neutrophil score are compared, but is not significant (r = 0.36, p = 0.39) when lactate
signal and macrophage score are compared.

4.3.4. Reconstructing CSI Images from In Vivo Studies
Having demonstrated the feasibility of HP [1-13C]pyruvate imaging for ex vivo studies in
the bleomycin-induced inflammation model, a set of in vivo studies using the spiral FIDCSI were subsequently carried out to determine the translatability of our technique.
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Figure 4.8: (A). The raw (orange) and de-blurred (blue) FID of the spiral CSI sequence. The
correction was based on the exponential fit at k0 as seen in (B). (C) The first 11 k-space acquisitions
as well as the repeat acquisition of k0 can been seen in this zoomed in sub-region of the FID.

Figure 4.8A shows a representative raw FID (orange) alongside the de-blurred FID (blue)
based on the exponential fitting of the repeated kx,y=0 acquisitions, as seen in Figure 4.8B.
Figure 4.8C is zoomed-in to the first 12 acquisitions of the acquired FID. The signal at
kx,y=0 has the largest SNR contribution to the final Fourier transformed image.
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The FID was processed as described in Methods section 3.2.4.C to generate a 16x16
spectroscopic image of the lungs (Figure 4.9A). The highest signal is observed in the
heart, followed by the lungs, with some signal apparent in the peripheral muscles as well.

Figure 4.9: (A): A representative carbon-13 MRSI overlaid on a proton image from a day 7 inflamed
animal. The inset (B) shows the signal from one manually selected voxel in the heart. The three
peaks that can be quantified are lactate (183 ppm), pyruvate (171 ppm) and bicarbonate (160 ppm).
The uncorrected (C) and de-blurred (D) reconstructed images can be seen, with the improved
resolution of the latter easily observable in the heart.

Figure 4.9B shows the spectrum from a single voxel in the heart. The pyruvate is centered
at 171ppm and the lactate peak can be observed at 183 ppm; a small bicarbonate peak
at 160ppm can also be observed. The latter peak is not typically found in the lungs, most
likely due to both a lower pyruvate signal and the lower metabolic activity of healthy lungs.
Figures 4.9C and 4.9D demonstrate the difference between an uncorrected and de-blurred
reconstruction. We can qualitatively observe the higher resolution of the de-blurred image:
the uncorrected reconstruction shows a blurry pyruvate distribution over the entire heart,
while the pyruvate distribution is resolved into two regions in the corrected version, each
of which is centered over a separate heart chamber.
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Figure 4.10: Representative HP pyruvate (top) and HP lactate (bottom) maps for the healthy, day
7, 14 and 21 cohorts. The pyruvate distribution is similar across all four cohorts; however, an
increased lactate distribution can be observed on day 7. The quantified lactate-to-pyruvate values
can be observed in Figure 11.

As described in Methods 3.2.4.C, the fitted pyruvate and lactate spectra were used to
generate their respective metabolic maps (Figure 4.10). The lactate-to-pyruvate ratio of
the heathy, day 7, day 14 and day 21 cohorts were 0.15±0.08, 0.25±0.8, 0.16±0.6 and
0.11±0.06, respectively. The day 7 cohort was significantly different than all three other
cohorts (p < 0.001 in all cases). The day 21 cohort was significantly different than the
control (p = 0.03) and day 14 (p = 0.003) cohorts. The control and day 14 cohorts were
not significantly different (p = 0.71). (Figure 4.11).
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Figure 4.11: Mean lactate-to-pyruvate ratios for all four cohorts from the in vivo MRI study.

4.4. Discussion
The main finding of this work is that a common experimental model of lung inflammation
affects the metabolic activity of the lung such that the overall apparent lactate labeling is
increased substantially 7 days post-induction. Activity largely returns to baseline 21 days
post-induction, although the smaller sample size at the latter timepoint means that there
is a possibility that activity remains somewhat elevated. Although the magnitude of change
was different between the ex vivo and in vivo models, both models showed this trend. We
believe that the observed increase at 7 days is indicative of direct uptake and metabolism
of pyruvate by inflammatory cells—primarily neutrophils—which have infiltrated the lung
in response to the bleomycin insult.

Several other explanations are possible, however, all of which we will discuss individually.
First, it is known that other conditions may affect apparent LDH activity. In a previous
study11, for instance, we showed that temporary hypoxia can increase lactate labeling in
the perfused lung by a factor similar to that observed here, most likely due to the increased
intracellular lactate pool size and consequent increase in oxidized nicotinamide adenine
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dinucleotide (NAD+ ) reduction rate. While it is possible that damage to the lung (e.g.
fibrosis or emphysema-like tissue degradation) may adversely affect gas transport and
tissue oxygenation, the primary means of oxygenation in this study is via the oxygenated
perfusate. Any tissue damage that prevents adequate contact with the perfusate would
also hinder access to the HP agent delivered through the same flow path, making HP
lactate signals unobtainable in these regions. Furthermore, the hypoxic lung exhibited a
distinctively low PCr and NTP signal in

31

P spectroscopy when studied previously11—

distinctive changes that were not observed in this study.

Another possible cause of increased lactate signal is a change in the uptake of pyruvate
by the lung tissue. Although transporter activity may be affected by energy status, pH and
other factors of the extra- and intracellular environment, no alteration in transport was
detected in the inflammatory model lungs12. We note that HP alanine signal is not
significantly increased in the inflammatory model animals; if pyruvate uptake by
pneumocytes were increased sufficiently to explain the increased lactate signal, we would
expect a measurably increased rate of transamination in these cells as well. It is possible
that pyruvate uptake and transamination were both significantly and inversely altered such
that label transfer to the alanine pool remained unchanged. However, we would consider
this an unlikely coincidence.

Third, it is possible that the increased apparent LDH activity observed arises in part from
extracellular LDH. Although intracellular in healthy tissue, LDH is known to be present in
substantial concentration in the extracellular space in regions experiencing cell death;
tests of bronchoalveolar lavage fluid LDH activity are a common non-specific indicator of
tissue damage13,14. In this case, however, the persistence of the lactate signal (along with
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pyruvate and alanine, but in contrast to pyruvate hydrate) is a clear indication of its
intracellular origin; extracellular signal would be washed out rapidly once ordinary
perfusion was restored, as is the case for the extracellular pyruvate hydrate and other
impurities (Figure 4.2). The continued linear increase of the lactate/pyruvate ratio during
this washout period most likely indicates the intracellular rate constant for forward LDH
activity, although it may also reflect the efflux of pyruvate from the lung epithelium—a
process which has been shown to be rapid and dynamic15.

A final possible cause of increased lactate signal in the inflammatory model lungs is the
change in redox status of the lung tissue due to reactive oxygen species originating from
the respiratory burst phase of neutrophil activity. These compounds may interact directly
with the NADH/NAD + redox couple, indirectly through modulation of glutathione-mediated
inhibition of LDH, or through a variety of other inflammatory signaling pathways16,17.
Although this possibility cannot be ruled out based on the studies described here, it seems
more likely that the increased lactate production arises from the rapid glycolysis of
inflammatory cells. With respect to the similarly increased

18

FDG-PET signal in

inflammation, autoradiographic studies18–20 have confirmed that the source of the increase
is primarily neutrophilic uptake rather than an inflammatory-mediated change in lung
tissue activity, and that the significantly greater glycolytic rate of neutrophils (11) is
sufficient to overwhelm signal originating in the lung epithelium1. Given that the neutrophil
glycolytic rate is not limited by LDH activity21, we expect that similar dynamics are
responsible for the substantial increase in lactate signal observed here.

It is possible that increased macrophage density is responsible for some of the lactate
signal as well. However, the results shown in Figure 4.6 provide evidence that the
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increased lactate labeling is primarily neutrophilic in origin. As seen in Table 1 (and
described previously22), neutrophil count in the bleomycin rat model peaks after
approximately 7 days before re-approaching baseline 21 days after insult. In contrast,
macrophage count continues to rise, peaking between 14 and 21 days. The neutrophil
count time course is in qualitative agreement with the observed lactate signal time course
(which is significantly higher at 7 days than at 21 days), and this agreement is reflected in
the significance of the corresponding correlation plot in Figure 4.6.

The degree of lactate increase is also fairly consistent with estimates of cell populations
and metabolic characteristics available from previous ex vivo or in vitro studies. Pyruvate
uptake and transformation to lactate in the normal lung is likely dominated by type II
pneumocytes due to both their rapid and highly glycolytic metabolism and large population
(~5.5 × 107 cells per lung, double that of type I pneumocytes and about six times that of
alveolar macrophages), as well as conclusions based on cell morphology and oxygen
uptake experiments23–25. Assuming, as demonstrated previously26, that the lavage cell
counts are representative of inflammatory cell sub-populations, bleomycin model lavage
results suggest that the total inflammatory cell population increases from baseline by a
factor of approximately six at 7 days and a factor of three at 21 days (Fig. 6 of Ref22), and
that this increase consists almost exclusively of neutrophilic and macrophagic
components27,28. Previous studies have also shown that the type II pneumocyte population
is slightly but not substantially diminished in this model29–31. Although the degree and type
of inflammatory cell activation is not known, we may approximate the expected relative
contribution to HP lactate signal by measured lactate production rates in cell culture;
published results show that per cell lactate production of isolated alveolar macrophages
(61 nmol/h/106 ) and neutrophils (53 nmol/h/106 ) are approximately equal, and exceed
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that of type II pneumocytes by approximately a factor of three (17 nmol/h/106 cells23,32,33).
These general considerations suggest that we should expect HP lactate produced in the
day 7 and day 21 bleomycin lungs to exceed that of the control lungs by factors of
approximately 2.7 and 1.7, respectively. These values are comparable to the observed
factors of 3.1 and 1.8, demonstrating that our explanation is at least plausible given what
is known about cell populations and metabolic activity.

The correlation between GPC/E levels as derived from

31

P NMR and lactate signal is

another indication that HP lactate imaging provides information about the extent and
location of lung inflammation. It has been previously demonstrated that granulocytes
contain very high levels of the phosphodiesters GPC and GPE, PG and related (and
spectroscopically indistinguishable) compounds34,35. We therefore believe that the GPC/E
levels of Figure 4.4 are indicative of elevated inflammatory cell count characteristic of
inflammation, and that the strong correlation with lactate signal seen in Figure 4.5 provides
evidence that both spectroscopic measures are further elevated in more severe
inflammation.

However, PET studies have also revealed the need to interpret the signal increase
carefully by showing that the period of most rapid neutrophil energy metabolism does not
correspond to the respiratory burst phase, but rather to cell migration and polarization36.
Because the former phase of neutrophil activity and the associated release of reactive
oxygen species is likely responsible for the lung tissue damage associated with
inflammatory exacerbations37,38, it is possible that the period of maximum deleterious
effect on the lung is not as conspicuous as the initial phase of neutrophil invasion when
using either HP [1-13C]pyruvate MRI or 18FDG-PET.
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A secondary finding of this study is that no systematic difference was observed between
repeated measurements of inflammation in the same model lung using either
spectroscopy. Although the number of repeated

13

C or

31

P

13

C spectroscopy measurements was

limited, it is clear that the effect of repeated or delayed measurement on the lung is much
smaller than the between-group differences. This serves as an indicator of model stability
during perfusion and suggests that small variations in timing do not affect the results of
the experiment.

As the ex vivo study was limited to two time-points (7 and 21 days), further investigation
and comparison to histological markers will be required to relate its findings to more
established measures of lung inflammation. In particular, we emphasize the highly
dynamic nature39 of cell counts and metabolic rates during acute inflammation. Alveolar
macrophages and neutrophils are known to take on a greatly increased glycolytic rate
during phagocytosis or when exposed to even the lowered O2 tension of the healthy lung40.
Thus, the quantitative estimate of expected metabolic activity in inflammation is intended
only as a plausibility argument based on cell populations, not as direct evidence for the
source of the observed signal.

Furthermore, although the perfused lung model chosen has been shown to recapitulate
many metabolic features of the ex vivo lung, the utility of this technique for localizing and
grading lung inflammation relies in part on a low baseline activity of the healthy tissue. The
lung has previously been demonstrated to play a substantial role in maintaining glycolytic
intermediate balance in the blood, which suggests that pyruvate and lactate transport and
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interconversion in the healthy organ may depend on whole-body metabolic activity,
dynamical perfusion effects, feeding and exercise status.

This can be seen by the difference in magnitude in lactate labeling between the ex vivo
and in vivo studies. In the ex vivo study, lactate labeling was increased by a factor of 3.1
and 1.8 on days 7 and 21, respectively, compared to the baseline. In comparison, the
lactate labeling was increased by a factor of 1.7 on day 7 but decreased by 0.7-fold on
day 21 compared to baseline in the in vivo study. As the same induction model was used,
this change may be due to a number of factors. Firstly, the concentration of HP [1-13C]
pyruvate in the ex vivo study was much higher than that used in the in vivo study. A final
concentration of 32 mM was used in the former studies, whereas in the latter studies the
effective bolus concentration was about 1.1mL of 80mM pyruvate diluted by the blood
volume. Based on estimated blood volumes41, this would be an approximate concentration
of 4-5 mM HP [1-13C] pyruvate. Although both concentrations are superphysiological42, the
lower dosage was used to minimize injected blood volume, acidosis, and signal saturation
given the SNR difference between the in vivo pyruvate and lactate signals. Lastly, the
observed difference in magnitudes between the two studies may also be a function of
acquisition timing. In the ex vivo study, the fresh HP pyruvate signal is replenished
continuously over a period of one minute. Any lactate that is converted from the stillmagnetized pyruvate signal would still be detected during acquisition. On the hand, the
HP pyruvate bolus is injected within 6s and imaging is acquired after 18s for a total of 9s.
The pyruvate has to traverse the vena cava and the heart before any pyruvate is delivered
to the lungs. Some blood cells that uptake pyruvate may already have converted HP
pyruvate to HP lactate before acquisition has even started. Furthermore, during the
imaging acquisition period, no new HP pyruvate is delivered, and any pyruvate within the
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RF coil will suffer RF-induced depolarization. Although pyruvate may be converted to
lactate, the SNR may be too low to quantify it. All these factors may have contributed to
the lower observed difference between the three relevant cohorts.

Lung regions may also express high apparent LDH activity during several other
pathologies, including cancer, environmental exposure to agents causing oxidative stress,
or interstitial inflammation43,44. It is important to note that, while the metabolic process
examined here is related to the uptake and sequestration of

18

FDG in that increased

glycolytic activity can be expected to yield a larger signal, the two measurements are not
equivalent. In particular, the imaging agents are transported into the cell via different
mechanisms (glucose transporter 1 versus, primarily, monocarboxylate transporter 245).
The two enzymatic conversion processes are also regulated through different means: e.g.,
hexokinase is inhibited by the FDG product FDG-6-phosphate and is the rate-limiting
enzyme in neutrophilic glycolysis21, while LDH depends directly on cytosolic redox state
and is regulated through a variety of other mechanisms including the inhibitory effect of
the redox-coupled reduced glutathione concentration16. Accurately assessing the relative
merits of each agent therefore requires further study in a model system.

4.5. Conclusions
We have demonstrated the use of non-ionizing, HP 13C spectroscopy to detect pulmonary
inflammation and have provided evidence that infiltrating neutrophils provide the primary
source of the observed signal. Although HP 13C spectroscopy is dependent on enzymatic
and transport processes different from those involved in 18FDG imaging, many features of
the techniques appear to be similar, including the several-fold increase of signal in
inflammation and the apparent sensitivity to direct metabolism of the neutrophilic
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inflammatory component. Because the baseline metabolic activity of the lung epithelium
is relatively low, neutrophilic activity is apparent in high contrast. The overall signal levels
are raised such that imaging applications become feasible, although the consistency of
this low baseline and potential sensitivity to other conditions must be further investigated
in both the isolated and in vivo lung46,47.
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Chapter 5: Detection of lung transplant rejection in a rat model using
hyperpolarized [1-13C] pyruvate-based metabolic imaging

Abstract:
The current standard for non-invasive imaging of acute lung rejection consists of X-ray/CT,
which derive their contrast from changes in ventilation, the presence of inflammation and
edema, and structural remodeling during rejection. We propose the use of hyperpolarized
[1-13C] pyruvate MRI—which provides real-time metabolic assessment of tissue—as an
early biomarker for tissue rejection. In this study, we used µCT-derived parameters and
HP

13

C MR-derived biomarkers to predict rejection in an orthotopic left lung transplant

model in both allogeneic and syngeneic rats. On day 3, the normalized lung density—a
parameter that accounts for both lung volume (mL) and density (HU)—was -0.335 (CI:0.598,-0.073) and -0.473 (CI:-0.726,-0.220) for the allograft and isograft, respectively,
showing no significant difference (p=0.40) between the two cohorts. On the other hand,
the respective HP 13C MRI-derived lactate-to-pyruvate ratios of 0.200 (CI:0.161,0.240) and
0.114 (CI:0.074,0.153) for the allograft and isograft were significantly different (p=0.020)
on day 3. Both techniques show tissue rejection on day 7. A separate sub-study revealed
CD8+ cells as the primary source of lactate-to-pyruvate signal. Our study suggests that
hyperpolarized (HP) [1-13C] pyruvate MRI is a promising early biomarker that may be able
to predict tissue rejection earlier than X-ray/CT by providing a real-time assessment of
changes in pulmonary cellularity as well as metabolic alterations in lung tissue and
infiltrating inflammatory cells.

This chapter has been adapted from Siddiqui et al., ‘Detection of lung transplant rejection in a rat
model using hyperpolarized [1-13C] pyruvate based metabolic imaging’ accepted for publication in
NMR in Biomedicine, 2019.
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5.1. Introduction
Over the last five decades, lung transplantation has evolved from a purely experimental
technique to an established treatment for end-stage pulmonary disease1. Advances in preand post-transplantation management have led to a continuous increase in the number of
lung transplants, with a reported 3973 performed worldwide in 20142. Yet immunological
rejection continues to contribute significantly to post-transplant morbidity and mortality3,4,
which remains far higher than that of any other solid organ transplant. Acute lung rejection
is currently monitored using radiographs or CT, followed by surveillance biopsies. An
improved biomarker would be able to detect lung rejection earlier and, ideally, noninvasively.

Several biomarkers have been proposed to improve the detection of lung transplant
rejection—including

1

H

magnetic

resonance

imaging

(MRI)

with

ultra-small

superparamagnetic iron oxide (USPIO) particles, very short echo time (TE) 1H MRI,
technetium-99m based single photon emission computed tomography (SPECT), as well
as blood-based biomarkers like transplant tissue-specific exosomal microRNA and
proteomic profiles5–8. None of these techniques are routinely used to detect lung rejection
in the clinic, however, where radiography remains the predominant screening method9–11.

After transplantation, the contrast observed in X-ray/CT images results from inflammation
and edema combined with changes in ventilation, as well as permanent structural
alterations due to remodeling during rejection. An imaging technique that derives its
contrast from the changes in the cellularity and metabolism of lung tissue and the
infiltrating inflammatory cells that precipitate lung tissue rejection might therefore be able
to predict tissue rejection earlier than X-ray/CT. Hyperpolarized (HP) [1-13C] pyruvate MRI
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is a novel imaging technique that provides such a real-time metabolic assessment of
tissue. The signal of an injected carbon-13 enriched molecular probe can be enhanced
more than 10,000-fold compared to thermal polarization via dynamic nuclear polarization
(DNP), allowing molecular pathways to be imaged within minutes12, and the lactate-topyruvate (LtP) ratio derived from this technique has been used in rat models of lung injury
as a biomarker for ischemia-reperfusion, acute injury and inflammation13–16. Given the
central role that these mechanisms play in lung tissue rejection, HP [1-13C] pyruvate MRI
appears to hold significant promise as a biomarker for its early detection.

In this study, we used an orthotopic left lung transplant model in both allogeneic and
syngeneic rats to investigate HP [1-13C] pyruvate MRI’s ability to generate metabolic
biomarkers for the non-invasive metabolic assessment of lungs post-transplantation. The
measured HP lactate-to-pyruvate ratio was compared to micro-CT imaging in predicting
lung rejection, and a histological sub-study was conducted to elucidate the source of the
observed signal.

5.2. Methods
5.2.1. Animals
20 pairs of rats (40 total) were used for this study. Syngeneic lung transplantation was
performed in 8 male Wistar-Furth to Wistar-Furth (295±35g) rat pairs, while allogeneic
transplantation was performed in 12 male Wistar to Lewis (305±27 g) rat pairs. n=5
recipients from each cohort were used for longitudinal imaging studies on days 3, 7 and
14, as described in Methods 5.2.3; the remaining recipients were used for the histological
studies described in Methods 5.2.4. All animal procedures and studies were approved by
the Institutional Animal Care and Use Committee of the University of Pennsylvania
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(Philadelphia, PA) and were performed in accordance with the relevant guidelines and
regulations.

5.2.2. Transplant Procedure
Detailed methods of the left orthotopic lung transplantation technique were published
previously12. Transplants was performed under clean, non-sterile conditions, and the
animals were heated continuously via an infra-red heating bulb. Anesthesia was induced
in both donor and recipient rats with 100 mg/kg ketamine and 4 mg/kg xylazine, and
maintained with 1.5% isoflurane/100% oxygen for the duration of the transplantation. Rats
were intubated with a 14-gauge catheter (BD, Franklin Lakes, NJ, USA) and mechanically
ventilated using pressure control (VentElite small animal ventilator, Harvard Apparatus,
Holliston, MA, USA) with the following settings: 16-18 cmH2O peak inspiratory pressure
(PIP), 2-4 cmH2O positive end-expiratory pressure (PEEP), 1:3 inspiration:expiration ratio
at a ventilation rate of 52 bpm. All transplantations were performed using a binocular
surgical microscope (Leica M651, Leica Microsystems, Buffalo Grove, IL, USA).

5.2.2.A. Donor Procedure
Donor rats were placed in supine position during lung harvest. A median incision from the
jugular notch to the pubic symphysis was used to access both thoracic and abdominal
cavities. First, donor animals were systemically heparinized (5000 IU) via the inferior vena
cava. The diaphragm was then incised, and a median sternotomy was performed to
access the thoracic cavity via the abdominal route. The thymus was removed, the left atrial
appendage was then cut, the pulmonary trunk was cannulated and the lungs were
perfused with 10 mL of cold (4oC) dextran-based preservation solution (Perfadex, XVIVO
Perfusion AB, Goteborg, Sweden). The thoracic cavity was filled with ice to induce cardiac
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arrest. The trachea was ligated at end inspiration, and the heart and lungs were removed
en bloc. On the back table, the left pulmonary vein and pulmonary artery were dissected,
cut to an appropriate length for secure anastomosis, and flushed with heparin (500 IU).
Lastly, the left main bronchus was dissected and the distal trachea and proximal right main
bronchus were ligated and cut to keep the lung inflated during cold ischemic storage.
Ischemia time was standardized to 2 hours. Subcutaneous buprenorphine (0.1 mg/kg)
was delivered every 8 hours for the first 24 hours, and subcutaneous meloxicam (2 mg/kg)
was delivered every 12 hours on days 2-4 for post-operational pain relief.

5.2.2.B. Recipient Procedure
Recipient rats were placed in a right lateral position for full access to the left hemithorax.
A transverse incision was made about 1 cm below the inferior margin of the scapula to
expose the chest wall. Access to the thoracic cavity was gained via the fourth intercostal
space. The ribs were retracted, after which the left lung was mobilized outside of the
thoracic cavity. When necessary, bipolar cautery (Erbe GmbH, Germany) was used
throughout the procedure. The pulmonary artery was clamped prior to the pulmonary vein
to minimize blood pooling in the lung. The distal pulmonary artery and the inferior
segmental vein were ligated (7-0 silk suture, Catgut, Markneukirchin, Germany) and cut
distally. The left main bronchus was clamped (Aesculap FE720 aneurysm clip, Center
Valley, PA, USA) and the native left lung was excised. A third-hand device was used to
stabilize the vascular clips for the anastomosis procedure.

The donor lung was placed into the recipient thoracic cavity and covered with ice-cooled
wet gauze to keep it cool during the implantation procedure. The donor left main bronchus
was shortened as needed before being anastomosed end-to-end with 10 interrupted
149

sutures (BV130-5, 8-0 Prolene sutures, Ethicon, Somverville, NJ). Anastomosis was
checked for patency by re-inflating the lung, and for air leakage by filling the left thoracic
cavity with warm normal saline. Vascular anastomoses (end-to-end pulmonary artery to
pulmonary artery and end-to-end pulmonary vein to pulmonary vein) were completed
using the cuff technique described previously12. In brief, recipient vessels were passed
through a 1mm cylinder cuff cut from a polyethylene catheter (18-gauge for the artery, 16gauge for the vein), everted over the cuff and secured with a 7-0 silk ligature. The donor
vessels were then pulled over the cuff and secured with a 7-0 silk ligature and the clips
were then removed for reperfusion and ventilation.

The thoracic cavity was drained with a 20-gauge catheter and the ribs were closed with 40 Prolene sutures. Muscular layers, subcutaneous layers and skin layers were reapproximated in multiple layers with running 4-0 vicryl sutures. Animals were weaned
from mechanical ventilation, extubated and monitored until fully awake.

5.2.3. Imaging Timeline
Micro-CT images were acquired on the following days: 0 (60-120 minutes post-surgery),
1, 2, 3, 7, 14. Proton MRI and hyperpolarized [1-13C] pyruvate MRS were acquired on days
3, 7 and 14.

5.2.3.A. CT Imaging
High resolution CT scans were acquired using a microCT scanner (eXplore CT120,
Gamma Medica, Inc., Northbridge, CA). Animals were anesthetized with isoflurane (2%)
on 100% O2 (1.5mL/min) during the scan. Because the animals’ breathing was unstable
under anesthesia on days 0, 1 and 2, non-gated scans were performed at those time
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points in order to keep the time under anesthesia under 10 minutes. End-expiratory gating
was used during imaging on days 3, 7 and 14, which extended the total time under
anesthesia to about 30 minutes. CT scans had the following parameters: voltage: 32.0
mA, current: 80 kV (70 kV for the non-gated sequence), exposure time: 16 ms, angle of
rotation: 0.877O, views: 220 (half-scan), reconstructed resolution = 200 μm (isotropic).
Total scan time for the non-gated scans was 30 s, whereas gated scans ranged between
6-9 minutes based on the respiration rate (typically 50-70 bpm).

5.2.3.B. Hyperpolarized Pyruvate Preparation
The HP [1-13C] pyruvate probe was prepared by adding 15mM OX063 radical (GE
Healthcare, Little Chalfont, UK) and 1.5mM gadoterate meglumine (Dotarem, Guerbet
LLC, Bloomington, IN, USA) to neat [1-13C] pyruvate (Cambridge Isotope Laboratories,
Tewksbury, MA, USA). 28.3mg of this mixture was polarized to a solid state polarization
of 19.8±1.3% using a commercial DNP polarizer (Hypersense, Oxford Instruments,
Abingdon, United Kingdom) in approximately 50 minutes. The polarized samples were
melted with a 4 mL neutral buffered solution (40mM TRIS base, 80 mM NaOH, 50 mM
NaCl, and 0.1 mg/L EDTA) at 10 bar and 180 °C to yield a 80 mM HP [1-13C] pyruvate
solution at 37 °C. 1.1±0.2 mL (4 mL/kg) of the HP solution was then transferred and
injected into the animal via a tail vein catheter within 10 s of dissolution. Injection lasted 6
s and was followed by a 200μL saline flush. The scan started 16 s after beginning injection.

5.2.3.C. MRI Imaging
MRI imaging was performed on a 4.7T horizontal bore magnet (Inova 200, Varian Inc,
Palo Alto, CA) using a 72mm dual tuned 1H/13C quadrature transmit/receive birdcage coil
(Polarean Imaging Plc., Cleveland, OH). A T1-weighted coronal 1H GRE of the lungs was
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acquired for positioning the slice-selective CSI with HP [1-13C] pyruvate. The acquisition
parameters were: TR/TE = 80/1.55 ms, FOV = 60x60x2 mm3, matrix = 128x128, slices =
16, averages = 16, flip-angle = 20o, scan time = 2:03 min. The lungs were manually
shimmed using the proton channel to a proton linewidth of about 100Hz using a 15mm
slice-selective pulse acquire sequence. HP [1-13C] pyruvate chemical shift imaging (CSI)
was performed immediately after shimming.

HP 13C CSI was performed using a 2D slice-selective phase-encoded free-induction
decay chemical shift imaging (FID-CSI) sequence. The 15mm slice was positioned on the
lungs superior to the dome of the diaphragm. The scan was started 16 s after the start of
the HP injection (see above). The acquisition parameters were: TR/TE =35/0.5 ms, FOV
= 45x45x15 mm3, matrix size = 16x16, spectral width = 4 kHz, spectral points = 128, flipangle = 9o, scan time = 9s. The MRI imaging session typically lasted 60-90 minutes.

5.2.3.D. CT Data Processing
The CT images were imported into ITK-SNAP for segmentation and quantification, and
the lungs were semi-automatically quantified via a two-step process. First, the lungs were
automatically segmented using active-contour technique with an upper threshold of -250
HU. Once segmentation was complete, the trachea was manually removed and the lung
masks were separated into native and transplanted. The segmented lungs were then used
to obtain the average lung density (HU)—a marker for ventilation— and volume (mL) for
each lung. Both the aforementioned parameters were also used to calculate normalized
lung density (L*HU), which accounts for the skewed lung density due to the upper bound
of -250 HU when segmenting the lungs.
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5.2.3.E. MRSI Data Processing
All data were processed offline using custom routines in MATLAB 2017b (MathWorks,
Natick, MA, USA). The free-induction decays (FID) were line-broadened by 30 Hz and
then Fourier transformed to obtain the spatially resolved spectra. The periodic acquisition
of the k-space center (kx,y = 0) was used to de-blur the spectra via amplitude
normalization, providing improved localization. The resultant spectra were then baselinecorrected (fourth-order polynomial), local zero-order and global first-order phasecorrected; the lactate and pyruvate peaks were then fit to Lorentzian functions. The
processed carbon-13 spectra were overlaid on the corresponding proton images of the
thorax, and voxels were manually selected from the native lung, transplanted lung and
heart for regional quantification. Voxels overlying large vessels in the lung parenchyma
were excluded from selection. As the number of selected voxels from each region varied,
the average pyruvate, lactate and lactate-to-pyruvate was calculated by summing the
respective spectra and dividing by the number of voxels. The fitted pyruvate and lactate
spectra were also used to generate corresponding metabolic maps, which were linearly
interpolated to match the voxel size of the underlying proton images for clearer
visualization.

5.2.4. Histology and Immunostaining of Lungs
Because the imaging study was longitudinal, a parallel assessment of both lung tissue
ultrastructure and distribution of cellular infiltrates post-transplantation on days 3 (n=3
rejected cohort) and 7 (n=4 rejected cohort, n=3 non-rejected cohort) was also performed.
After euthanasia, lungs were excised and filled with 10% formalin at a tidal volume of
10mL/kg to keep the alveoli open. After fixation, lungs were sectioned and sliced axially.
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The slides were stained with either hematoxylin and eosin (H&E) or Masson Trichrome to
assess tissue morphology or fibrotic changes, respectively. For H&E staining, each slide
was divided into 10 sections that were then visually scored at 20x magnification for semiquantitative grading. Injury was assessed in the H&E stains by a combination of infiltration
(scale of 0-2), alveolar structure disruption (scale of 0-3), remodeling (scale of 0-5) and
edema (scale of 0-3) (Table 5.1). Fibrosis was assessed using the Ashcroft Score of the
Trichrome stained sections, ranging from 0 (normal lung) to 8 (total fibrous obliteration of
the field) (Table 5.2)13,14. The final score was expressed as a mean of individual scores
observed on all microscopic fields across three axial slides from the superior, medial and
inferior regions of the lungs.
Feature
Infiltration

Alveolar
Structure
Disruption

Remodeling

Edema

Score

Findings

0

No infiltrate

1

Infiltrate in the perivascular compartment

2

Infiltrate in alveolar compartment

0

Regular

1

Distorted

2

Collapsed with torn capillary-alveolar membrane

3

Collapsed with opacity

0

None

1

Detected in 1 or 2 areas

2

Detected in 3 or 4 areas

3

Detected in 5 or 7 areas

4

Detected in 7 or 8 areas

5

Detected in 9 or 10 areas

0

Regular alveolus

1

Slight thickening

2-3

Dilated vessels in alveolar walls and proteinaceous
material in alveolus
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Table 5.1: Grading H&E sections for lung injury based on four sub-categories

Additional slices were used to assess polymorphonuclear leukocytes (PMN) by monitoring
myeloperoxidase expression as well as CD4+ and CD8+ T lymphocytes in grafts posttransplant. Briefly, the paraffinized sections were deparaffinized in xylene and, after
sequential ethanol and PBS washes, were immunostained with both anti-MPO and ratCD4+/CD8+ primary antibodies. The secondary antibodies used were goat-anti-rat Alexa
488 (green). Fluorescence imaging was done using a Nikon fluorescence microscope
(Nikon Diaphot TMD, Melville, NY). Images were acquired at an excitation wavelength of
488 nm (for MPO, CD4+ and CD8+). All images were acquired at 100 ms exposure time
using a preset scale of 0-4095. The PMN, CD4+ and CD8+ were assessed by quantifying
fluorescence intensity over 5 fields using Metamorph Software (Molecular Devices,
Downington PA).
Grade

Histological Features

0

Normal lung

1

Minimal fibrous thickening of alveolar or bronchiolar walls

2-3
4-5
6-7
8

Moderate thickening of walls without obvious damage to
lung architecture
Increased fibrosis with definite damage to lung structure
and formation of fibrous bands or small fibrous masses
Severe distortion of structure and large fibrous areas
(“Honeycombing”)
Total fibrous obliteration of the field

Table 5.2: Criteria for grading lung fibrosis to derive the Ashcroft Score

5.2.5. Statistical Analysis
Statistical significance between the transplanted and non-transplanted lungs was tested
using two-way analysis-of-variance (ANOVA). Post-hoc analysis was performed using
Tukey’s honest significance test. If no significance was observed using ANOVA, a
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Student’s t-test with the Bonferroni correction was used for post-hoc analysis. α=0.05 was
considered statistically significant. All data were expressed as mean±SD.

5.3. Results
5.3.1. HP [1-13C] Pyruvate Imaging
Figure 5.1 shows representative 13C spectroscopic images overlaid on the corresponding
proton images (Figure 5.1A,B) for syngeneic and allogeneic rats on day 7.

Figure 5.1: Representative carbon-13 MRSI overlaid on proton images in day 7 syngeneic (A) and
allogeneic (B) rats. Voxels in the graft (red), native lung (green) and heart (blue) were manually
selected for regional quantification (insets C-I) of HP pyruvate and HP lactate. The signal in the
heart is generally much higher than in either lung. Linewidths are broadest in the native lungs and
narrowest in the heart (Table 5.3).
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The insets for figures 5.1A-D show a zoomed-in view of the average spectra in the
selected voxels for the native lung, transplant lung and heart, respectively. As can be seen
from these spectra, the linewidths of the voxels depend on the region and state of the
organ. The quantified linewidths of each tissue are summarized in Table 5.3.
Day 3

Day 7

Day 14

Syngeneic

Allogeneic

Syngeneic

Allogeneic

Syngeneic

Allogeneic

Heart

10.2 ± 1.8

11.5 ± 4.4

12.6 ± 0.8

10.9 ± 3.7

12.0 ± 2.6

8.2 ± 6.6

Native

28.4 ± 6.0

34.2 ± 3.6

32.6 ± 3.3

32.7 ±
11.2

30.1 ± 8.3

34.8 ± 0.5

Graft

20.3 ± 9.2

12.7 ± 4.8

22.7 ± 6.6

10.6 ± 2.2

25.6 ± 8.1

10.7 ± 2.9

Table 5.3: Pyruvate linewidth (Hz) quantification in the heart, native lung and grafted lung in
syngeneic and allogeneic cohorts on days 3, 7 and 14 (n=5 for both cohorts on all three timepoints).
The average linewidth was 11.0±3.2 Hz and 31.8±6.0 Hz in the heart and native lung, respectively,
across both cohorts and all three timepoints. In contrast, the average linewidth across all three
timepoints in the isograft was 22.7±7.7 Hz (compared to 11.0±3.2 Hz in the allograft).

As described in the Methods section, the fitted pyruvate and lactate spectra were used to
generate their respective metabolic maps (Figure 5.2). While the metabolites cannot be
absolutely quantified, their respective mean intensities from each lung were normalized to
those from the heart for comparison (Table 5.4). On day 3, the normalized pyruvate
intensities in the native and transplanted (isograft) lungs of the syngeneic cohort are
0.44±0.11 and 0.55±0.11, respectively (Figure 5.3A). On day 7, these intensities decrease
to 0.42±0.10 and 0.45±0.09, respectively, and further decrease to 0.37±0.12 and
0.42±0.19 on day 14 (not significant, minimum p >0.69).
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Figure 5.2: HP pyruvate (top), HP lactate (middle), and lactate-to-pyruvate (bottom) maps for
syngeneic (left) and allogeneic (right) cohorts on days 3 and 7. In each map, the transplanted lung
is displayed on the left and the native lung is on the right. The scale is normalized to the maximum
metabolite signal in each map. In the syngeneic (non-rejected) cohort, pyruvate hyperperfusion can
be observed, most likely due to IR injury; this dissipates by day 7, as the tissue returns to baseline.
The lactate signal is increased over the lungs (compared to the heart) on day 3 but decreases by
day 7. Though we see similar hyperperfusion in the allogeneic (rejected) cohort, some of the
pyruvate is shunted towards the native lung. The allograft has minimal perfusion by day 7 (see
Figure 5.3), yet a large lactate distribution is observed in that lung. The lactate-to-pyruvate ratio is
low in both lungs on days 3 and 7 the syngeneic cohorts. On the other hand, the lactate-to-pyruvate
ratios of the allograft and native lung in the allogeneic cohort are measurably different on day 3;
this difference is enhanced further by day 7, when the transplanted lung is fully rejected.

In contrast, the pyruvate distribution in the allogeneic cohort has a greater difference
between the native and transplanted (allograft) lungs. On day 3, the former’s intensity is
0.75±0.37, whereas the latter’s is 0.48±0.25 (p=0.22). Pyruvate intensity in the native lung
drops to 0.47±0.10 by day 7, and to 0.45±0.05 by day 14, which is within the range of both
lungs from the syngeneic cohort and suggests a return to baseline perfusion. In contrast,
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pyruvate intensity in the transplanted lung was less than the native lungs on days 7
(0.24±0.12, p=0.004) and 14 (0.29±0.09, p=0.075) post-transplant.

Table 5.4: Quantitative analysis summary for pyruvate, lactate and lactate-to-pyruvate ratio in the
native and transplanted (graft) lungs in both syngeneic and allogenic cohorts. The isograft and
allograft are the transplanted lungs in the syngeneic and allogeneic cohorts, respectively. The
pyruvate and lactate signals are normalized to that of the heart. The sample size for both cohorts
was n=5 at all three timepoints (day 3, 7, 14).

In the syngeneic cohort, the HP lactate intensity is higher in the grafts than in the native
lungs at all three timepoints (significant, maximum p<0.007) (Figure 5.3B). Lactate
intensity for the isografts is 0.64±0.19, 0.43±0.11, and 0.39±0.11 on days 3, 7 and 14,
respectively. In comparison, the normalized intensity for the native lung is 0.36±0.13,
0.29±0.09, and 0.27±0.04 at the same timepoints. Although lactate intensity decreases by
32.8% in the isografts between days 3 and 14, it is still 44.4% higher than in the native
lungs on day 14, suggesting incomplete recovery from the transplant procedure.
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The native and transplanted lungs in the allogeneic cohort show no significant difference
in lactate intensity on day 3 (0.50±0.17 and 0.45±0.27, respectively). However, lactate
intensity in the allografts increases to 0.56±0.16 and 0.38±0.19 on days 7 and 14,
respectively, whereas it decreases to 0.36±0.08 and 0.28±0.11 on days 7 and 14 in the
native lungs.

Figure 5.3: Biomarkers derived from quantified HP [1-13C] pyruvate MRI. A) The average pyruvate
signal in each lung, normalized by the average signal in the heart. The sample size for both cohorts
was n=5 at all three timepoints (day 3, 7, 14). On day 3, a much larger pyruvate signal is observed
in the native lung of the allogeneic cohort compared to the other three lungs; by day 14, this signal
is within the range of both syngeneic lungs, while the signal from the allograft remains
comparatively low, most likely because perfusion is hampered due to rejection. B) The average
lactate signal in each lung, normalized by the average lactate signal in the heart. Both syngeneic
lungs and the native lung from the allogeneic cohort show a decreasing lactate signal with time,
most likely due to recovery from post-transplant ischemia-perfusion injury. In the allograft, on the
other hand, lactate signal does not show a monotone decrease, and is similar to that in the isograft
lungs despite lower perfusion. C) The average HP lactate-to-pyruvate (LtP) ratio in each lung. On
day 3, The LtP of the allograft is significantly greater than that of the isograft, and continues to

160

increase on day 7, when the lung is fully rejected. The other three lungs show a similar LtP on day
14, while that of the allograft remains high.

5.3.2. HP Lactate-to-Pyruvate (LtP) Ratio
Although the pulmonary lactate and pyruvate intensities reported above are normalized
against the heart, the LtP provides the metabolic state of each lung independent of any
other organ’s metabolic status. On day 3, the native lungs in the syngeneic and allogeneic
cohorts have a LtP of 0.078±0.028 and 0.160±0.083 (p=0.090), respectively, whereas the
grafts show respective ratios of 0.114±0.045 and 0.200±0.05 (p=0.020) (Figure 5.3C).
There is no significant difference between the native lungs and grafts within the same
cohort (minimum p > 0.18); however, there is a significant difference between the same
types of lung in different cohorts. Furthermore, the LtP of the transplanted lung in the
allogeneic (rejected) cohort is 75.4% greater than in the syngeneic (non-rejected) cohort,
making it a viable predictor for lung rejection.

On day 7, the LtP in the native lungs is 0.113±0.037 and 0.123±0.029 in syngeneic and
allogeneic cohorts, respectively. The LtP of the isografts is 0.153±0.027, whereas it has
increased to 0.413±0.146 in allografts (p=0.0015). This increased LtP coincides with full
lung rejection, as observed in CT images of the non-aerated allografts. On day 14, the LtP
of the native lungs in the syngeneic and allogeneic cohorts is 0.079±0.027 and
0.131±0.065 (p=0.29), respectively; the transplanted lungs have respective LtPs of
0.100±0.032 and 0.257±0.097 (p=0.097). Although less than on day 7, this is still a 2.57fold inter-cohort difference between transplanted lungs.
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5.3.3. Qualitative Assessment of CT Imaging
CT images for both cohorts show large aeration variances on day 0 (Figure 5.4A,E):
typically, the native lungs are partially to fully aerated, while the grafts are non- or slightly
aerated. By day 3, the native lungs in both cohorts appear almost fully aerated (Figure
5.4B,F); however, the allogeneic cohort tends to display a higher variance than the
syngeneic cohort. Meanwhile, the transplanted lungs remain either poorly or partially
aerated on day 3, with minimal discernible difference between the two cohorts. It is
therefore difficult to predict the fate of the transplanted lungs based on the day 3 CT
images. On days 7 and 14, the allografts are completely non-aerated (Figure 5.4G,H),
whereas both lungs appear fully aerated in the syngeneic cohort (Figure 5.4C,D).

Figure 5.4: Representative coronal CT slices for syngeneic (top) and allogeneic (bottom) transplanted lungs.
The slices displayed here best represent the median lung density of their respective cohorts. In general, there
was a much larger variation in both lungs on days 0 and 3 compared to days 7 and 14, as seen in Figure 5.5.

5.3.4. Quantitative Assessment of CT Imaging
The quantitative parameters—ventilated lung volume (mL), lung density (HU), and
normalized lung density (L*HU)—confirm the qualitative assessment of the CT images.
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On day 3, the volume of the native lungs in the syngeneic and allogeneic cohorts is
3.63±0.51mL and 3.91±0.1.67mL (p=0.71), respectively; the respective volumes of the
grafts are 1.1±0.63mL and 0.53±0.71mL (Figure 5.5A). Although the mean volume of the
isografts is more than double that of the allografts, this difference is insignificant (p=0.40)
due to their large overlapping ranges. On day 7, the volume of the native lungs in the
syngeneic and allogeneic cohorts is 3.88±0.27mL and 4.17±1.025mL (p=0.62),
respectively, while the respective volumes of the grafts are 1.27±0.17mL and
0.01±0.01mL (p<0.00001), suggesting that the allografts have been completely rejected
by day 7. The isograft volume increases by 21% to 1.54±0.15mL on day 14, whereas the
allograft volume remains unchanged. The native lung volume increased by 5.3% to
4.09±0.65mL and by 21.3% to 5.063±.91mL in the syngeneic and allogeneic cohorts,
respectively.

Similarly, the difference in lung density between the two cohorts on day 3 is insignificant.
The native lungs of the syngeneic and allogeneic cohorts have a density of -512±24 HU
and -486±66 HU (p=0.60), respectively, compared to respective densities of -438±29 HU
and -425±39 HU (p=0.40) in the grafts on day 3 (Figure 5.5B). The density of the native
lungs in both cohorts decreases slightly on days 7 and 14 as the lungs recover ventilation.
The isografts have a density of -517±52 HU and -498±59 HU on days 7 and 14,
respectively, also suggesting recovering ventilation. The nominal density in the allograft
on day 7 is meaningless given the almost zero volume of the lung at that time point
(indicating complete consolidation).
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Figure 5.5: The aerated lung volume (A), lung density (B) and normalized lung density (C) in native
(left) and transplanted (right) lungs in both cohorts, based on segmentation of gated CT images.
CT images could not be accurately segmented before day 3 due to heavy motion artifacts in the
non-gated CT images. (A) The volume of the native lungs was larger than that of the transplanted
lungs, as donor rats were typically about 50g smaller than recipient rats. The volume of the native
lung increases to compensate for the failing transplanted lung on days 7 and 14 in the allogeneic
cohort. (B) Because values are based on an upper threshold of -250 HU, these lung densities are
biased towards aerated regions of the lung and, as a result, cannot distinguish between a lung with
very low overall aeration (high density) versus a lung with high aeration in some regions (low
density); they are therefore of minimal use as diagnostic markers. (C) The normalized lung density
(L*Hu) is the product of lung volume and density, and serves as a quantitative surrogate for the
visual inspection of a radiograph or CT image by a radiologist. The results show a similar trend to
the previous two CT-derived parameters: the native lungs in both cohorts share a similar
longitudinal trajectory, whereas the transplanted lungs show similar normalized densities on day 3
before lung failure in the allogeneic cohort starting on day 7. Note that there are no lung density
and normalized lung density values on day 14 for the allograft in the allogeneic cohort because the
segmented lung volume of 0mL. The sample size for both cohorts was n=5 at all three timepoints
(day 3, 7, 14).

The normalized lung density –which attempts to succinctly quantify the qualitative reading
of a radiograph—similarly reflects CT imaging’s lack of predictive power. On day 3, the
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native lungs in the syngeneic and allogeneic cohorts have a normalized density of 1.87±0.31 L*HU and -1.98±0.99 L*HU (p=0.80), respectively, whereas the transplanted
lungs show respective normalized densities of -0.47±0.29 L*HU and -0.34±0.13 L*HU
(p=0.53) (Figure 5.5C). The normalized density of the native lungs in both cohorts and the
isografts continues to decrease on days 7 and 14, reflecting the increased lung volume
and improved ventilation seen above. In contrast, given the complete consolidation of the
allografts, the normalized density is zero L*HU on day 7.

5.3.5. H&E and Trichrome Staining
On day 7, isografts presented with minor infiltration in the peribronchiolar regions, but no
edema. The native lung showed very little particulate infiltration. Overall, the isograft
showed no signs of rejection. Isografts and native lungs scored 4.0 and 3.1, respectively
(Figure 5.6A,C).

In contrast, allografts showed extensive infiltration as well as complete remodeling of the
graft, with granulated tissue filling the lumen of the airway. There was alveolar collapse
and tissue consolidation in most of the graft tissue, marked proliferation of the intima along
the vessels, and the lumen of most of the vessel had disappeared. Extensive fibrotic
lesions were observed throughout the graft. Thus, all the classic features of rejection were
noted. Infiltrates and edema were also observed in the native lungs of the allogeneic
(rejected) cohort. On our semi-quantitative scale, allografts and native lungs scored 13
and 5.8, respectively (Figure 5.6E,G).
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Figure 5.6: H&E staining (left panel) and Masson’s Trichrome (right panel) of both non-rejected (AD) and rejected (E-H) cohorts on day 7 post-transplant. A sub-field is magnified in the adjacent
panels. The blue arrows show collagen deposition in the isograft (D) and allograft (H). The alveolar
structure and lung architecture appear normal in the non-rejected cohort, with some minor
remodeling seen in the isograft. In the rejected cohort, the black arrow (E) is proteinaceous edema
in the alveolus, while the grey arrow (G) shows thickening (smooth muscle proliferation) of an
airway. Airways are obliterated and the lung architecture is completely destroyed in the allograft.
Collagen deposition (blue) indicates extensive remodeling of lung tissue. Scale bar is 100 microns.

The average Ashcroft score for both lungs in the syngeneic cohort was 1.0 (Figure
5.6B,D). Isografts showed the presence of infiltrates and thickening of the alveolar septa
in some areas. In contrast, allografts showed extensive fibrosis, massive infiltrate
accumulation and tissue consolidation, and total obliteration of alveoli and extensive
collagen deposition throughout the graft (Figure 5.6F,H). The allograft’s Ashcroft score
was 7-8, whereas the native lung’s was 2.5.
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5.3.6. Immunostaining for Myeloperoxidase (MPO)
Fluorescence microscopy of immunostained lungs showed high MPO expression in the
allografts on days 3 and 7 compared to the native lungs (not shown) and the isograft
(Figure 5.7). In the allograft, MPO expression was marginally higher on day 7 compared
to day 3, but that difference was not significant (Table 5.5). MPO was predominantly
expressed along the vessel wall, with some PMN accumulation in the alveolar space.

Figure 5.7: MPO Staining – Immunostaining for immune cells (neutrophils and macrophages) in
post-transplant grafts from both allogeneic and syngeneic transplants. Lung sections were stained
for myeloperoxidase (MPO) using rabbit polyclonal anti-MPO. Goat anti-rabbit-Alexa 488 was used
as a secondary antibody. The boxed inset is expanded to show the presence of MPO positive (i.e.
azurophilic granulocytes) neutrophils, which are seen as clusters within the allogeneic lung graft
tissue and were not limited to the lumen. No such cell clusters were observed in syngeneic grafts.
The black arrow shows an obliterated lumen. Quantifying fluorescence signal (Table 5.5) suggested
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a high expression of MPO in the transplanted grafts compared to the isograft; in allografts, MPO
was slightly higher on day 7 than on day 3. Scale bar is 10 microns.

5.3.7. Immunostaining for CD4+ and CD8+ Cells
The syngeneic cohort showed minimal staining for both CD4+ (Figure 5.8E) and CD8+
(Figure 5.9E) in both lungs. Fluorescence imaging showed high CD4+ expression in
allografts on days 3 and 7 (Figure 5.8A,C, Table 5.5). There was no appreciable
expression of CD4+ in the native lungs (Figure 5.8B,D). In contrast, CD8+ expression was
low in day 3 allografts (Figure 5.9A), but increased several-fold at day 7 (Figure 5.9C).
Both CD4+ and CD8+ expressing T cells accumulated predominantly along the obliterated
lumen, with little to no accumulation in either the alveolar region or other areas of the lung
tissue; some T cells were also found along the endothelial layer of the original vessel.

Figure 5.8: Sections depicting airways and lumen are shown (Aw=airway; L=lumen). The presence
of T-lymphocytes using anti-CD4+ antibodies is indicated by green fluorescent signal in the
allogeneic cohort on days 3 (A, B) and 7 (C, D), as well as in the syngeneic cohort on day 7 (E, F).
The syngeneic cohort showed minimal staining for CD4+. The lung allografts showed appreciable
signal on both day 3 and day 7 (A, C), while the native lungs in this cohort showed minimal signal
(B,D)—see Table 5.5 for quantification.
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Figure 5.9: Sections depicting airways and lumen are shown (Aw=airway; L=lumen). Green
fluorescent signal indicates the presence of T-lymphocytes using anti-CD8+ antibodies in the
allogeneic cohort on days 3 (A, B) and 7 (C, D), as well as in the syngeneic cohort on day 7 (E, F).
Most of the CD8+ T lymphocytes were expressed along the lumen. Minimal CD8+ expression is
apparent in the native lungs in all three cohorts as well as the isograft on day 7. The allograft shows
elevated fluorescence on day 3, which more than doubles by day 7 (see Table 5.5 for
quantification).

5.4. Discussion
In this animal study, we assessed HP [1-13C] pyruvate MRI’s potential as a predictor for
lung rejection compared to micro-CT, an appropriate analog to clinical radiography. We
found that the lactate-to-pyruvate (LtP) ratio derived via our technique was able to
discriminate allografts and isografts better than micro-CT-derived parameters on day 3.
While the transplanted allografts were completely rejected by day 7 in our model, the
normalized lung density derived via micro-CT showed no significant difference between
allografts- and isografts on day 3, whereas the LtP showed a significant difference
between the two cohorts at this timepoint.
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Images derived using both these modalities reflect the underlying mechanism of graft
rejection, which is primarily driven by the adaptive immune system. The recognition of the
donor MHC complexes by CD4+ and CD8+ T-cell lymphocytes stimulates the
development of cytotoxic CD8+ T-lymphocytes (CTL) which lyse the cells and tissue,
leading to organ destruction20,21. While the relative contributions of CD4+ and CD8+ T cell
subsets to rejection are unclear, the CD4+ alloimmune response is typically short-lived
due to the destruction of donor antigen-presenting cells (APCs) post-transplantation22–24.
The principal alloimmune response therefore appears to be largely mediated by CD8+
CTLs, although this response may vary according to the transplant model and species25–
27

. In our study, both CD4+ and CD8+ seemingly play a role in the rejection process on

day 3; the CD4+ signal declines on day 7, however, while the CD8+ signal doubles,
suggesting that the CD8+ T-cell response is the principal mediator of rejection (Figure
5.8,9).

Although the adaptive immune response is the major driver for tissue rejection, other
immune responses driven by neutrophils also occur during the rejection process.
Ischemia-reperfusion (IR) injury due to the transplant procedure results in infiltrating
leukocytes28 and vascular permeability29,30, and the cascade of events up-regulates
fibroblast activity in the allograft, eventually resulting fibrosis31,32. Indeed, a major hallmark
of graft rejection is the complete solidification of the graft tissue, as observed in Figure
5.6.

Because of its sensitivity to most of the physiological changes described above, CT
imaging is useful for monitoring post-transplant tissue rejection. The lack of aeration
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immediately after transplantation, along with any edema or inflammation due to IR injury,
increases the lung density. Effects of IR injury have been demonstrated in the contralateral
lungs33–35, suggesting that the observed decrease in CT lung density from day 3 to 14 in
the native lungs of both cohorts is most likely due to recovery from such IR injury.
Transplanted lungs from both cohorts are non-aerated immediately post-transplant
(Figure 5.4AE), but are partially aerated by day 3. The isograft recovers from the IR injury
between days 3 and 7, as confirmed by H&E histology. In contrast, the lung density of the
allografts increases and the lung aeration decreases as the CTL lyse donor lung cells,
typically those in the endothelium of the vessels and airway epithelium, as seen in Figure
5.636. Despite its utility as a monitoring tool for lung rejection, however, CT is only capable
of detecting this rejection after native immune cells have induced these structural
changes37. This deficiency is most apparent in our model on day 3, when both the
allografts and isografts show overlapping CT volumes and densities despite only the
allograft staining positive for CD4+ and CD8+ cells.

As seen in our Results, there is a significant difference in LtP between the allograft and
isograft on day 3, suggesting that this technique can be used as an earlier predictor of
lung rejection than CT, which does not differentiate between the two grafts at this
timepoint. The HP lactate signal measured by HP [1-13C] pyruvate MRI is generally based
on the metabolism and cellularity of the imaged tissue15. The lung has both low cellularity
and a low glycolytic rate, whereas immune cells have high aerobic glycolysis

38,39

.

Importantly, both activated CD8+ cells and neutrophils have high aerobic glycolysis, so an
increased lactate and LtP could be attributed to either source40–42; a combination of both
mechanisms likely produces the contrast observed in our imaging technique.
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The observed LtP in the syngeneic cohort is likely primarily due to post-transplant IR injury.
Although no immunohistochemistry was done on day 3 for this cohort, day 7 results show
minimal fluorescence for CD4+/CD8+, but ~40% signal for MPO compared to the allografts
(Table 5.5). Furthermore, the HP [1-13C] pyruvate signal, which has been previously used
as a perfusion marker43–45, shows that both the isograft and native lung have a high
pyruvate signal (normalized to the heart) on day 3 that continues to decrease until day 14,
most likely as inflammation subsides. In contrast, the LtP in the allogeneic cohort is most
likely a function of both IR injury and T-cell response. Both MPO and CD4+ fluorescence
of the allografts on day 3 and 7 increase about 2.3-fold and 15-fold, respectively,
compared to the day 7 isograft—suggesting an origin of the increased LtP. Additionally,
CD8+ fluorescence of the allografts increases from 7.5-fold to 18.9-fold of the day 7
isografts between days 3 and 7, suggesting that the observed 2-fold increase in LtP
between days 3 and 7 results from the increased CD8+ cells in the allografts.
IHC

MPO

Cohort

Lung

Day 3

Day 7

Mean

SD

Mean

Allogeneic

Allograft 1159.1

49.6

1226.6 195.2

Syngeneic

Isograft

-

-

512.6

49.7

Native

65.6

10.5

91.5

21.6

Allograft

848.7

58.7

921.6

282.6

Native

-

-

118.3

70.4

Isograft

-

-

76.2

40.1

Native

74.9

14.8

135.5

32.4

Allograft

858.8

115.5 2169.1 243.7

Native

-

-

114.7

48.9

Isograft

-

-

71.9

35.5

Allogeneic
CD4+
Syngeneic

Allogeneic
CD8+
Syngeneic

SD

Table 5.5: Fluorescence quantification of MPO, CD4+ and CD8+ immunohistochemical stains on
days 3 (n=3 allogeneic cohort) and 7 (n=4 allogeneic cohort, n=3 syngeneic cohort). MPO
expression is used as a marker for neutrophil activity, whereas CD4+ and CD8+ T-cells play a role
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in the immune rejection of allogeneic tissue. The images were acquired at an excitation wavelength
of 488 nm. All images were acquired at 100 ms exposure time using a preset scale of 0-4095. The
PMN, CD4+ and CD8+ were assessed by quantifying fluorescence intensity over 5 fields, and the
averages are presented here. The data suggests that the majority of the observed lactate-topyruvate signal likely originates from increasing CD8+ cell presence in the allografts.

Based on our day 14 imaging data, both the CT-derived volume and normalized density,
as well as the perfusion and LtP based on HP [1-13C] pyruvate MRI, suggest recovery to
baseline in the native lungs and isografts. The CT images clearly show the rejected
allograft on day 14. The corresponding LtP is 2.6-fold greater than that of the day 14
isograft, likely due to a decrease in lymphocyte activity since day 7, after the onset of lung
fibrosis.

Although this study employed HP [1-13C] pyruvate MRI in contrast to CT, other MR or
imaging-based techniques have been used previously to study graft rejection.
Conventional T1-weighted gradient echo images and T2-weighted spin echo images result
in poor SNR of the lung parenchyma due to their long echo times and the lung’s short T2*;
however, ultra-short echo (UTE) imaging has been shown to differentiate between
allografts and isografts as early as day 3 based on their relaxation characteristics in a
murine model37. UTE also has a number of advantages compared to our HP
sequence; for example, UTE has a much higher spatial resolution than HP

13

C CSI

13

C CSI and,

compared to carbon-13 imaging, would require little or no new hardware (broadband
amplifier, coils, polarizer, etc.) for translation to modern clinical MRI scanners. It should
be noted, however, that the implementation of

13

C HASTE imaging would provide

enhanced in-plane spatial resolution comparable to that of UTE46,47. In a different murine
study, FDG-PET differentiated between allografts and isografts, showing a significant
difference in %injected dose per cc of lung (%ID/cc) by day 7; this study further showed
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that the largest glucose utilization was by CD8+ T cells in particular48, a finding echoed in
our study.

This work demonstrates the sensitivity of HP [1-13C] pyruvate MRI for the early detection
of lung rejection. However, both our own and other future small animal studies37,48 of novel
imaging methods must address a number of shortcomings if this technique is to be
extended to a clinical setting. Comparison with human pathophysiology is limited, as the
time course of rejection in rat lungs is quite distinct from that in humans; in rats, the onset
of rejection occurs within days, whereas acute and chronic rejection in humans are distinct
in both time and presentation49,50. Furthermore, the use of immunosuppressive drugs in
transplant patients means that the effects of ischemia-reperfusion—which are seen within
the first few days post-transplantation—can be separated from those of rejection, which
typically occurs weeks or months later. In this study, the use of syngeneic animals as a
sham cohort was intended to minimize the complications arising from the use of
immunosuppressive drugs and account for ischemia-reperfusion injury while investigating
the feasibility of our imaging technique; further studies should develop a chronic rejection
model by using immunosuppressive drugs in allografts to better represent the clinical
presentation.

Although this study proposes that the lactate signal may be attributed to the activity and
cellularity of both leukocytes and lymphocytes, other possible sources of this increased
lactate signal are extracellular LDH activity due to cell death during rejection51, or even
increased B-cell activity and humoral response. However, these avenues were not further
investigated, as previous findings have shown that in most cases the dominant response
is T-cell mediated rejection52–54. Another limitation of investigating this technique in an
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animal model is that it lacks specificity with other differential diagnoses, e.g. aspirationinduced injury or infections4,55. This is also a limitation of FDG-PET imaging, which relies
on glucose uptake to drive cellular contrast48. However, given the broad range of available
HP probes, HP [1-13C] pyruvate could potentially be combined with more specific probes
to address that shortcoming12,56,57. Overall, this technique has the potential to be a
promising new tool for post-transplantation monitoring of lung rejection.
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Chapter 6: Conclusions and Future Work

6.1. Conclusions
Improving lung transplant outcomes is a vital but imposing endeavor: challenges include
the limited availability of donor lungs, the necessity preserving and/or revitalizing lungs
before transplant, and high rates of post-transplant graft failure compared to other solid
organs. Although a number of novel techniques such as ex vivo lung perfusion are
currently used to maintain or improve the viability of donated lungs during acquisition and
transit, there is no established non-invasive assessment tool for evaluating the health of
the tissue before transplantation. In addition, current post-transplant assessment tools—
primarily spirometry and X-ray radiography or CT—each have their own inherent
limitations. Because spirometry only provides whole-lung measurements, a large number
of differential diagnoses must be ruled out by further testing. Both radiography and CT, on
the other hand, provide only low sensitivity in the early stages of rejection. We showed
that HP carbon-13 magnetic resonance imaging, since it generates contrast due to the
metabolism of the tissue or the infiltrating inflammatory cells, is therefore a promising
technique for both assessing the viability of lungs before transplantation and predicting
post-transplant lung rejection.

In our first set of studies, we used HP [1-13C] pyruvate MRS and 31P MRS to show that the
energy status of the lung declines as a function of time during EVLP. The decline in
conversion of HP [1-13C] pyruvate to 13C bicarbonate showed that the energy decline was
most likely linked to reduction in pyruvate dehydrogenase complex (PDHc) activity and
the subsequent decrease in oxidative phosphorylation. As such, we concluded that a part
of the energy depletion and loss of viability observed in reperfused ischemic lungs is due
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to perfusion alone. We also demonstrated that ascorbate upregulates oxidative
phosphorylation in the ex vivo perfused lung. Although previous studies have postulated
that ascorbate’s role in minimizing ischemia-reperfusion injury is via its anti-oxidative
properties1,2, our HP [1-13C] pyruvate studies suggest that ascorbate slows the decline in
pulmonary mitochondrial activity through an independent interaction with ETC complexes.
Based on the observation that lungs experiencing significant decline in energy status are
highly prone to edema, it seems clear that maintaining mitochondrial function during EVLP
is critical to maintaining organ viability. One of the applicable findings of this set of studies
was that the addition of ascorbate to the perfusate during EVLP may be beneficial in
prolonging the viability of the lungs being excised, transported and reperfused before
transplantation. Furthermore, this study also established that HP [1-13C] pyruvate MRS
can be used to assess the response to treatment during EVLP for improving procurement
and preservation of lungs for transplantation.

In our second set of studies, we demonstrated that ex vivo HP [1-13C] pyruvate
spectroscopy can be used to detect pulmonary inflammation and provided histological
evidence that infiltrating neutrophils are the most likely source of increased signal
compared to heathy tissue. Although the transport and enzymatic processes of HP [1-13C]
pyruvate differ than those involved in

18

FDG imaging, many features of the techniques

appear to be similar, including the several-fold increase of signal in inflammation and the
apparent sensitivity to direct metabolism of neutrophils. We also successfully translated
these findings into in vivo HP [1-13C] pyruvate imaging using a FID-CSI sequence. Due to
the inherent problems of imaging lungs in vivo—such as the blood-dependent T1
depolarization, susceptibility due to the air-tissue interface, and the movement of the chest
cavity—we see lower metabolite signals than via ex vivo spectroscopy; however, we were
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able to detect a significant increase in the HP lactate-to-pyruvate ratio in inflamed lungs
compared to healthy tissue, paving the way for in vivo studies for lung transplant rejection.

In our last set of studies, we applied our developed in vivo HP [1-13C] pyruvate imaging
technique to predict lung graft rejection in an orthotopic left lung transplant model in rats.
We showed a significant increase in the HP lactate-to-pyruvate ratio as early as day 3 in
the allogenic graft compared to the syngeneic graft. This signal increased further by day
7 and remained much higher than the isograft or native tissue in either cohort at day 14.
We also acquired post-transplant microCT imaging at the same timepoints, and found that
the HP lactate-to-pyruvate was an earlier predictor of lung rejection compared to CTderived parameters. Our immunohistochemical staining suggested that the source of this
signal was a combination of neutrophils, CD4+, and CD8+ cells, with the largest signal
deriving from CD8+ cells on day 7. However, our study leaves a number of unanswered
questions, which must be tackled in future studies: how can the role of ischemiareperfusion injury be separated from that of the tissue rejection process? Can this
technique be used to separate differential diagnoses, e.g. aspiration-induced injury or
infections? Can the technique be used for long term assessment for predicting bronchitis
obliterans syndrome or restrictive allograft dysfunction? Given the broad range of available
HP probes, can HP [1-13C] pyruvate potentially be combined with more specific probes to
address the shortcomings of this technique? Lastly, can this technique be successfully
translated towards imaging humans?

6.2. Planned Future Studies
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6.2.1. Post-transplant HP [1-13C] pyruvate MRI of lungs acquired after induction of
donor brain-death in a rat model
We have already established the metabolic profile of syngeneic and allogeneic grafts in a
rat model. As donor brain death (DBD) has been associated with increased ischemiareperfusion injury and primary graft dysfunction (PGD), we will transplant lungs obtained
after DBD into healthy rats and compare their graft performance with our established
transplant model. We will determine whether syngeneic grafts from DBD lungs show a
similar metabolic profile compared to our current donor model with normotensive brain
death. We will also image allogeneic grafts from DBD lungs to test the hypothesis whether
these lungs will show rejection or graft failure earlier than the findings in our current model.

We also plan to use ex vivo

13

C MR and

31

P spectroscopy to measure the tissue energy

status in of DBD lungs using EVLP, and we will assess the metabolism as a function of
perfusion time, perfusate composition and other factors that have shown to ameliorate or
degrade EVLP lungs. Graft performance post-transplantation will be assessed to confirm
the success of any therapeutic strategies.

6.2.2. Imaging Post-Transplant Allogeneic Rats with Acquired Immune Tolerance
Using Hyperpolarized [1-13C] Pyruvate MRI
Our findings from imaging post-transplant lungs suggest that the lactate-to-pyruvate signal
in the allograft originates from both neutrophils and CD3+ lymphocytes. One of the more
pressing questions in the field of lung transplantation is the role of inflammation after
ischemia-reperfusion injury in the tissue rejection process. In this study (in progress), we
plan to image a transplanted allogeneic lung in a recipient rat with acquired immune
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tolerance to resolve the signal contribution of ischemia-reperfusion injury from that of
tissue rejection3. Figure 6.1 shows a schematic for generating an adult rat with an acquired
immune tolerance for a different rat strain. The first step involves crossing two different
strains to produce a crossbred F1 generation. In our case, inbred Lewis (L) rats were
crossed with inbred Wistar-Furth (WF) rats to generate a WFxL (F1) rats. The bone marrow
from the F1 rats is extracted immediately after birth—before T cells are have matured to
identify self and non-self MHC molecules4,5—and injected into Lewis neonates (also
immediately after birth). This allows the inoculated Lewis (iL) neonates to develop self
recognition for both F1 and Lewis MHC molecules. The F1 generation is required to avoid
graft versus host disease (GVHD) in the inoculated Lewis rat. Once the iL rat is mature, it
can be used as a recipient for allogeneic lung transplant.

Figure 6.1: Schematic for generating a recipient rat with acquired immune tolerance for an
allogeneic graft.

As figure 6.2 shows, the lung transplant is performed similarly to as described in our
previous studies (chapter 5). The donated lung is the F1 rats. The recipient is an iL rat. As
the iL rat recognizes the F1 MHC as self, the lung is not rejected. In our preliminary study,
we imaged allogeneic, syngeneic, and the acquired immune tolerant rats on days 3, 7,
and 14. On day 3, the average lactate-to-pyruvate ratios of all three transplanted lungs
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ranged between 0.08 to 0.11 compared to a range of 0.05 to 0.07 for the native lungs. By
day 7, the rejected allograft had a lactate-to-pyruvate ratio of 0.3±.04, a 2.7-fold increase
compared to the other cohorts, which remained below 0.11. Most importantly, the immune
tolerant allograft followed a similar trajectory to the syngeneic graft—showing no signs of
rejection. A similar trend is observed on day 14: lactate-to-pyruvate remains elevated in
the allograft (0.23±.02), whereas the other transplanted and native lungs remain below
0.08. The immune tolerant cohort was also imaged on day 28 to assess the presence of
chronic rejection; the lungs remained viable at this timepoint, based on their low lactateto-pyruvate ratio (below 0.04). Representative pyruvate and lactate maps acquired on day
7 post-transplantation from our preliminary results can be seen in Figure 6.2. As
mentioned, the allograft clearly shows a much greater lactate signal than any of the other
lung cohorts, whereas the syngeneic lungs and acquired immune tolerant lungs show
similar findings.

Figure 6.2: Preliminary results from a HP [1-13C] pyruvate MRI study showing the pyruvate and
lactate distribution on day 7 post-transplantation in allogeneic (left), syngeneic (middle), and
acquired immune tolerant (right) rats.
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The next step in this study is to abolish the the acquired immune tolerance by injecting
mature T-cells from any inbred Lewis rat (Figure 6.3). As the recipient rat and the injected
T-cells are inbred Lewis rats, they will recognize each other as self and no immune
response will be triggered in the host tissues.

Figure 6.3: Abolishing acquired immune tolerance after lung transplantation by injection of mature
T-cells from inbred Lewis rats.

However, the injected mature Lewis T-cells will not recognize the F1 MHC molecules as
self. When CD4+ or CD8+ cells will be presented with the appropriate MHC via various
antigen presenting cells (APC), they will recognize the F1 molecules as foreign antigens
and activate an immune response, triggering graft rejection. HP [1-13C] pyruvate MRI
acquired after inducing this lung rejection process will allow us to differentiate between the
signals emanating from ischemia-reperfusion injury and rejection.

6.3. Further Studies
Once the answers to the questions posed by the above studies are answered, we can add
further complexity to our animal models to better mimic the clinical transplantation
process. This includes using recipients with models of end-stage progressive diseases,
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such

as

radiation-induced

or

bleomycin-induced

fibrosis,

or

elastase-induced

emphysema. Furthermore, we can use a multimodal approach to imaging, combining the
findings from HP [1-13C] pyruvate imaging with pre-existing methodologies, as well novel
imaging techniques such as HP gas imaging, all for the ultimate goal of improving posttransplant outcomes clinically.
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